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Abstract 
Ventilator-associated pneumonia (VAP) is pneumonia developing 48-hours or more 
after tracheal tube insertion and mechanical ventilation. VAP is associated with 
significant morbidity, mortality and costs. The excessive use of antimicrobial agents 
in VAP treatment and prevention is contributing to antibiotic resistance. Introduction 
of the tracheal tube is thought to be a key contributing factor in VAP development, 
providing a conduit for invasion of the airways with virulent microorganisms. The 
subglottis (the region located immediately below the vocal cords, and directly above 
the tracheal tube cuff) is key to VAP development. The subglottis in intubated ICU 
patients has not previously been characterised, and therefore therapeutic targets for 
preventing VAP are limited.  
I have demonstrated the presence of a diverse population of oropharyngeal 
commensal bacteria in the subglottic mucus of newly intubated, non critically ill 
control patients. In a cohort of ICU patients, intubated for four or more days, there 
was a less diverse population of more virulent bacterial and fungal organisms. 
I have also established that the subglottic mucus of long-term ventilated ICU patients, 
compared to newly intubated controls, is more viscous, has increased neutrophil 
counts, and increased concentrations of mucins, cytokines and neutrophil proteases.   
I was able to demonstrate in vitro that neutrophils isolated from the blood of healthy 
volunteers, when incubated with purified ICU-derived mucin, showed impaired 
chemotaxis, phagocytosis and bacterial killing, which was reversible upon treatment 
with a mucolytic agent. These effects were concentration dependent and only found at 
mucin levels found in ICU patients, not controls.  
Finally I describe the establishment of a successful method to culture primary human 
subglottic epithelial cells, at air-liquid interface (ALI). This provides the first in vitro 
model of this region of the airway. This model suggests that high concentrations of 
purified ICU-derived mucin applied to ALI cultures, may induce bacterial growth and 
invasion of the epithelial membrane. 
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1.1 Ventilator-associated pneumonia  
1.1.1 Ventilator-associated pneumonia (VAP) overview 
Tracheal intubation and mechanical ventilation is a life-saving procedure in critical 
illness and respiratory failure (1). An adverse consequence of this intervention is the 
development of ventilator-associated pneumonia (VAP) (2). VAP is defined as 
pneumonia developing 48 hours or more after tracheal intubation and mechanical 
ventilation (1). It is the most common hospital-acquired infection in the intensive care 
unit (ICU) (3). The reported incidence of VAP varies, depending on the diagnostic 
criteria, but between 9 and 27% of patients in the ICU develop VAP (4). It also 
remains the most commonly fatal infection in critical illness, with an overall 
attributable mortality of 13%, and is associated with a significantly increased length 
of ICU stay and cost (5, 6).  
VAP is frequently associated with antibiotic-resistant pathogens (7-9), particularly 
late onset pneumonia, developing after four days (1, 9). Furthermore VAP is 
estimated to account for half of all antibiotics given in ICU (10). The individual 
organisms identified from VAP bronchoalveolar lavage samples are highly variable, 
depending on several factors, including the geographical location and patient group. 
Gram positive bacteria such as Staphylococcus aureus, including methicillin resistant 
S. aureus  (MRSA), represent a large proportion of isolates in VAP. Other VAP-
causing pathogens include aerobic Gram negative bacilli such as Pseudomonas 
aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter species and 
Acinetobacter species (7-9, 11) 
Prevention of VAP is focused around three key strategies; reduced colonisation of the 
aerodigestive tract with pathogenic bacteria; prevention of aspiration of infective 
contents into the alveolar regions of the lung; and limiting the duration of mechanical 
ventilation (1). Introduction of various combinations, or bundles, of interventions into 
international ICU guidelines has been associated with some recent reduction in VAP 
rates (12, 13).  
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1.1.2 The pathogenesis of VAP 
The key causative factor in VAP development is the presence of the tracheal tube 
(endotracheal or tracheostomy tube) (Figure 1) (14). The tube provides a conduit for 
invasion of the lower airway with virulent microorganisms (1, 14, 15). It is postulated 
that infected secretions gravitationally pool above the tracheal tube cuff, in the 
subglottic region (16). These infected secretions, on or immediately above the tracheal 
cuff, can then be micro-aspirated around the tracheal cuff, or pass en masse into the 
lower airway when the cuff is deflated or removed (1, 14, 15). The tracheal cuff 
further facilitates lung infection through prevention of these aspirated secretions being 
cleared from the lower airways, acting both as a physical barrier and in preventing an 
effective cough reflex. These organisms are then at liberty to infect the lower airways 
of compromised ICU patients, culminating in VAP development (Figure 2) (1, 14, 
15).  
Longitudinal studies of ventilated ICU patients have previously demonstrated a strong 
correlation between oropharyngeal or tracheal microbiology samples and organisms 
subsequently found in the lungs (11, 17, 18). Berdal et al (11) in a small ICU cohort 
demonstrated correlation between the organisms recovered from oropharyngeal 
swabs, tracheal aspirates (below the cuff) and lung lavage samples at various intervals 
up to 14 days after intubation. In a further small series specifically looking at VAP 
derived microbiology, Gil-Perotin et al (17) compared the microbiology findings of 
ICU tracheal aspirates and found a strong correlation with VAP lavage cultures taken 
some days later. In a much larger study Pirracchio et al (18) demonstrated strong 
correlation between upper airway samples at admission and later VAP recovered 
microorganisms. All these studies have significant limitations, furthermore the 
correlation of organisms at these different airway subsites does not prove migration 
from the upper to the lower airway.  
The origin of these VAP-causing organisms is much debated in the literature. Some 
suggest that deterioration of oral hygiene, with persistent mouth opening and poor oral 
care, leads to pathogenic oral colonisation. However interventions to prevent this have 
had variable effects (19). Reflux and aspiration of infected stomach contents has also 
been suggested. The extensive use of acid suppression therapy in critical illness, to 
prevent gastric ulcer formation, is thought to generate overgrowth of gastric bacteria, 
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which are subsequently aspirated into the airway (20). Other potential reservoirs that 
have been postulated include the oropharynx and paranasal sinuses (21). There is also 
the unknown contribution of medical devices and healthcare workers, introducing 
organisms into the instrumented airway (21). Biofilm formation is also frequently 
found on the tracheal tube cuffs of ventilated patients and likely contributes to 
infection (17, 22). 
Over recent years numerous strategies have been introduced with the aim of 
preventing VAP. These include selective digestive decontamination, use of oral 
mouthwashes and tooth brushing, changes in body positioning, coated endotracheal 
tubes and subglottic suction drainage (SSD) (16, 19, 21, 23-25). The aim of all these 
interventions has been to reduce upper airway bacterial load (21, 25). The most 
effective of these interventions has been the use of SSD (24). In a recent meta-
analysis of SSD and VAP incidence by Mao et al (24) the authors identified twenty 
randomised control trials (RCTs). Of these the authors acknowledged only four high-
quality (low-bias) trials with 901 pooled participants (spread relatively equally 
between the studies). The studies included varying drainage techniques (continuous or 
intermittent), and had slightly differing criteria for VAP diagnosis. The participants in 
all studies were from general ICU populations and did not specifically investigate 
high risk VAP patients (such as burns or trauma patients (2)). They demonstrated that, 
overall SSD was associated with a significantly reduced incidence of VAP (relative 
risk 0.54, 95 % confidence interval 0.40–0.74). However, interestingly, subgroup 
analysis demonstrated no significant differences in late onset VAP, ICU mortality, 
hospital mortality, or ICU length of stay. These secondary outcome measures were 
however analysed with the inclusion of all twenty studies (including high-bias 
studies), furthermore specific outcomes were only available in certain studies, 
introducing further potential bias.  
 
1.1.3 The subglottic region and VAP development  
The anatomical and clinical definitions of the laryngeal sub-sites vary in the literature, 
however the most commonly used definition of the subglottis is from the inferior 
arcuate line of the vocal folds to the lower boarder of the cricoid cartilage (26). The 
subglottis is the region immediately above the tracheal tube cuff in intubated patients. 
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Despite the fact that almost all studies implicate the subglottis in VAP development 
and identify SSD as an effective intervention to prevent VAP, very little is known 
about specifically how this part of the airway contributes to the pathophysiology of 
VAP (1, 14, 15, 24). SSD involves the use of specially designed tracheal tubes that 
have an additional port to allow aspiration of subglottic secretions by clinical staff. It 
is hypothesised that this reduces the burden of infected secretions above the 
endotracheal tube cuff, reducing the reservoir of pathogenic organisms for aspiration 
(14). Recent meta-analyses of large-scale trials have demonstrated that SSD use is 
associated with lower VAP rates (27, 28). However, these reviews were unable to 
demonstrate a reduction in the duration of mechanical ventilation, length of ICU stay, 
antibiotic usage or importantly mortality (27). There are also concerns regarding 
mucosal injury and subsequent negative outcomes with SSD, that require further 
investigation (28). It is likely that the limitations of VAP interventions are due to a 
lack of understanding of VAP pathophysiology, in particular the role of the subglottis 
and important host defences in this region. Given that the subglottic region is a 
respiratory epithelial sub-site, host defences are primarily the mucus layer, 
mucociliary clearance and resident and recruited immune cells (29).  
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Figure 1.1 - Diagram of endotracheal tube placement. 
Adapted from The tracheal tube: gateway to ventilator-associated pneumonia 
Zolfaghari et al 2011 (14). 
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Figure 1.2 - The pathogenesis of VAP development.  
Adapted from The tracheal tube: gateway to ventilator-associated pneumonia 
Zolfaghari et al 2011 (14). 
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1.2 Innate immunity  
1.2.1 Innate immunity overview 
The normal host defence response has been artificially divided into innate (non-
specific) and adaptive (specific) immune responses. The innate immune system is an 
evolutionarily ancient part of the host defence mechanism (30). Its role is to protect 
the host from insults related to microbes or chemicals. It consists of structural 
defences, such as epithelial mucosal membranes, antimicrobial molecules, the 
complement system, as well as immune cells. These include neutrophils, monocytes, 
macrophages, eosinophils, mast cells, and natural killer cells (31).  
 
1.2.2 Innate immunity in critical illness and VAP 
Critical illness usually constitutes an acute illness or injury resulting in organ 
dysfunction and failure (32). Critically ill patients have a higher rate of hospital-
acquired infection than other patient groups (10, 33). VAP is the most commonly fatal 
infection in critical illness (3, 5, 6). Various factors may contribute to this increased 
risk of infection, including the underlying illness (34). The high prevalence of 
secondary infections across all critical illness suggests a common underlying immune 
cause. Innate immune cells typically drive the initial inflammatory response to critical 
illness; these cells include principally neutrophils, monocytes, and macrophages (32, 
35, 36). It is this initial inflammatory response that is responsible for many of the 
pathophysiologic features of critical illness (32). There is however also a 
compensatory anti-inflammatory response, including the amplification of anti-
inflammatory mediators and impairment of innate immune cell function (35, 37, 38). 
In severe cases this can lead to immunoparalysis and markedly increased risks of 
secondary infection and death in the ICU. This immune suppression has been best 
described in sepsis, but can be present in any state of critical illness found in an ICU 
(39-41). The mechanism by which this immune suppression leads to infection and 
death is poorly understood. However, immune suppression has been demonstrated in 
most innate immune cell types in critical illness, including neutrophils, monocytes, 
macrophages and dendritic cells (41-44). 
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1.2.3 Innate immunity in tracheal intubation 
There is limited understanding about the direct impact of tracheal intubation on local 
innate immunity in the airway. Animal models have previously demonstrated 
reduction of mucociliary clearance and an increase in local inflammation with tracheal 
intubation (45-49). It has previously been demonstrated that even short-term (median 
time 3 hours) tracheal intubation can result in significant tracheal mucosal 
inflammation in humans, with a significant migration of neutrophils, rise in cytokines 
interleukin (IL)-6 and IL-1β, and a significant increase in C5a concentration in a 
longitudinal theatre patient cohort (50).  
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1.3 Neutrophils  
1.3.1 Neutrophil overview 
Neutrophils are polymorphonuclear leukocytes that represent 50 – 70% of blood 
circulating leukocytes in humans (51). Neutrophils play a key role in acute 
inflammation and infection and are crucial to the clearance of bacterial and fungal 
pathogens (52, 53). This is best exemplified by the increased rate of infection in 
neutropenia or neutrophil dysfunction (54, 55). Neutrophil homeostasis requires not 
only a balance between production and destruction, but also margination, which refers 
to the prolonged transit of neutrophils through specific organs (56, 57). These 
marginalised pools are found in the spleen, liver and lung (56, 57). In physiological 
conditions, it is thought that neutrophils are mainly cleared from the circulation in the 
liver, spleen and bone marrow (58). 
Inflammation can lead to rapid shifts in the location of these circulating and 
marginalised neutrophils (58). At inflammatory sites within tissues, bacterial-derived 
(such as lipopolysaccharide (LPS)) and host-produced (such as IL-1β, C5a and IL-8) 
inflammatory molecules are abundant (58). These compounds are detected by 
neutrophil surface receptors, via endothelial cell signalling, and allow neutrophils to 
migrate from the systemic circulation to the site of inflammation. This process is 
broadly called chemotaxis. Neutrophils are traditionally considered short lived with a 
circulating half-life of 6 – 8 hours. However during inflammation neutrophils become 
activated by various cytokines, growth factors and bacterial products, and their 
longevity can increase several fold (58, 59). 
 
1.3.2 Neutrophils and the clearance of pathogens   
Neutrophils can eliminate pathogens by both intra- and extracellular means (58). 
Their killing mechanism can be broadly divided into three groups; pathogen 
phagocytosis, degranulation and neutrophil extracellular traps (NETs) (Figure 3) (58). 
Phagocytosis involves the direct encapsulation of a pathogen in a phagosome. The 
pathogen is then killed through nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH) oxidase-dependent mechanisms. NADPH oxidase generates superoxide, 
which forms hydrogen peroxide, and ultimately reactive oxygen species (ROS) (53). 
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Neutrophils are also able to generate antibacterial proteins, including cathepsins, 
defensins, lactoferrin and lysozyme (53). The antibacterial proteins are released from 
the neutrophil granules into either phagosomes or the extracellular space (53). NETs 
are composed of DNA, histones, proteins and enzymes (such as neutrophil elastase), 
which are released from neutrophil granules. NETs are through to immobilise 
pathogens, facilitating subsequent phagocytosis of trapped microorganisms (60, 61). 
They are also thought to directly kill pathogens by means of antimicrobial histones 
and proteases (60, 61). 
While neutrophils are primarily responsible for the acute phase of inflammation, they 
also have a role in modifying the overall immune response (both innate and adaptive). 
This is achieved by communication with other immune cells (such as macrophages 
and dendritic cells) via direct cell-cell contact and release of mediators such as 
chemokines and cytokines (62). 
Through the anti-microbial properties described, neutrophils are highly inflammatory 
and destructive cells and this raises the potential for neutrophils to cause damage to 
healthy tissues. This occurs through the release of pro-inflammatory cytokines and 
proteases, such as neutrophil elastase (52, 53, 63-67). This damage is evident in many 
inflammatory airway diseases, such as acute respiratory distress syndrome, cystic 
fibrosis (CF), asthma, chronic obstructive pulmonary disease (COPD) and 
bronchiectasis (63, 68-71).  
 
1.3.3 Neutrophils in critical illness  
The neutrophil is the key innate immune cell involved in the clearance of bacterial 
pathogens, which are often responsible for secondary infection in critical illness (52, 
53). Conversely, organ dysfunction in critical illness is driven, to a large part, by 
neutrophils (72). Neutrophils from critically ill patients demonstrate an activated 
phenotype, with enhanced release of proteolytic enzymes and impaired transmigration 
and chemotaxis (72, 73). This hyper inflammatory state is however paralleled by 
profound neutrophil dysfunction in key roles, such as phagocytosis of pathogens (41, 
42, 72, 73). A number of mechanisms of dysfunction have been hypothesised in 
critical illness. One of the best-described mechanisms of neutrophil dysfunction is the 
role of the anaphylatoxin C5a (39-41). C5a is derived from complement C5 and 
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released in large quantities in critical illness (74, 75). It has previously been proposed 
that high levels of C5a may inhibit RhoA activation, preventing actin polymerisation 
and phagocytosis by systemic neutrophils in critical illness (39-41). The authors were 
however unable to identify any underlying mechanism responsible for the 
demonstrated dysfunction of airway mucosa neutrophils.  
 
1.3.4 Neutrophil-mucus interactions  
In health, the number of neutrophils in airway mucus membranes is relatively small 
(58). During inflammation, neutrophils are rapidly recruited from the systemic 
circulation to the epithelium due to a chemoattractant gradient (58). At this stage, the 
interactions between neutrophils and mucus membranes are crucial to the appropriate 
function of both these parts of the innate immune system. A number of respiratory 
diseases demonstrate corresponding mucus hyperviscosity, neutrophil accumulation 
and tissue damage, most evidently demonstrated in CF disease progression (63). Little 
is known, however, about the interaction between these two key pillars of innate 
immunity, mucus and neutrophils. It has previously been suggested in one in vitro 
study that viscous mucus, with high mucin concentrations, may adversely affect 
neutrophils’ ability to migrate and kill bacteria (76). 
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Figure 1.3 - Neutrophil killing mechanisms. 
Adapted from Neutrophil recruitment and function in health and inflammation 
Kolaczkowska et al 2013 (58). 
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1.4 Airway mucus and mucins 
1.4.1 Mucus and mucins overview 
Airway epithelial cells are continually exposed to pathogens, toxins and particulate 
matter (77, 78). A crucial early host defence against these challenges is mucus, which 
covers all epithelial linings, including the respiratory tract (79-81).  
Mucus consists mainly mucin, which are large molecular weight biopolymers, and 
water (77, 81). Furthermore, mucus contains a multitude of other constituents, such as 
DNA, lipids, ions, proteins, cells and cellular debris (77, 81). Its physical behaviour is 
complex (non-Newtonian), with highly variable properties that are best described as 
representing those of a viscous liquid and an elastic solid (81). Changes in the 
rheological properties of mucus may greatly affect its ability to function as a 
lubricant, selective barrier, and the body’s first line of defence against infection (81).  
Mucins are a family of high molecular weight (2–20 x 105 Da) glycoproteins with a 
high carbohydrate content (50 - 90% by weight) (77). Airway mucins are secreted by 
both goblet cells and the seromucinous glands of the lamina propria at the apical 
epithelium (82). Once mucins are produced they are stored in secretory granules 
within the epithelium ready for release onto the apical surface in response to mucin 
secretagogues (in the case of secreted mucins) or integrated into the membrane (in the 
case of membrane-tethered mucins) (82). More than 20 mucins are described, 
however only a subset occurs in the airway, MUC1, MUC4 and MUC13, which are 
membrane bound, and MUC2, MUC5AC, MUC5B, MUC7 and MUC19, which are 
secreted (83). By far the most predominant secreted (and gel-forming) mucins within 
the airway are MUC5AC and MUC5B (77, 84).  
Mucin molecules contain a MUC protein backbone (encoded by the MUC gene) that 
has a high number of tandem repeats, a characteristic that distinguishes mucins from 
other glycoproteins (77, 85). The specific number of tandem repeats in turn 
distinguishes different mucin molecules. This area also provides numerous sites for 
glycosylation, resulting in the high carbohydrate content of mucins (79). Most mucin 
glycoproteins also have a high sialic acid and sulphate content, which leads to a 
strongly negatively charged surface that increases the rigidity of the polymer via 
charge repulsion (Figure 4) (81).  
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1.4.2 Secreted mucins in airway disease 
In health, mucus is a key constituent of the innate immune system (77, 78). The 
physical properties of mucus, attributed primarily to mucins, produce a chemical 
barrier against harmful agents, protecting the airway epithelium beneath (78, 79, 84, 
86). Mucus is able to trap particulate matter and infectious agents (78, 79). These 
trapped particles are then cleared by ciliary movement that propels the mucus up to 
the oropharynx for swallowing, or expectoration, allowing clearance from the airway 
(78, 79).  
Airway inflammatory factors, including bacterial-derived (such as LPS), and host-
derived (such as tumour necrosis factor-α, IL-1β, IL-6, IL-13, IL-17, C3a and 
neutrophil elastase) and environmental factors (such as cigarette smoke and allergens) 
have all been shown to stimulate hypersecretion of various mucins (87, 88). Acute 
challenges to the respiratory tract will induce rapid release of mucin granules and 
mucin hypersecretion. More sustained challenge will result in increased expression of 
the MUC gene and increased glycosyltransferase activity and gene expression. In 
chronic diseases, such as asthma and COPD, this persistent mucin stimulation leads to 
goblet and glandular cell hyperplasia and persistent over-secretion (77). Acute mucin 
hypersecretion is thought to be a protective mechanism, however it is poorly 
understood on a molecular level. Prolonged mucin hypersecretion has been implicated 
in many respiratory disease processes, such as asthma, COPD and CF, through small 
airway obstruction and poor pulmonary clearance of pathogens, due to hyperviscous 
mucus (77, 78, 88). Additionally, in response to acute and chronic stimulation, mucins 
are not only over produced, but also tend to undergo further sulphation and 
glycosylation, resulting in further increased mucus viscosity (77, 79, 82, 89). 
It has previously been suggested that mucins may play more than a passive role in 
pathogen propagation in the airway. Mucins have been implicated in aiding bacterial 
biofilm formation through acting as binding sites for pathogens, (90-92). Furthermore, 
previous studies have proposed that VAP-causing bacteria, such as P aeruginosa, may 
have mucin sulphatase activity, allowing them to overcome mucins’ repulsive forces 
(89, 93). This would potentially allow bacteria to expose the mucin carbohydrate and 
protein cores to bacterial glycosidases and proteinases. It is hypothesised that this 
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could then lead to mucins being digested by bacterial pathogens, potentially 
promoting bacterial growth (89, 93-95). 
 
1.4.3 Secreted mucins in VAP development 
Despite the increasing focus on mucins in a multitude of airway diseases, very little is 
known about mucin in VAP development. One study has previously investigated the 
lower airway mucin concentrations in patients with VAP, intubated ICU patients and 
a cohort of healthy controls (96). The authors demonstrated that patients with VAP 
had eight-fold higher mucin concentrations in lower airway lavages, compared with 
healthy outpatient bronchoscopy controls. No significant difference was found 
between the intubated ICU patients and outpatient controls. The study was well 
designed and included reasonably large patients cohorts. Unfortunately no correction 
was made for the lavage samples dilution factor (97). Therefore direct correlation of 
absolute mucin values with other studies is not possible. The importance of mucins in 
the subglottic region and in further VAP development is unknown. 
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Figure 1.4 - Diagram representing a secretory mucin glycoprotein.  
The tandem repeat domains are depicted in yellow and may be of varying length. 
Adapted from Rose et al, 2006 (77). 
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1.5 Models of VAP development 
1.5.1 Animal models 
A number of animal models of tracheal tube placement, ventilation and VAP 
development have been described, these include murine, porcine, primate, dog and cat 
models (98-105). These models have studied the local impacts of intubation on 
mucociliary clearance and innate immunity (45-49), of ventilation on the lungs (106, 
107) and of instillation of pathogens in the ventilated airway, as a model of VAP 
(108-111). Pig models in particular are able to best approximate the human airway 
physiology, however mice have also been extensively used due to their size and 
practicality (100, 112). The obvious strength of animal models is that they allow 
whole body in vivo study of disease pathogenesis, or the evaluation of novel 
therapeutic strategies (100, 113). These investigations or interventions would, in many 
cases, not be technically or ethically possible in humans. There are, however, a 
number of limitations to animal models, including important inter-species differences 
in innate immunity, the need for different ventilation and anaesthetic techniques from 
humans, and the absence of co-morbidities, common in VAP patients (108-111). 
Furthermore there are limited antibodies designed for animal testing, for examples 
inflammatory cytokines or mucins, restricting experimental use of many particularly 
non-murine animals. There are also the additional costs associated with animal 
husbandry, chiefly with larger animals such as pigs or primates (108-111). 
 
1.5.2 in vitro models  
The airway epithelium is the first line of defence against potentially pathogenic 
microorganisms. Its importance goes far beyond its role as a barrier and it is an 
important component of the innate immune system, initiating signalling to activate 
and recruit immune cells to the airways (114-116). It has been possible to culture 
human airway epithelial cells in vitro for a number of decades (117). Human primary 
cell cultures and immortalised cell lines have been established from respiratory 
epithelial sub-sites, including the trachea and small airways of the lung (118-120). 
Cells may be cultured under submerged conditions on plastic petri dishes or flasks, 
however these assume a poorly differentiated phenotype (121). Advanced culture 
techniques, such as an air-liquid interface culture system (Figure 5), where cells are 
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cultured on semi-permeable supports, enable cellular polarisation and a cell phenotype 
which more closely recapitulates that of the normal in vivo airway (121). The 
limitation of these models is the lack of a whole body system; conversely they do 
utilise relevant, human-derived tissue that should better represent human responses to 
stimuli or interventions (121). 
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Figure 1.5 - Graphical depiction of submerged cultures and air-liquid interface 
(ALI) cultures.  
Epithelial cells are initially cultured in submerged conditions (A) prior to the apical 
fluid being removed (B). In these air-liquid interface (ALI) conditions the respiratory 
epithelial cells will often differentiate into a pseudo-stratified respiratory epithelium. 
Adapted from Lee et al 2016 (122). 
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1.6 Hypothesis  
That the tracheal tube induces local deregulation of subglottic host defences, resulting 
in detrimental microbiological shifts within the mucus layer:  
To address this hypothesis my PhD was divided into the following areas of study: 
1. Microbiology of mucus derived from the subglottis. 
2. Subglottic mucosal host defences. 
3. The effect of mucin on neutrophil function and epithelial-pathogen 
interactions. 
4. Development of subglottic epithelial cell cultures. 
 
 
	
	
	
	
	
	
  
Jason Powell  Chapter 2  
 
   22 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Materials and methods 
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2.1 Recruitment  
2.1.1 Intensive care unit patients  
Intensive care unit (ICU) study participants were identified through screening of 
inpatients in the Newcastle upon Tyne Hospitals ICUs from November 2016 – May 
2017. Patients who met the inclusion criteria (Table 2.2) and were likely to be 
intubated and mechanically ventilated for 4 or more days were identified. Agreement 
to approach the family/next of kin was obtained from the patient’s clinical team. The 
study research nurse approached the family/next of kin initially. Family members 
were given at least 24 hours to consider the patient information sheet (PIS) prior to 
consent being taken by me. Sampling was then performed, usually within 24 hours of 
consent being given. Clinical and demographic details were collected by the research 
nurse, who also recorded the patient’s subsequent clinical course. A letter was sent to 
the patient’s general practitioner (GP) informing him/her about the patient’s 
participation in the study. 
 
2.1.2 Theatre attenders  
Patients listed for upper airway examination under general anaesthesia were screened 
for inclusion in the study after being listed at the Department of Otolaryngology-Head 
and Neck Surgery, Freeman Hospital, Newcastle upon Tyne. This cohort was a 
control group to the ICU patients for mucus sampling and epithelial brushings (Table 
2.1). Patients were approached if they were having a planned laryngeal examination in 
theatre under general anaesthesia. Patients who met the inclusion criteria (Table 2.3) 
were identified through theatre booking lists and screening of clinic letters. Potentially 
eligible patients were those deemed unlikely to have structural laryngeal 
abnormalities and who had no history of upper aerodigestive tract malignancy. 
Recruitment packs were sent by post, including a patient invitation letter and PIS. 
Patients had at least two days prior to their theatre attendance to consider participation 
in the study. Patients were approached on the day of theatre attendance and consented 
by me. Demographic details were collected, including age, sex, medication use and 
co-morbidities. A letter was sent to the patient’s GP informing him/her about the 
patient’s participation in the study.  
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2.1.3 Healthy volunteers 
Healthy volunteers with no personal history of autoimmunity, infection or other 
significant medical conditions (Table 2.4) were recruited from Newcastle University 
(staff and students) and the general population through flyer advertisements. 
Demographic details (age and gender) were again collected. This cohort was a control 
group to the ICU blood samples (Table 2.1). A separate group of healthy volunteers 
was also recruited to provide blood in order to generate healthy neutrophils for in 
vitro experiments. 
 
2.1.4 Ethical approval and consent 
The subglottic samples collected from theatre attenders came from one of two 
Research Ethics Committee (REC) approvals. The first submission was approved by 
the South East Scotland 01 REC, reference number 14/SS/1015, based on an 
application submitted by Professor Janet Wilson and I. A further submission approved 
by the West Midlands REC, reference number 15/WM/0349, based on a further 
application submitted by Professor Janet Wilson and I. Ethical approval was obtained 
for the collection of samples from incapacitated ICU subjects from the Newcastle and 
North Tyneside 2 REC, reference number 15/NE/0323, based on an application by Dr 
Stephen Wright and I. Healthy volunteers’ blood samples were used based on an 
approval from the County Durham & Tees Valley REC, reference number 
12/NE/0121 (principal investigator Professor John Simpson). All submissions were 
also approved by the Research and Development Department of the Newcastle upon 
Tyne Hospitals NHS Foundation Trust. Ethical approval forms and associated 
documents are listed in Appendix B. Inclusion and exclusion criteria for all cohorts 
are listed in Tables 2.2, 2.3 and 2.4. 
Consent was obtained from participants prior to sampling in the theatre attender and 
blood volunteer cohorts. Personal consultee consent was obtained from the next of kin 
or a family member in the ICU cohort due to loss of capacity of the person being 
sampled. Retrospective consent was taken from the sampled patient in cases where 
capacity was regained. 
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Table 2.1 - Sampling approvals in place for each of the three study cohorts 
 
 
 
 
 
 
 
 
Group Blood samples Mucus aspirates Epithelial brushings 
ICU patients ✔ ✔ ✔ 
Theatre attenders 
(controls) 
✖ ✔ ✔ 
Healthy blood 
volunteers 
(controls) 
✔ ✖ ✖ 
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Inclusion criteria Exclusion criteria 
Age 18+ years of age 
 
Known current or previous malignancy of the 
subglottic region 
Participant expected to be intubated 
and mechanically ventilated for 4 or 
more days on the ICUs within the 
Newcastle upon Tyne Hospitals 
NHS Foundation Trust  
Known current or previous radiotherapy to the 
subglottic region 
 
 Patients who the clinical team judge would not 
tolerate the procedure (i.e. delirium)  
No personal legal representative (i.e. 
relative/friend/carers) to give consent 
PaO2<8kPa on FiO2>0.7 
Positive end-expiratory pressure >15cmH2O 
Peak airway pressure >30 cmH2O 
Heart rate >140 bpm 
Mean arterial pressure <60mmHg 
Bleeding diathesis (including platelet count 
<20x109 per litre of blood or Prothrombin time or 
activated partial thromboplastin time greater than 
1.5 time the reference range) 
Poorly controlled intracranial pressure 
(>20mmHg), if measured 
ICU consultant deems procedure not to be safe 
Allergic to local anaesthetic agents 
 
Table 2.2 – ICU cohort inclusion and exclusion criteria 
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Inclusion criteria Exclusion criteria 
Age 18+ years of age 
 
Known current or previous malignancy of the 
upper aerodigestive tract. 
 
Having a planned laryngeal 
examination under general anaesthetic 
 
Known current or previous chemo-radiotherapy 
of the upper aerodigestive tract.  
 
Laryngeal mucosal appearances at both 
clinic appointment and general 
anaesthetic examination demonstrate 
no clinically apparent malignancy 
(variations of normal such as mild 
injection or benign looking cysts will 
be allowed).  
 
Any patient in whom such an increase in GA 
duration of 10 to 15 minutes is deemed in 
appropriate by the anaesthetist for whatever 
reason 
 
 
Table 2.3 – Theatre attender controls inclusion and exclusion criteria 
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Inclusion criteria Exclusion criteria 
Age 18+ years of age 
 
Donated blood (e.g. to the Blood Transfusion 
Service or to research studies) in the previous 90 
days. 
 Donated >1 litre of blood in the previous year 
(this equates to around 3 donations to the Blood 
Transfusion Service in the past year). 
Anaemia in the past year. 
Taking any regular, prescribed medication (the 
oral contraceptive pill is permissible in female 
participants). 
 
Table 2.4 – Healthy blood volunteers inclusion and exclusion criteria 
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2.2 Collection of subglottic mucus samples 
2.2.1 Subglottic mucus sampling  
Subglottic mucus aspirates were collected from ICU patients either 1) directly from 
the subglottic suction drain (SSD) attached to the endotracheal (ET) cuff, or 2) if a 
SSD was not in place mucus was collected directly from the subglottic region, via a 
bronchoscope, at the time of epithelial brushing. In both cases samples were trapped 
in a sterile system using a mucus trap (MST-3000, Pennine Healthcare, Derby, UK). 
Subglottic mucus aspirates were collected from theatre attenders (controls), via a 
sterile theatre suction catheter and mucus trap, at the time of epithelial brushing. In all 
cases the mucus sample was immediately placed in a cooled container and transported 
to the laboratory for processing (transit time less than 30 minutes). 
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2.3 Microbiological assessment of subglottic mucus samples 
2.3.1 Mucus sampling and processing for microbiological assessment 
Mucus samples were aseptically collected as described in section 2.2.1. In both the 
ICU and theatre attender cohorts a sterile microbiology swab (MW172P, Medical 
Wire & Equipment, Swindon, UK) was immersed in the mucus immediately after 
collection, rotated 5 - 10 times, and sheathed.   
 
2.3.2 Semi-quantitative microbiology culture 
Semi-quantitative microbiology culture was performed by Professor John Perry, 
Department of Microbiology, Freeman Hospital, following protocols based on 
standard NHS culture techniques. In brief, samples were mixed with 5 mL 0.1% DTT 
solution and incubated for 30 minutes at room temperature, with repeated vortexing. 
Serial dilutions were then performed in 0.85% saline. Samples were then plated onto 
the following media and cultured at 37°C for 48 hours: 
1) Chocolate agar incubated in air plus 5% CO2. This allows growth of the vast 
majority of aerobic and capnophilic bacteria. 
2) Fastidious anaerobe agar incubated anaerobically.  This allows growth of the 
majority of anaerobic bacteria. 
3) Sabouraud agar incubated in air.  This allows growth of the majority of yeasts or 
fungi likely to be encountered. 
All different colony types were then quantified and identified using matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). 
 
2.3.3 Bacterial and fungal DNA isolation and gene profiling  
DNA extraction  
Microbiology swab samples were placed in a cold tissue transportation container and 
transported immediately to the laboratory for storage in a -80°C freezer. Not more 
than 6 months later samples were defrosted fully and processed using a PowerLyzer 
PowerSoil DNA Isolation Kit (Mo Bio laboratories, CA, USA). The swab was 
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vigorously vortexed with bead solution (Mo Bio laboratories, CA, USA) to extract the 
sample from the swab and then the solution was placed in glass bead tubes (Mo Bio 
laboratories, CA, USA). Samples were then processed according the manufacturer’s 
instructions. A NanoDrop 1000 spectrophotometer (Thermofisher, MA, USA) was 
used to quantify DNA yield and purity. 1 µL of each sample was loaded onto the 
spectrophotometer, zeroed against the DNA diluent (ultra pure water). Measurement 
of absorbance was taken at 260 nm to estimate DNA yield and ratios of 260/280 nm 
and 260/230 nm to estimate levels of contamination. Extracted DNA was then stored 
in a -80°C freezer for later analysis.  
16S rRNA bacterial and ITS fungal profiling  
Dr Andrew Nelson at NU-OMICS, Northumbria University, performed the bacterial 
and fungal profiling and community analysis. In brief, polymerase chain reaction 
(PCR) amplification of the V4 region of the bacterial 16S rRNA gene was performed 
with primers targeting the region as previously described (123). Fungal communities 
were amplified with primers targeting the internal transcribed spacer (ITS) 1 region as 
described previously (124). Libraries were normalised using the Sequel normalisation 
kit (Invitrogen, CA, USA) and quantified using KAPA Library Quantification Kits for 
NGS (KAPA Biosystems, MA, USA). The libraries were sequenced using a V3 600 
cycle kit on the MiSeq system (Illumina, CA, USA). 
Bacterial community analysis 
Fastq files generated for bacterial communities were trimmed to 250bp using 
Cutadapt before being processed in Mothur according to the MiSeq SOP (123, 125). 
Paired reads were merged using the make.contigs command and processed to remove 
sequences containing ambiguous bases, homopolymers >8bp and sequences with a 
length >275bp. Sequences were aligned to the SILVA database and chimeras were 
removed using the vsearch algorithm. The remaining sequences were classified using 
the RDP database and sequences not identified as bacteria were removed from the 
downstream analysis. Operational taxonomic units (OTUs) present in PCR negative 
controls were removed using the remove.otulabels command and the positive control 
was removed using the remove groups command. Reads were normalised by 
subsampling to 1000 reads per sample, which resulted in exclusion of samples with 
low coverage.  
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Fungal community analysis  
Fungal fastq files were trimmed to remove adapter sequences using cutadapt from 5’ 
and 3’ ends of the sequence before being processed using Mothur (125). Paired reads 
were assembled using the make.contigs command with trimoverlap set to true. Reads 
were quality filtered to remove sequences with ambiguous bases and homopolymers 
>8bp. Chimeric sequences were removed using vsearch and a distance matrix 
generated using the dist.seqs command to allow for varied sequence length. 
Sequences were classified against the UNITE database (126). Reads were normalised 
by subsampling to 100 reads per sample, which resulted in exclusion of samples with 
low coverage.  
 
Statistical analysis 
Subsampled BIOM files were imported into the phyloseq package which was used to 
generate diversity box plots and nonmetric multidimensional scaling (NMDS) 
analysis using Bray-Curtis distances (127). Bar plots of proportional taxa abundance 
and Kruskal-Wallis tests for difference between groups were performed as described 
previously (128). All P values were adjusted for multiple comparisons with the false 
discovery rate algorithm as previously described (129). 
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2.4 Extraction and processing of subglottic mucus-derived leukocytes 
2.4.1 Extraction of subglottic mucus-derived leukocytes 
Extraction of mucus derived leukocytes was performed using methods adapted from 
those previously described (130). All procedures were performed in a class II laminar 
flow cabinet. A proportion of the mucus sample was aliquoted into 2 mL 
microcentrifuge tubes (Sigma-Aldrich, Dorset, UK) and immediately placed in a -
80°C freezer for later analysis. The remaining mucus was used for leukocyte 
extraction and quantification. This sample was mixed with 0.08% dithiothreitol (DTT) 
Sputolysin Reagent (Merck Millipore, MA, USA) in phosphate-buffered saline (PBS, 
Sigma-Aldrich, Dorset, UK), and gently agitated for 5 minutes at room temperature, 
followed by further dilution in an equal volume of PBS. The mucus was then filtered 
through a wet 30-micron filter (Miltenyi Biotec, Surrey, UK) and centrifuged (300g, 
at 10°C for 10 minutes).  
 
2.4.2 Differential cell count  
The pellet was re-suspended in 0.5 mL PBS. 10 µL of this suspension was then mixed 
with 5 µL of 0.4% Trypan Blue solution (Sigma-Aldrich, Dorset, UK). Cells were 
then counted using a light microscope using four quadrants of a haemocytometer 
(Sigma-Aldrich, Dorset, UK). Live cells were visualised through exclusion of Trypan 
Blue. An average number of leukocytes, both alive and dead, was thereby ascertained 
in each sample. 
 
2.4.3 Cytospin preparation  
The cell pellet was re-suspended in PBS. The final volume was adjusted to give a 
concentration of 0.5 million cells/mL. Cytospins were prepared on glass slides using 
100 µL aliquots and then spun at 300 rpm for 3 minutes (Cytospin 3, Shandon, 
London, UK). The cytospins were then fixed in acetone (Sigma-Aldrich, Dorset, UK) 
at room temperature for 10 minutes and air-dried. Slides were finally treated with 
10% Giemsa stain (Sigma-Aldrich, Dorset, UK) for 10 minutes, rinsed in distilled 
water and air-dried. Slides were counted by an expert pathology technician (Kasim 
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Jiwa, William Leech Lab, Freeman Hospital, Newcastle upon Tyne, UK) under a light 
microscope to elicit an average number of each cell type. 
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2.5 Collection and extraction of whole blood-derived leukocytes 
2.5.1 Blood sampling 
Whole blood samples were collected from ICU patients by aspiration from a central 
arterial or venous line already in situ. Aseptically, 10 mL of whole blood was 
aspirated and discarded. Then 36 mL of whole blood was aspirated and placed in a 50 
mL centrifuge tube (Corning, NY, USA) with 4 mL citrate solution (Sigma-Aldrich, 
Dorset, UK), for immediate transportation to the laboratory. In the case of healthy 
volunteers, blood samples were aseptically taken via venepuncture of a peripheral 
vein and placed in a 50 mL centrifuge tube with 1 mL of citrate solution per 10 mL of 
blood, for immediate transportation to the laboratory.  
 
2.5.2 Extraction of whole blood-derived leukocytes 
All procedures were performed in a class II laminar flow cabinet. The whole blood-
citrate mix was initially centrifuged at 300g for 20 minutes at room temperature. The 
platelet rich plasma was then removed to leave a cell pellet. The plasma was aliquoted 
into 2 mL microcentrifuge tubes and immediately stored in a -80°C freezer for later 
analysis. Serum was prepared by adding 220 µL of 1 M CaCl2 solution (Sigma-
Aldrich, Dorset, UK) per 10 mL of plasma and incubated in a 37°C water bath for 30 
– 60 minutes. The cell pellet was then dextran-sedimented by addition of 2.5 mL of 
37°C 6% dextran (Pharmacosmos, Holbæk, Denmark) per 10 mL of cell pellet. The 
total volume was made up to 40 mL with 37°C 0.9% NaCl saline (Sigma-Aldrich, 
Dorset, UK). The tube was mixed and allowed to sediment for 30 minutes at room 
temperature, leaving a leukocyte rich upper layer that was collected. 
 
2.5.3 Differential cell count and cytospin preparation 
Purity was confirmed via differential cell count of leukocytes with Trypan Blue 
exclusion and cytospin preparation as described in section 2.4.3/2.4.4.  
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2.6 Functional studies of subglottic mucus and whole blood-derived neutrophils 
2.6.1 pHrodo S. aureus bioparticle assay 
Measurement of neutrophil phagocytosis was performed using methods adapted from 
those previously described (131). Stock pHrodo® Green S. aureus Bioparticles® 
(Thermofisher, MA, USA) at 1 mg/mL were opsonised by incubation at a 1:10 
dilution in 50% Iscove's Modified Dulbecco's Medium (IMDM, Thermofisher, MA, 
USA) / 50% serum for 30 minutes at 37°C in a shaking water bath, in the dark. Mixed 
leukocytes (50 µL, fresh from extraction, at 0.5 - 1 million cells per mL in IMDM) 
were then incubated with 5 µL of opsonised bioparticles in 2 mL round bottom 
microcentrifuge tubes for 90 minutes, in the dark. For each condition or sample three 
leukocyte tubes were prepared; a tube with particles incubated in a water bath at 37oC, 
a control tube without bioparticles, and a second control tube with bioparticles kept on 
ice during the incubation. For the final 30 minutes of incubation all tubes were stained 
with a neutrophil marker (Pacific blue-conjugated anti-CD66b antibody) together with 
a viability marker (Near-IR Dead Cell Stain Kit) (Table 2.5). Mixed leukocytes were 
then washed using flow cytometry buffer (PBS containing 1% bovine serum albumin 
(BSA)) and centrifuged at 200g for 5 minutes, twice. Cell pellets were re-suspended 
in flow cytometry buffer at a final volume of 300 µL and data were acquired 
immediately on a calibrated FACSCanto II (Becton, Dickinson and Company (BD), 
NJ, USA) flow cytometer.  
 
2.6.2 Annexin V and propidium iodide assay 
Measurement of neutrophil viability and apoptosis was performed using an Annexin 
V and propidium iodide assay, utilising methods adapted from those previously 
described (132). Mixed leukocytes (50 µL, fresh from extraction, at 0.5 - 1 million 
cells per mL in Hank’s balanced salt solution without Ca2+ and Mg2+ (HBSS-)) were 
incubated for 30 minutes on ice with a neutrophil marker, Pacific blue-conjugated 
anti-CD66b antibody (Table 2.5). Mixed leukocytes were then washed as previously 
described and re-suspended in Annexin V buffer (Thermofisher, MA, USA) at a 
volume of 50 µL. Leukocytes were then incubated for 15 minutes on ice with 
Allophycocyanin (APC)-conjugated Annexin V and propidium iodide (Table 2.5). A 
control tube constituted unstained cells. Leukocytes were then re-suspended in 
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Annexin V buffer (Thermofisher, MA, USA) at a final volume of 300 µL. Data were 
acquired immediately on a calibrated FACSCanto II (BD, NJ, USA) flow cytometer. 
 
2.6.3 Surface marker expression 
Mixed leukocytes (50 µL, fresh from extraction, at 0.5 - 1 million cells per mL in 
HBSS-) were incubated for 30 minutes on ice with a panel of antibodies to cell 
surface markers: CD62L/CD66b/CD11b/CD88 (Table 2.5). Isotype controls were also 
prepared for each antibody (Biolegend, CA, USA). A viability marker, Near-IR Dead 
Cell Stain Kit, was also added to all samples. Mixed leukocytes were then washed as 
previously described and re-suspended in flow cytometry buffer at a final volume of 
300 µL. Data were acquired immediately on a calibrated FACSCanto II (BD, NJ, 
USA) flow cytometer. 
 
2.6.4 Flow cytometry analysis  
Initial gating strategy 
All data were analysed using FlowJo Version 8.7.1 (Treestar Inc., OR, USA). Cellular 
debris was excluded by its characteristic position on the forward and side scatter area. 
Dead cells were excluded by Near-IR Dead Cell Stain Kit, where positive uptake 
indicated cell death. Neutrophils were identified by positive staining with anti-CD66b 
antibody, relative to an isotype control (133). 
Phagocytosis gating 
Ingestion of pHrodo® Green S. aureus Bioparticles® by phagocytic cells was 
determined through cellular florescence measured at 509⁄533 nm excitation⁄emission 
on the flow cytometer. Control samples kept on ice were used to determine the gating 
threshold of background fluorescence. This allowed calculation of the percentage of 
cells involved in phagocytosis (by the percentage of positively fluorescent cells) 
(131). 
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Annexin V and propidium iodide gating 
Viable, necrotic, early and late apoptotic neutrophils were identified via gating four 
quadrants against APC Annexin V and propidium iodide fluorescence, as previously 
described (132). 
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Marker Fluorophore Clone Dilution 
factor 
Isotype control Company 
CD66b Pacific blue G10F5 1/10 Pacific Blue Mouse 
IgM, κ, Clone MM30 
Biolegend, 
CA, USA 
CD62L APC DREG-56 
 
1/5 APC Mouse IgG1, κ, 
clone MOPC-21 
Biolegend, 
CA, USA 
CD88 PE S5/1 1/5 PE Mouse IgG2a, κ,  
Clone MOPC-173 
Biolegend, 
CA, USA 
CD11b FITC CBRM1/5  1/10 FITC Mouse IgG1, κ, 
clone MOPC-21 
Biolegend, 
CA, USA 
Annexin V APC - 1/50 - Thermofisher, 
MA, USA 
Propidium 
iodide 
- - 1/500 - Thermofisher, 
MA, USA 
LIVE/DEAD
® Fixable 
Near-IR 
Dead Cell 
Stain Kit 
- - 1/500 - Thermofisher, 
MA, USA 
 
Table 2.5 - Fluorophore labelled antibodies used in flow cytometry experiments.  
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2.7 ELISAs, fluorometric assays and cytometric bead arrays  
2.7.1 MUC5AC indirect ELISA 
In a 96 well microtitre plate (Thermofisher, MA, USA) standard concentrations were 
prepared in duplicate (100 µL) using MUC5AC (in house purified pig gastric mucin) 
diluted in PBS in the range of 0 - 10 µg/mL. Samples were mixed in PBS to a dilution 
of 1/10 and 1/20 or higher, and 100 µL placed in wells, in duplicate, and allowed to 
absorb overnight. The following day, the plate wells were completely emptied and 
washed three times with PBS containing 0.05% Tween20 (Sigma-Aldrich, Dorset, 
UK). This wash process was repeated after every step. Unoccupied binding sites were 
blocked with 300 µL of 1% casein (Sigma-Aldrich, Dorset, UK) in PBS for 2 hours. 
Then 100 µL of primary monoclonal antibody for MUC5AC (45M1 mouse anti-
human MUC5AC (Abcam, MA, USA)), diluted 1/100 in antibody diluent (0.1% 
casein/0.05% Tween20 in PBS)) was added and incubated for 2 hours. 100 µL of 
secondary antibody was added and incubated for 2 hours (horseradish peroxidase-
conjugated goat anti-mouse (Dako, CA, USA), diluted 1/5000 with antibody diluent). 
Finally 100 µL of peroxidase substrate ABTS (2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid)) was added and the plate allowed to develop. Absorbance at 405 nm 
was measured after 5 - 10 minutes with a plate reader (M200, Infinite, Männedorf, 
Switzerland). Lower limit of detection 0.156 µg/mL. 
 
2.7.2 MUC5B indirect ELISA 
In a 96 well microtitre plate (Corning, NY, USA) standard concentrations were 
prepared in duplicate (100 µL) using MUC5B (in house purified human salivary 
mucin) diluted in PBS in the range of 0 - 5 µg/mL. Samples were diluted in PBS to a 
concentration of 1/2000 and 1/5000 or higher, and 100 µL placed in wells, in 
duplicate, and allowed to absorb overnight. The next day the plate wells were 
completely emptied and washed three times with PBS containing 0.05% Tween20. 
This wash process was repeated after every step. Unoccupied binding sites were 
blocked with 300 µL of 1% casein in PBS for 2 hours. 100 µL of primary monoclonal 
antibody for MUC5B (EPR6920, rabbit anti-human MUC5B (Abcam, MA, USA)), 
diluted 1/200 in antibody diluent (0.1% casein/0.05% Tween20 in PBS)) was added 
and incubated for 2 hours. 100 µL secondary antibody was then added and incubated 
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for 2 hours (horseradish peroxidase-conjugated goat anti-rabbit (Dako, CA, USA)), 
diluted 1/5000 with antibody diluent). Finally 100 µL of ABTS was added and the 
plate was left to develop. Absorbance at 405 nm was measured after 5 - 10 minutes 
with a plate reader (M200, Infinite, Männedorf, Switzerland). Lower limit of detection 
0.078 µg/mL. 
 
2.7.3 Human neutrophil elastase ELISA 
Human neutrophil elastase was measured in mucus (diluted 1/500 and 1/1000) using 
Human PMN Elastase ELISA (ab119553, Abcam, MA, USA) as per the 
manufacturer’s instructions. Lower limit of detection 1 ng/mL. 
 
2.7.4 MSD multiplexing technology 
Quantification of cytokines in plasma (diluted 1/2) and mucus supernatants (diluted 
1/100) was performed by Meso Scale Discovery (MSD) technology using the V-
PLEX Proinflammatory Panel 1 (human) kit (K15049D, Meso Scale Diagnostics, 
MD, USA), measuring interferon (IFN)-γ, interleukin (IL)-10, IL-12p70, IL-13, IL-
1β, IL-2, IL-4, IL-6, IL-8, Tumour necrosis factor (TNF)-α, according to the 
manufacturer’s instructions. Quantification of IL-8 in mucus supernatants (diluted 
1/10,000) was performed using a U-PLEX (Human) IL-8 Kit (K151TYK, Meso Scale 
Diagnostics, USA), according to the manufacturer’s instructions. Quantification of 
GM-CSF was measured in mucus supernatants (diluted 1/5) using a U-PLEX 
(Human) GM-CSF Kit (K151UMK, Meso Scale Diagnostics, USA), according to the 
manufacturer’s instructions. Lower limits of quantification were as follows; IL-8 0.15 
pg/mL, IL-6 1.58 pg/mL, IL-1β 2.14 pg/mL, IL-10 0.68 pg/mL, GM-CSF 0.12 
pg/mL. 
 
2.7.5 dsDNA quantification  
dsDNA was measured from mucus supernatants (diluted 1/10) using a Quant-iT 
dsDNA fluorometric assay kit (Q33120, Thermofisher, MA, USA) as per the 
manufacturer’s instructions. Lower limit of detection 0.2 ng/mL. 
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2.7.6 Complement quantification  
The Cytometric Bead Array (CBA) Human Anaphylatoxin Kit (561418, BD, NJ, 
USA) was utilised to quantify C4a, C3a, and C5a, and their desArg forms. 
Quantification was performed on plasma (diluted 1/100) and mucus supernatants 
(diluted 1/100) according to the manufacturer’s instructions. Analysis was performed 
on a calibrated FACSCanto II (BD Biosciences, USA) flow cytometer. Lower limit of 
detection 1.15 pg/mL. 
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2.8 Physical properties of subglottic mucus 
2.8.1 Dry weight  
The percentage dry weight of mucus was calculated by using a microbalance (Pioneer, 
OHAUS, Greifensee, Switzerland) to compare weight before and after drying the 
sample at 80°C overnight (134). 
 
2.8.2 Rheology   
Subglottic mucus was fully thawed and shear viscosity was rheologically analysed at 
37°C using a Kinexus Pro (Malvern Instruments, Worcester, UK) with 60 mm parallel 
plates, used according to the manufacturer’s instructions. A table of shear rates was 
produced over the range of 0 – 100 s-1. Analysis was performed on rSpace software 
(version 1.6, Malvern Instruments, Worcester, UK) (135). 
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2.9 Neutrophil functional assays with ICU-derived mucin 
2.9.1 Purification of ICU-derived subglottic mucus 
Caesium chloride equilibrium density gradient ultracentrifugation and dialysis. 
Subglottic mucus was collected from the ICU patient cohort, as described in section 
2.2.1. The methods used to isolate and purify mucin from mucus are based on 
methods previously described (136-139). The individual ICU mucus samples were 
defrosted, pooled and mixed with an equal volume of an enzyme inhibitor buffer 
cocktail (pH 6.7 with NaOH) (Table 2.6), to inhibit any proteolytic activity. The 
sample was extensively homogenised and centrifuged at 10,000g for 1 hour at 4 °C to 
remove any debris. The supernatant was adjusted to a density of 1.42 g/mL (± 0.005g) 
by the addition of solid caesium chloride (CsCl) (Sigma-Aldrich, Dorset, UK). 
Ultracentrifugation was then performed at 100,000g, for 48 hours, at 4°C (T-1170, 
Centricon, USA), to generate a CsCl gradient. Eight fractions were then recovered 
from the gradient and individually dialysed against distilled water extensively for 72 
hours. The proportion of DNA/protein in the fractions was calculated using the 
260/280 nm ratios on a spectrophotometer (8625 UV/VIS, Unicam, NJ, USA).  
Periodic Acid Schiff assay 
The fractions were then subjected to Periodic Acid Schiff assay to determine 
glycoprotein concentrations (135). Samples were diluted 1:20 and 1:40 with PBS. 
Porcine mucin (Sigma-Aldrich, Dorset, UK) was used as a standard. The fractions and 
mucin standards were plated, in duplicates (200 µL), onto a 96 well microtitre plate. 
20 µL of periodic/acetic acid solution (10 µL of 50% periodic acid solution (Sigma-
Aldrich, Dorset, UK) to 5 mL of 7% acetic acid solution (Sigma-Aldrich, Dorset, 
UK)) was added to each well and incubated at 37°C for 45 minutes. This was 
followed by addition of 20 µL of Schiff’s reagent (containing 17 mg/mL sodium 
metabisulphate (Sigma-Aldrich, Dorset, UK)). The reaction was allowed to develop 
for 30 minutes at room temperature. Readings were taken with a spectrophotometer 
read at 550 nm (8625 UV/VIS, Unicam, NJ, USA).  
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Lyophilisation 
The glycoprotein-rich, protein-low fractions were pooled and lyophilised for 72 hours 
using a vacuum freeze dryer (Shanghai Bilon Instrument, Shanghai, China). 
Remaining fractions were discarded. The fractions of purified solid 
MUC5B/MUC5AC were then stored at -20°C for later use. 
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Constituent Molar concentration (mM) 
KH2PO4 42 
NA2HPO42H2O 25 
α-anionohexanoic acid 100 
Ethylenediamine tetra-acetic acid 
(EDTA) 
10 
Lodoacetamide 1 
N-ethyl maleimide 10 
Benzamide HCL 5 
Phenylmethylsulfonyl fluoride 
(PMSF) (dissolved in 2 mL warm 
propan-2-ol) 
1 
 
Table 2.6 - Inhibitor buffer used to prevent mucus proteolytic activity (all 
supplied by Sigma-Aldrich, Dorset, UK) 
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2.9.2 Healthy volunteer blood-derived neutrophil collection and isolation  
Whole blood samples were collected from healthy volunteers as described in section 
2.5.1. All procedures were performed in a class II laminar flow cabinet. Neutrophils 
were isolated from whole blood by means of dextran sedimentation and fractionation 
over discontinuous Percoll gradients, as previously described (140, 141). The blood-
citrate mix was initially centrifuged at 300g for 20 minutes at room temperature. The 
platelet rich plasma was then removed to leave a cell pellet. Serum was prepared by 
adding 220 µL of 1 M CaCl2 (Sigma-Aldrich, Dorset, UK) per 10 mL of plasma and 
incubated in a 37°C water bath for 30 – 60 minutes. The cell pellet was then dextran 
sedimented using 2.5 mL of pre-warmed (37°C) 6% Dextran (Pharmacosmos, 
Holbæk, Denmark) per 10 mL of cell pellet. The volume was then made up to the 
original whole blood volume with 0.9% NaCl saline at 37°C (Sigma-Aldrich, Dorset, 
UK). The tube was mixed and allowed to sediment for 30 minutes at room 
temperature, leaving a leukocyte rich upper layer that was transferred to a new 
centrifuge tube and topped up with 50 mL of 0.9% saline at 37°C. The sample was 
then centrifuged at 200g for 5 minutes at room temperature. The supernatant was 
removed and the pellet re-suspended in 55% Percoll (GE Healthcare, IL, USA) in 
PBS. This was then overlaid onto a 70% Percoll layer on top of an 81% Percoll layer 
and centrifuged at 700g for 20 minutes at room temperature. The neutrophils were 
then extracted from the bottom band in the 70%/81% interface. The cells were then 
washed with HBSS- and centrifuged at 200g for 5 minutes at room temperature. 
Purity was confirmed via differential cell count of leukocytes with Trypan Blue 
exclusion as well as cytospin preparations as described in section 2.5.3. 
 
2.9.3 pHrodo S. aureus bioparticle assay 
Healthy volunteer whole blood derived neutrophils were resuspended in HBSS+ 
(1x107 cells per mL). 5 µL of the cell solution was mixed with 50 µL of purified 
mucin solution, containing 5 µL of serum opsonised pHrodo S. aureus bioparticles (as 
previously described), in round bottom 2 mL microcentrifuge tubes. Samples were 
incubated for 1 hour at 37°C in a shaking water bath, in the dark. For each experiment 
a control without bioparticles, and a second control with bioparticles kept on ice 
during the incubation, were also prepared. Cells were removed from the mucus 
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mixture by incubating for 5 minutes with 0.08% DTT. An equal volume of PBS was 
then added to dilute the DTT. The neutrophils were then pelleted by centrifugation at 
300g for 5 minutes. All samples were then re-suspended in 50 µL HBSS+ and 
incubated with a neutrophil marker, Pacific blue-conjugated anti-CD66b antibody 
(Table 2.5), as well as a viability marker, Near-IR Dead Cell Stain Kit, for 30 minutes 
on ice. Cells were then washed twice in flow cytometry buffer (PBS containing 1% 
BSA) by centrifuging at 200g for 5 minutes. Cell pellets were re-suspended in flow 
cytometry buffer at a final volume of 300 µL and data were acquired immediately on 
a FACSCanto II (BD, CA, USA). Initial and phagocytosis-specific gating strategies 
are described in section 2.6.4. 
 
2.9.4 Annexin V and propidium iodide assay 
Healthy volunteer whole blood-derived neutrophils were resuspended in HBSS+ 
(1x107 cells per mL). 5 µL of the cell solution was mixed with 50 µL of purified 
mucin solution, in a round bottom 2 mL microcentrifuge tube. Samples were 
incubated for 1 hour at 37°C in a shaking water bath, in the dark. Cells were removed 
from the mucus mixture by incubating for 5 minutes with 0.08% DTT. An equal 
volume of PBS was then added to dilute the DTT. The neutrophils were then pelleted 
by centrifugation at 300g for 5 minutes. All samples were then re-suspended in 50 µL 
HBSS+ and incubated with a neutrophil marker, Pacific blue-conjugated anti-CD66b 
antibody (Table 2.5). Cells were then washed as previously described and re-
suspended in Annexin V buffer (Thermofisher, MA, USA) at a volume of 50 µL. 
Neutrophils were then incubated for 15 minutes on ice with APC-conjugated Annexin 
V and propidium iodide (Table 2.5). A control sample constituted unstained cells. 
Cells were then re-suspended in Annexin V buffer (Thermofisher, MA, USA) at a 
final volume of 300 µL. Data were acquired immediately on a calibrated FACSCanto 
II (BD, CA, USA). Initial and Annexin V and propidium iodide-specific gating 
strategies are described in section 2.6.4. 
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2.9.5 Neutrophil killing of live bacteria  
Measurement of neutrophil killing of live bacteria was performed utilising methods 
adapted from those previously described (42, 142). P. aeruginosa (lab strain PA01) 
was taken from frozen stock (ATCC, TX, USA), thawed and diluted 1:1000 in a 50 
mL Falcon tube (Sigma-Aldrich, Dorset, UK) containing 10 mL Roswell Park 
Memorial Institute-1640 (RPMI) medium (Sigma-Aldrich, Dorset, UK) and incubated 
at 37°C in an orbital shaker overnight (Barnstead Max Q4000, Hyland Scientific, 
WA, USA). The next morning, optical density was measured at 600 nm using a 
spectrophotometer (8625 UV/VIS, Unicam, NJ, USA), zeroed against a control of 
RPMI without bacteria. The bacterial culture was then diluted with RPMI to an 
optical density of 0.2 (approximately 2x107 colony forming units (CFU)/mL 
determined by previously plating out serial dilutions). Bacteria were opsonised with 
10% autologous serum for 30 minutes, then 5 µl of opsonised PA01 was placed in a 
round bottom 2 mL Eppendorf tubes with 50 µl of purified mucin and mixed. Healthy 
volunteer whole blood-derived neutrophils were resuspended in HBSS+ (1x107 cells 
per mL). 5 µL of the cell solution was mixed with the mucin/bacteria solution and 
incubated for 30 minutes (37°C 5% CO2). After co-culture the mixture was treated 
with 0.08% DTT containing 0.01% Triton X-100 (Sigma-Aldrich, Dorset, UK), in 
HBSS+, for 30 minutes at room temperature, with repeated vortexing. Bacterial 
viability was determined by serial dilution and incubation on agar plates (Lennox B 
agar (Thermofisher, MA, USA), diluted in distilled water and autoclaved). Plates were 
incubated overnight (37°C 5% CO2) and CFU were counted. A control sample 
without neutrophils was used to determine neutrophil-specific bacterial killing. 
 
2.9.6 Neutrophil chemotaxis 
The methods used in this section are adapted from Matsui et al (76). Whole blood-
derived healthy volunteer neutrophils were stained with carboxyfluorescein 
succinimidyl ester (CFSE, 1/1000, Thermofisher, MA, USA) for 30 minutes, 
protected from the light in a 37°C water bath, then washed and the cells re-suspended 
in HBSS+ (1x107 cells per mL). In the lower chamber of a 96-well transwell 
permeability support (3.0 µm pore size, Corning, NY, USA) 10 µL of 10,000 pg/mL 
reconstituted IL-8 solution (Sigma-Aldrich, Dorset, UK) was incubated for 1 hour at 
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room temperature. 2 µL of the neutrophil suspension (1x107 cells per mL) was then 
mixed with 22 µL of purified ICU mucin and placed in the upper chamber of the 
transwell permeable support. The lower chamber was then flooded with 117.5 µL 
warm HBSS+ and incubated at 37°C in a 5% CO2 incubator for 3 hours. Imaging was 
performed with a confocal fluorescent camera (Axio Imager II, Zeiss, Oberkochen, 
Germany) to quantify the number of neutrophils in the lower chamber as a percentage 
of the total cells incubated in the upper chamber. A control sample comprised a well 
without IL-8-containing solution. Neutrophils in each chamber were quantified by an 
automated programme utilising the JOBS module of NIS Elements (Nikon, Tokyo, 
Japan). 
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2.10 Subglottic epithelial cell culture 
2.10.1 Harvesting of subglottic epithelial cells   
The surgeon operating on participants performed a full laryngeal examination and any 
further procedures as required. The surgeon then confirmed the absence of structural 
laryngeal abnormalities prior to subglottic brushing. I performed sampling in most 
cases though in a limited number of cases samples were obtained by the operating 
surgeon. Assessment of the subglottis was performed under direct vision using the 
operating surgeon’s rigid laryngoscope. If the operating surgeon had the operating 
microscope set up for the procedure this was also utilised. Under direct vision a 
sheathed cytology brush (BC-202D-5010, Olympus, Tokyo, Japan) was passed 
through the vocal cords into the subglottis. The brush was unsheathed in the subglottis 
to reduce contamination from the rest of the airway. Vigorous brushing was 
performed with at least 5 - 10 strokes of the mucosal surface of the subglottis. The 
brush was removed and the tip cut off and placed in an individual 10 mL centrifuge 
tube (E1415-0500, Starlab, UK) containing 5 mL tissue culture medium, RPMI 
(Sigma-Aldrich, Dorset, UK), for immediate transport to the laboratory (transit time 
<30 minutes).  
 
2.10.2 Differential cell count  
Differential cell count was performed to ascertain the number of ciliated respiratory 
epithelial cells harvested from the subglottic brushing. All procedures were performed 
in a class II laminar flow cabinet. Samples were first gently manually agitated to 
separate cells from the brush head. The brushes were removed using forceps before 
centrifugation (200g at 10°C for 7 minutes). The pellet was then re-suspended in 0.5 
mL PBS. 20 µL of this suspension was then mixed with 20µl of 0.4% Trypan Blue 
solution (Sigma-Aldrich, Dorset, UK) and placed in a haemocytometer. Cells were 
then counted under a light microscope using four quadrants on the haemocytometer. 
Live cells were identified by exclusion of Trypan Blue. An average number of ciliated 
respiratory epithelial cells (both alive and dead) was thereby ascertained for each 
sample. 
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2.10.3 Cytospin preparations 
The cell pellet was re-suspended in PBS to give a final concentration of 0.5 million 
cells/mL. Cytospins were prepared on glass slides using 100 µL aliquots and then 
spun at 300 rpm for 3 minutes (Cytospin 3, Shandon, London, UK). The cytospins 
were fixed in acetone (Sigma-Aldrich, Dorset, UK) at room temperature for 10 
minutes and then air-dried. The cytospins were next treated with 10% Giemsa stain 
(Sigma-Aldrich, Dorset, UK) for 10 minutes, rinsed in distilled water and air-dried. 
 
2.10.4 Cell expansion and passage  
Samples were gently agitated by hand to separate cells from the brush head. The 
brushes were removed using forceps before centrifugation (200g, at 10°C for 7 
minutes). The pellet was then re-suspended in 2 mL fresh Bronchial Epithelial Growth 
Medium (BEGM, CC-4175, Lonza, Basel, Switzerland), warmed to 37°C, and 
supplemented with 100 µg/mL streptomycin (Sigma-Aldrich, Dorset, UK) and 100 
U/mL penicillin (Sigma-Aldrich, Dorset, UK). The cell suspension was then 
transferred to a 25 cm2 cell culture flask (Corning, NY, USA) pre-coated with 1% 
collagen (Thermofisher, MA, USA), containing a further 3 mL of medium. Cells were 
incubated at 37°C in a humidified atmosphere of 5% CO2. Medium was changed 
every 2 - 3 days. Cells were observed daily to ensure satisfactory growth and to check 
for any evidence of infection. In the latter event the flask was immediately removed 
from the incubator and the contents sent for routine bacterial and fungal cultures to 
identify the infecting organism and relevant antimicrobial sensitivities.  
Passage was performed when cells reached 70 - 80% confluence. The cells were 
removed from the culture surface with trypsin 0.05% in 0.02% EDTA. 5 mL of 
trypsin/EDTA was added to the flask and incubated at 37°C with 5% CO2 for 2-4 
minute. Trypsin was inactivated by addition of 5 mL RPMI medium supplemented 
with 10% fetal calf serum (FCS) (Sigma-Aldrich, Dorset, UK). This cell suspension 
was then centrifuged at 200g, at 10°C for 7 minutes. The supernatant was removed 
and the cell pellet re-suspended with fresh BEGM medium prior to transfer to another 
growth flask. 
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2.10.5 Cryopreservation 
5 mL of trypsin/EDTA was added to the cell culture flask and incubated at 37°C with 
5% CO2 for 2-4 minute. When the cells were dislodged and in suspension, trypsin was 
inactivated using 5 mL RPMI medium supplemented with 10% FCS. The cells were 
transferred to a 15 mL tube and centrifuged at 200g, at 10°C for 7 minutes. The 
supernatant was discarded and the pellet re-suspended in 1 mL of freezing media 
(90% FCS and 10% Dimethyl sulfoxide (DMSO)). The cell suspension was then 
transferred into a cryovial and placed in the freezer at -80°C for 24 hours before being 
transferred to liquid nitrogen.  
 
2.10.6 Reconstitution of cryopreserved cells 
The samples were retrieved from liquid nitrogen and immediately thawed in a 37°C 
water bath. Once defrosted, the suspension was diluted in 10 mL BEGM and 
centrifuged at 200g, at 10°C for 7 minutes. The supernatant was discarded and the cell 
pellet immediately re-suspended in 2 mL pre-warmed BEGM. The cell suspension 
was then transferred to a 25 cm2 cell culture flask (Corning, NY, USA) pre-coated 
with 1% collagen (Thermofisher, MA, USA), containing a further 3 mL of medium. 
 
2.10.7 Air-liquid interface (ALI) culture 
In a class II laminar flow cabinet 12 µm polyester transwell inserts (0.4 µm pore, 
Corning, NY, USA) were pre-coated with 1% collagen (Thermofisher, MA, USA) and 
seeded with 0.5 mL cell suspension at approximately 200,000 cells per mL. At this 
density cells were 80-100% confluent after adherence. The lower chamber was filled 
with 1.5 mL of BEGM medium supplemented with 100 µg/mL streptomycin and 100 
U/mL penicillin (Sigma-Aldrich, Dorset, UK). Cells were incubated at 37°C in a 
humidified atmosphere of 5% CO2. At 24 hours the apical medium was replaced to 
remove cell debris. Once at 100% confluence, the apical medium was removed so that 
the cells were exposed to air at the apical membrane. At this stage the medium in the 
basolateral chamber was substituted with 1.5 mL ALI medium (Table 2.7), changed 
every 2 - 3 days.   
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Constituent Volume or concentration 
Bronchial epithelial basal medium (Lonza, Basel, 
Switzerland) 
250 mL 
Dulbecco's Modified Eagle’s Medium (DMEM), high 
glucose (Thermofisher, MA, USA) 
250 mL 
1% Penicillin /Streptomycin (Sigma-Aldrich, Dorset, 
UK) 
5 mL 
Human epidermal growth factor (R&D systems, UK) 0.5 ng/mL 
Retinoic acid (Sigma-Aldrich, Dorset, UK) 100 ng/mL 
CaCl2 (Sigma-Aldrich, Dorset, UK) 1mM 
Bovine pituitary extract 2mL* 
Insulin 500µL* 
Hydrocortisone 500 µL* 
Transferrin 500 µL* 
Epinephrine 500 µL* 
Tri-iodothyronine 500 µL* 
 
Table 2.7 - Air-liquid interface culture medium 
*concentrations not published by the manufacturer (available as product number CC-
4175 from Lonza, Basel, Switzerland). 
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2.11 Characterisation of the epithelial cell cultures 
2.11.1 Scanning electron microscopy and transmission electron microscopy  
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) 
were performed by the Electron Microscopy Research Services at Newcastle 
University. In brief, air-liquid interface (ALI) cultures of primary subglottic epithelial 
cells (PSECs) were fixed by treatment with glutaraldehyde followed by osmium 
tetroxide. This was followed by dehydration through graded alcohols and embedding 
in resin. SEM was performed using a Cambridge Steroscan 240 electron microscope 
and TEM with a Philips CM100, both with digital image capture. 
 
2.11.2 Immunohistochemistry for pan-cytokeratin 
The transwell epithelial membrane was washed extensively three times, both apically 
and basolaterally with 37°C PBS to ensure thorough removal of the mucus layer. 
Cells were then fixed and permeabilised with 100% methanol at -20°C for 10 minutes. 
The wash step was repeated and the cells stained for 3 hours at room temperature with 
5 µg/mL (diluted in 5% FBS/PBS) monoclonal anti-cytokeratin (pan-reactive) 
antibody (raised in mouse), conjugated with Alexa Fluor® 647 (Biolegend, CA, 
USA). This pan-cytokeratin recognises cytokeratins 4, 5, 6, 8, 10, 13, and 18. The 
wash step was then repeated. The transwell membrane supporting the epithelial cells 
was then entirely removed from the insert with a scalpel blade and fixed onto a glass 
slide below and glass cover slip above using an aqueous mounting medium containing 
DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) for nuclear counterstaining 
(using Vectashield with DAPI, Vector Labs, Cambridgeshire, UK). Imaging was 
performed with a confocal fluorescent camera (Axio Imager II, Zeiss, Oberkochen, 
Germany). A control sample compromised an epithelial membrane, processed in 
parallel, without anti-cytokeratin antibody staining. 
 
2.11.3 Preparation of paraffin-embedded blocks and sections 
The transwell epithelial membrane was washed apically and basolaterally with 37°C 
PBS. The wash and aspiration process was repeated 3 times to ensure thorough 
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removal of the mucus layer. Cells were then fixed with 4% paraformaldehyde for 20 
minutes at room temperature. The transwell membrane was then entirely removed 
from the insert using a scalpel blade and placed in cassettes (Simport, Beloeil, 
Canada). The cassettes were then dehydrated through graded alcohols. This was 
performed by immersion for 10 minutes in 70% industrial methanol spirits (IMS), 
70% IMS, 80% IMS, 80% IMS, 95% IMS, 95% IMS, 74 over proof (op) IMS, 74op 
IMS and 74op IMS respectively. Finally the sample was submerged in xylene (VWR, 
Lutterworth, UK) for 20 minutes, twice, and then embedded in paraffin for 1 hour at 
60°C. Sections of the paraffin blocks were then cut to 5 µm thickness using a 
microtome (Thermofisher, MA, USA). 
 
2.11.4 Haematoxylin and eosin staining 
The paraffin-embedded sections were pre-heated at 60°C for 1 hour before de-waxing. 
De-waxing was performed by soaking the sections in xylene for 5 minutes, twice, and 
then rehydrating through graded alcohols, for 1 minute each in 95% IMS, 99% IMS 
and 99% IMS. The sections were then washed in water and stained in freshly filtered 
Carrazzi’s Haematoxylin (Thermofisher, MA, USA) for 1 minute. The staining 
process was assessed dynamically under the light microscope. The sections were then 
washed in running tap water for 2 - 3 minutes before being placed in 0.1% acid 
alcohol (Sigma-Aldrich, Dorset, UK) and washed in running tap water until the nuclei 
were appropriately blue. The sections were then counterstained with Eosin Y (Fisher 
Scientific, UK) for 2 minutes. Finally the sections were washed in tap water and 
dehydrated back through graded alcohols and xylene. The sections were then mounted 
with DPX (VWR, Lutterworth, UK). 
 
2.11.5 Diastaseresistant periodic acid-Schiff staining 
Diastase-resistant periodic acid-Schiff (DPAS) staining was used as a stain for mucin 
glycoproteins in the paraffin-embedded epithelial section. The DPAS staining was 
performed by the Department of Histopathology, Royal Victoria Infirmary, Newcastle 
upon Tyne. In brief, the sections were de-waxed and rehydrated via an automated 
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process, then stained for DPAS and counter-stained with Haematoxylin and Eosin Y, 
also via an automated process. 
 
2.11.6 MUC5B immunohistochemistry  
The sections were de-waxed as previously described. Endogenous peroxidase was 
blocked with 0.3% H2O2 in methanol for 30 minutes. Samples were washed for at least 
10 minutes in gently running tap water, then rinsed in tris-buffered saline (TBS). The 
primary polyclonal antibody for human MUC5B (Tepa II, raised in rabbit, diluted 1 in 
1,000 in antibody diluent (0.1% non-fat milk protein in TBS)) was then added to the 
sample in a bioassay-incubating tray containing moist tissue, at room temperature, and 
incubated for 30 minutes. The sample was then washed in TBS for 5 minutes twice. 
Secondary antibody was added for 30 minutes (horseradish peroxidase-conjugated 
goat anti-rabbit, diluted 1 in 200 with antibody diluent) in a bioassay incubating tray. 
The sample was then washed in TBS for 5 minutes twice. The sections were then 
treated with 3,3'-diaminobenzidine (DAB) for 5-10 minutes and then neutralised by 
chlorine bleach. Sections were then washed in running tap water. Counter-staining 
was performed with Carrazzi’s Haematoxylin for 1 minute and samples were then 
washed in tap water until blue. Finally the sections were washed in tap water and 
dehydrated back through graded alcohols and xylene, as described in section 2.11.3. 
The sections were then mounted with DPX (VWR, Lutterworth, UK). A control was 
also tested in place of the primary antibody (Rabbit IgG 1:40,000, Sigma-Aldrich, 
Dorset, UK). Human tonsil tissue was also used as a negative tissue control. 
 
2.11.7 MUC5AC immunohistochemistry 
The sections were de-waxed as previously described. Endogenous peroxidase was 
blocked with 0.3% H2O2 in methanol for 30 minutes. Samples were washed for at least 
10 minutes in gently running tap water, then rinsed in TBS. The primary monoclonal 
antibody for MUC5AC (45M1 epitope a, Thermofisher, MA, USA, diluted 1 in 100 in 
antibody diluent (0.1% non-fat milk protein in TBS)) was then added to the sample in 
a bioassay incubating tray containing moist tissue, at room temperature, and incubated 
for 30 minutes. The sample was then twice washed in TBS for 5 minutes. Secondary 
antibody was added for 30 minutes (horseradish peroxidase-conjugated goat anti-
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mouse, diluted 1 in 100 with antibody diluent) in a bioassay incubating tray. The 
sample was then twice washed in TBS for 5 minutes. The sections were treated with 
3,3'-diaminobenzidine (DAB) for 5-10 minutes and then neutralised by chlorine 
bleach. Counter-staining was performed with Carrazzi’s Haematoxylin for 1 minute 
and samples were then washed in tap water until blue. Finally the sections were 
washed in tap water and dehydrated back through graded alcohols and xylene. The 
sections were then mounted with DPX (VWR, Lutterworth, UK). An isotype control 
was also tested in place of the primary antibody (Mouse IgG 1a 1:100, Sigma-Aldrich, 
Dorset, UK). Human tonsil tissue was also used as a negative tissue control. 
 
2.11.8 Trans-epithelial resistance 
Prior to trans-epithelial resistance (TER) measurement, 0.5 mL of pre-warmed BEGM 
was applied to the apical surface of ALI cultured PSECs and allowed to equilibrate 
for 20 minutes. TER measurements were performed using an epithelial volt-ohmmeter 
(World Precision Instruments, FL, USA) according to the manufacturer’s instructions.  
 
2.11.9 Ussing chamber electrophysiological studies  
Experiments were performed using a static chamber system (World Precision 
Instruments, FL, USA) (143). Snapwell semi-permeable supports were mounted in the 
Ussing chamber to measure epithelial membrane properties. Apical and basolateral 
compartments were electrically isolated and separated by the polarised epithelial 
monolayer. A symmetrical Krebs solution was added to both compartments to 
eliminate potentially influential osmotic and chemical effects. Calomel voltage-
sensing electrodes were placed on each side of the membrane. Trans-epithelial 
potential difference was clamped to 0 mV by current injection with silver-silver 
chloride electrodes to eliminate the voltage gradient. Under these conditions, the 
injected current, or short circuit current (Isc), was a direct measure of net trans-
epithelial ion transport. 3M potassium chloride salt bridges containing 3% agar were 
used to connect chambers to the electrodes. The chamber was maintained at 37°C and 
continuously gassed with 5%CO2/95%O2, pH 7.4. A 1 second 5 mV pulse was 
applied at 30-second intervals to monitor resistance changes, calculated by applying 
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Ohm’s law. After 20 minutes of stabilisation, relevant ion channel inhibitors and 
activators were added and resultant Isc responses recorded. Apical amiloride (Sigma-
Aldrich, Dorset, UK) was added to inhibit epithelial sodium channel (ENaC). Apical 
forskolin (Sigma-Aldrich, Dorset, UK) was added to activate Cystic fibrosis 
transmembrane conductance regulator (CFTR)-mediated chloride transport through 
adenylate cyclase stimulation and intracellular cAMP increase. CFTR was inhibited 
by apical addition of CFTRinh172 (Sigma-Aldrich, Dorset, UK). The resultant 
analogue signal was digitised with a Powerlab 200 interface (AD instruments, 
Australia) and recorded by a computer with Scope 3 software (AD instruments, 
Australia).  
  
2.11.10 Apical mucus characterisation  
Mucus was harvested by direct aspiration from the apical aspect of ALI cultures and 
stored at -80°C for later analysis. Quantification of cytokines and mucins (MUC5B 
and MUC5AC) in the mucus layer produced by fully differentiated ALI epithelial cell 
cultures was performed via ELISA techniques described in section 2.7.1/2.7.2. 
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2.12 Bacterial-subglottic epithelial co-cultures 
2.12.1 Pathogen-epithelial co-cultures  
The methods used in this section are adapted from Garnett et al (144-146). PSECs 
cultured to differentiation at ALI, were placed in ALI medium (Table 2.7) without 
antibiotics for at least 24 hours prior to experiments. In a class II laminar flow cabinet 
the apical mucus layer was removed from the cultures by extensive washing with 
37°C PBS. The mucus layer was then replaced with 50 µL of purified ICU-derived 
mucin (in HBSS+), or HBSS+ only control, and incubated (37°C 5% CO2) for 1 hour. 
P. aeruginosa PA01 was prepared as previously described in section 2.9.5. Then 5 µL 
(2x107 CFU/mL determined previously by plating out serial dilutions) PA01 was 
applied apically onto the mucin solution and incubated for 7 hours (37°C 5% CO2) 
(Figure 1). After co-culture the mucin layer was removed by repeated washing with 
0.08% DTT (Merck Millipore, MA, USA) and 0.01% Triton X-100 (Sigma-Aldrich, 
Dorset, UK), in HBSS+. The epithelial layer was removed by scraping and repeated 
washing (0.08% DTT/0.01% Triton X-100 in HBSS+). The samples were incubated 
for 30 minutes and extensively homogenised by repeated pipetting. Bacterial growth 
in the mucin layer and epithelial homogenate was determined by serial dilution and 
incubation on agar plates (Lennox B agar (Thermofisher, MA, USA), diluted in 
distilled water and autoclaved). Plates were incubated overnight (37°C 5% CO2) and 
CFUs counted (144-146). 
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Figure 2.1 - Pictorial demonstration of pathogen-epithelial co-cultures performed 
on primary subglottic epithelial cells (PSECs) cultured at air-liquid interface. 
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2.13 Statistical methods 
Statistical advice was sought as part of the design of this study and appropriate sample 
sizes obtained for a proof of concept/pilot study (147). Statistical analyses and 
preparation of graphs were performed using Prism 7.0a for Mac (GraphPad software, 
CA, USA). Non-parametric methods were used to tested test the null hypothesis by 
the most conservative approach possible. A P value <0.05 was considered to be 
statistically significant. Specific statistical tests used are stated in the figure legends.  
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Chapter 3: Microbiology of mucus derived from the subglottis 
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3.1 Introduction  
Ventilator-associated pneumonia (VAP) is defined as pneumonia developing 48 hours 
or more after tracheal intubation and mechanical ventilation (1, 2). It is the most 
common hospital-acquired infection in the intensive care unit (ICU) (3). It also 
remains the most commonly fatal infection in critical illness, with an overall 
attributable mortality of 13%, and is associated with a significantly increased length 
of ICU stay and cost (5, 6). VAP is frequently associated with antibiotic-resistant 
pathogens (7-9), particularly late onset pneumonia, developing after four days (1, 9). 
Furthermore VAP is estimated to account for half of all antibiotics given in ICU (10). 
The individual organisms identified from VAP lung lavage samples are highly 
variable, depending on several factors, including the geographical location and patient 
group. Gram positive bacteria such as Staphylococcus aureus, including methicillin 
resistant S. aureus  (MRSA), represent a large proportion of isolates in VAP. Other 
VAP-causing pathogens include aerobic Gram negative bacilli such as Pseudomonas 
aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter species, and 
Acinetobacter species (7-9, 11). 
Subglottic suction drainage has been demonstrated to effectively prevent VAP (27). 
The rationale for this intervention is to remove infected subglottic secretions prior to 
their aspiration into the lungs (14, 15). This hypothesis is supported by previous 
studies that have demonstrated a strong correlation between organisms found in the 
oropharynx, on the tracheal tube cuff (after removal) or in the trachea (bellow the 
trachea cuff) prior to development of VAP, and organisms subsequently found in the 
lungs (11, 17, 18). 
While these studies have investigated local microbiology, they have not examined the 
actual subglottic mucus that is thought responsible for VAP development. I therefore 
aimed to characterise the microbiology of subglottic mucus from long-term ventilated 
ICU patients and a control cohort of newly intubated theatre attenders. 
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3.2 Chapter aims 
In this chapter I wished to answer the following questions: 
1. What is the microbiology of subglottic mucus from long-term intubated ICU 
patients and newly intubated control patients, as assessed by microbiology 
cultures? 
2. What is the microbiology of subglottic mucus from long-term intubated ICU 
patients and newly intubated control patients, as assessed by bacterial and 
fungal gene sequencing? 
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3.3 Results 
3.3.1 Cohort demographic data 
There were 24 patients in the ICU cohort and 27 in the control cohort, and their 
summarised demographic and clinical data are shown in Table 3.1. Briefly, ICU 
patients were a heterogeneous cohort, unified by being intubated, and mechanically 
ventilated, for four or more days. Controls comprised patients attending theatre for a 
general anaesthetic laryngeal examination, with no structural laryngeal abnormalities 
identified. Therefore the cohorts are described as long-term intubated ICU patients 
and newly intubated controls. There was no significant difference in the age or sex of 
the patients in the two cohorts (Table 3.1). The overall mortality during the 
subsequent ICU/hospital stay was in keeping with previous UK studies of ICU 
mortality (148). The rates of immunosuppressive and antibiotic use were also in 
keeping with previously published studies (Table 3.1) (149, 150). Detailed description 
of the ICU demographic and clinical data is listed in Table 3.2.  
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Table 3.1 - Summary demographic and clinical data for patient and control 
groups 
Definition of abbreviations: ICU = intensive care unit; IQR = interquartile range; * By 
Mann–Whitney U test, † By Chi Squared test. 
 
 
 
 
 
 
 
 
ICU patients 
(n=24) 
Newly intubated 
controls (n=27) 
P Value 
Median age, years (range) 66 (20 – 79) 58 (35 – 79) 0.43* 
Percentage of patients male 63 59 >0.99† 
Median (IQR) mechanically ventilated 5 (4 – 6) days 9 (5 – 10) minutes  
Mortality, % 42 0  
Percentage receiving systemic 
immunosuppressive drugs (including 
corticosteroids) 
21 0  
Percentage receiving inhaled 
corticosteroids 
0 15  
Percentage receiving antibiotics 83 0  
Percentage smokers 42 26  
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Table 3.2 Extended clinical and demographic details for the ICU cohort 
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3.3.2 Semi-quantitative microbiology culture 
A semi-quantitative culture technique was used to detect bacterial and fungal 
organisms in the subglottic mucus samples of long-term intubated ICU patients and 
newly intubated control patients (as described in Chapter 2 of this thesis).  
I examined the organisms cultured from these two cohorts. Initial investigation of the 
number of individual organisms cultured demonstrated significantly fewer isolates in 
the ICU samples, compared with control samples (Figure 3.1). 
I then went on to examine the organisms identified in each cohort. There were 
significant differences in the species identified between the two cohorts (see appendix 
A).  Due to the vast array of organisms identified I grouped the species into genera. 
When grouped in this way there was a significantly greater proportion of samples 
containing Streptococcus, Rothia and Actinomyces in the newly intubated controls, 
compared to ICU patients. There were significantly more Candida and Enterococcus 
species isolated in the ICU samples, compared to controls. There was also a large 
number of different species, of varying genus, that were all in the family 
Enterobacteriaceae. These included important airway pathogenic organisms, such as 
Escherichia, Enterobacter and Klebsiella. When grouped there were significantly 
more organisms from the Enterobacteriaceae family recovered from the ICU cohort 
than controls mucus samples (Figure 3.2). A full list of organisms identified from 
both cohorts is detailed in Appendix A.  
Next I investigated the quantity of each organism recovered from the mucus samples. 
Using the results of semi-quantitative culture I was able to demonstrate which 
organism was the most concentrated within each samples. This showed that the 
species/family with the highest colony forming units (CFU) recovered in each sample 
was significantly more often Streptococci in control samples and Enterobacteriaceae 
in ICU samples (Figure 3.3). 
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Figure 3.1 - Number of individual bacterial/fungal isolates from subglottic mucus 
samples. 
Subglottic mucus samples were cultured and the individual number of isolates 
recovered recorded. Horizontal bars depict median values. Mann–Whitney U test, 
**p<0.01, ICU n = 23, control n = 25. 
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Figure 3.2 - Number of subglottic mucus samples yielding each species/family of 
bacteria/fungus. 
Subglottic mucus samples were cultured and the number of samples containing each 
species/family was recorded. Significant results are demonstrated for each species 
(Streptococcus, Rothia, Actinomyces, Candida, Enterococcus). The family 
Enterobacteriaceae was also included due to the number of different individual 
species recovered. Horizontal bars depict median values. Fisher’s exact test, *p<0.05, 
**p<0.01, ***p<0.001 ****p<0.0001, ICU n = 23, control n = 25. 
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Figure 3.3 - Number of subglottic mucus samples yielding the highest colony 
forming units (CFU) for each species/family of bacteria/fungus  
Subglottic mucus samples underwent semi-quantitative bacterial/fungal culture. The 
organism with the highest CFU count was recorded. Significant results are 
demonstrated for each species (Streptococcus) and family (Enterobacteriaceae). 
Horizontal bars depict median values. Fisher’s exact test, **p<0.01, ***p<0.001, ICU 
n = 19, control n = 24. 
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3.3.3 16S rRNA bacterial profiling  
16S rRNA bacterial profiling was used to identify bacterial organisms in the 
subglottic mucus samples of long-term intubated ICU patients and newly intubated 
control patients (as described in Chapter 2 of this thesis).  
I recruited 24 ICU patients and 27 control patients to the study. Of these 4 controls did 
not have enough mucus to extract DNA. A further 3 control samples were excluded at 
the gene sequencing stage due to low coverage, having less than 1000 reads per 
sample. This resulted in data being available for 24 ICU mucus samples and 20 
control samples.  
Firstly I examined the diversity of organism found within the subglottic mucus of the 
two cohorts. This demonstrated significantly less diversity of bacterial organisms in 
the ICU cohort compared to the controls (Figure 3.4). Next I investigated the 
individual taxonomic classification of bacterial reads as a measure of the organism 
identified. This indicated distinct differences between the two cohorts’ microbiomes. 
There were 25 operational taxonomic units (OTUs) that were significantly more 
abundant between the two cohorts (Figure 3.5). In all but one case these were 
organisms found more frequently in the control cohort, included Streptococcus, 
Rothia and Actinomyces, but also a plethora of other mainly anaerobic organisms. 
There was significantly more Mycoplasma detected in the ICU cohort compared to 
controls. I then investigated the similarity of the microbial communities between 
samples using a nonmetric multidimensional scaling (NMDS) plot based on Bray-
Curtis distances (Figure 3.6). This demonstrated similarity between the microbiomes 
of the individual control samples, with heterogeneity in the ICU samples. 
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Figure 3.4 - Box plots of bacterial alpha diversity measured using observed 
operational taxonomic units (OTUs) and Shannon diversity. 
Subglottic mucus samples were processed using 16S rRNA bacterial profiling. 
Observed OTU and Shannon alpha diversity are demonstrated. The boxplot shows the 
upper and lower quartiles and median, whiskers represent the range. Observed OTU 
diversity p = 0.018, Shannon diversity p = 0.003. Kruskal-Wallis test, ICU n = 24, 
control n = 20.  
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Figure 3.5 - Taxonomic classification of bacterial reads.  
Subglottic mucus samples were processed using 16S rRNA bacterial profiling. 
Bacterial reads at operational taxonomic units (OTUs) level demonstrating the top 20 
bacterial OTUs in each sample, ICU n = 24, control n = 20. 
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Figure 3.6 - Boxplot analyses of the significantly distinct bacterial operational 
taxonomic units (OTUs). 
Subglottic mucus samples were processed using 16S rRNA bacterial profiling. 
Proportional taxa abundance is demonstrated. The boxplot shows the upper and lower 
quartiles and median. Mann–Whitney U test, ** p<0.001 *p<0.05, ICU n = 24, 
control n = 20. 
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Figure 3.7 - Nonmetric multidimensional scaling (NMDS) plot. 
Subglottic mucus samples were processed using 16S rRNA bacterial profiling. NMDS 
plot based on Bray-Curtis distances were generated using phyloseq package. The two 
most distinct taxonomic variables are plotted as correlations with control (red circles) 
and ICU (blue triangles) samples. ICU n = 24, control n = 20. 
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3.3.4 ITS fungal profiling  
ITS fungal profiling was used to identify fungal organisms in the subglottic mucus 
samples of long-term intubated ICU patients and newly intubated control patients (as 
described in Chapter 2 of this thesis).  
I recruited 24 ICU patients and 27 control patients to the study. Of these 4 controls did 
not have enough mucus to extract DNA. A further 15 ICU and 21 control samples 
were excluded at the gene sequencing stage due to low coverage, having less than 100 
reads per sample. This resulted in data being available for 9 ICU mucus samples and 2 
control samples. There was no significant difference in the diversity of fungal 
organisms in the ICU cohort compared to the controls (Figure 3.8). Next I 
investigated the individual taxonomic classification of fungal reads as a measure of 
the organism identified (Figure 3.9). 	
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Figure 3.8 - Box plots of fungal alpha diversity measured using observed 
operational taxonomic units (OTUs) and Shannon diversity. 
Subglottic mucus samples were processed using ITS bacterial profiling. Observed 
OTU and Shannon alpha diversity are demonstrated. The boxplot shows the upper and 
lower quartiles and median. Observed OTU diversity p = 0.16, Shannon diversity p = 
0.45. Kruskal-Wallis test, ICU n = 9, control n = 2. 
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Figure 3.9 - Taxonomic classification of fungal reads.  
Subglottic mucus samples were processed using ITS fungal profiling. Fungal reads at 
operational taxonomic units (OTUs) level demonstrating the top 20 fungal OTUs in 
each sample, ICU n = 9, control n = 2. 
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3.4 Discussion 
In this chapter I sought to identify differences in the microbiology of subglottic mucus 
from long-term intubated ICU patients and newly intubated control patients.  
I was able to demonstrate, by microbiology culture and gene sequencing, significantly 
reduced subglottic bacterial diversity in long-term intubated ICU patients, compared 
with newly intubated control patients. This is in keeping with previous studies of the 
lower airway and oropharynx of intubated ICU patients, which have shown reduced 
microbiological diversity over time (151-153). A key consideration of this finding is 
the potential cause of this reduced diversity - intubation and ventilation, critical 
illness, antibiotic administration or other factors (150). Zakharkina et al performed 
longitudinal bacterial sequencing of the lower airway of ICU patients. They 
demonstrated reduced microbiological diversity, however in subgroup analysis they 
were able to suggest that this was independent of antibiotic administration (151). 
Subgroup analysis of antibiotic or immunosuppressive use in my ICU cohort was not 
possible due to the small patient cohorts. Reduced microbial diversity has been 
extensively demonstrated in other inflammatory respiratory conditions, particularly 
cystic fibrosis, where reducing diversity correlates with disease progression in many 
studies (154-157).  
The less diverse microbiology in the ICU cohort, compared to controls, was paralleled 
by distinct differences in the organisms identified. The bacterial gene profiling and 
microbiology culture data demonstrate that the control cohort consistently had a 
broad, heterogeneous microbiology, with characteristic oral commensal organisms 
(158, 159). It seems likely that these organisms have been introduced at the time of 
endotracheal intubation. Conversely, however, this may simply represent a normal 
flora of this sub-site. It has been repeatedly demonstrated that even areas previously 
considered sterile, such as the lung, still contains a distinct microbiome, largely 
indistinguishable from upper respiratory flora, just at a much lower density (160, 
161). To my knowledge, while many other airway sub-sites have been studied, the 
microbiology of the subglottic airway has never been defined (162). Nevertheless, this 
cohort of newly intubated patients does provide an appropriate control group to the 
long-term intubated ICU patients. 
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There was little concordance between the microbiology of different patients’ mucus 
samples in the ICU cohort, by culture or gene profiling. In many of the ICU patients 
one organism was dominant, in contrast to the more diverse microbiology found in the 
control cohort. These dominant organisms were often pathogenic organisms such as 
Pseudomonas, Enterococcus or Enterobacteriaceae. Semi-quantitative microbiology 
cultures also frequently confirmed these organisms to be the dominant in CFU counts. 
The individual organisms identified from VAP lung lavage samples are highly 
variable, depending on several factors, including the geographical location and patient 
group, however these organisms are commonly found in VAP (8, 9, 11). The origin of 
VAP-causing organisms is debated. Traditionally it has been suggested that the 
organisms migrate from the oral cavity or sinuses, or are introduced by healthcare 
workers (19, 21). Others suggest that these organisms are aspirated into the airway 
with infected stomach contents (20). It has also been postulated that the extensive use 
of acid suppression therapy in critical illness, to prevent ulcer formation, leads to 
overgrowth of gastric bacteria, which is subsequently aspirated into the airway (20). 
In microbiological culture I did identify a number of organisms in the ICU cohort that 
are associated with the gastrointestinal tract, such as Enterococcus and 
Enterobacteriaceae (163, 164). However it is impossible to confirm the origin of 
these organisms without doing multiple sub-site sampling. Another consideration is 
the role of biofilms, which have frequently been identified on the tracheal cuff of ICU 
patients (17, 165). Biofilms are of course important in terms of increasing 
antimicrobial resistance (166). Measurement of biofilm markers was not performed in 
this current work, but would be an area for potential further investigation.  
Overall there was reasonable concordance between the standard cultures and gene 
sequencing in the ICU cohort. While direct comparisons are limited by the different 
methodologies and grouping of organisms there are nevertheless clear parallels. An 
interesting finding was the presence of significantly more Mycoplasma in the ICU 
mucus samples, which was identified by bacterial gene profiling. This was not 
detected on microbiology culture, as this would require specialised culture media and 
lengthy incubation periods that were not performed. A high incidence of Mycoplasma 
has recently been identified in a series of VAP lavage samples, and has been linked 
with immunomodulation (167, 168). While I only detected Mycoplasma in a limited 
number of samples it may be an area for further investigation. Routine microbiology 
Jason Powell  Chapter 3  
 
   85 
cultures performed in standard healthcare culture panels would in most cases not 
detect this organism. In the control cohort there was some concordance between the 
standard cultures and gene sequencing. Streptococcus was frequently identified by 
both techniques, however other organisms, such as Veillonella, were only identified 
on bacterial gene sequencing. This is probably because the microbiology culture 
techniques used were comparable with standard NHS culture techniques, which are 
biased towards the culture of pathogenic organism and are not exhaustive. They did 
not include specialised culture medium and lengthy incubation periods as would be 
required by some organisms, such as many anaerobes. 
The presence of fungus, in particular Candida, in many of the ICU mucus samples on 
culture, was an intriguing finding. Fungus is identified in only a small proportion of 
VAP cases, however its importance in VAP is debated in the literature (8, 9, 11). 
Some studies suggest that fungal organisms alone are direct VAP causing agents, 
others that they act synergistically with pathogenic bacteria, and some suggest that 
fungal species are unrelated to VAP entirely (8, 9, 11, 169-171). Obvious potential 
contributors to the presence of fungus in the subglottic mucus samples would be the 
use antibiotic or systemic immunosuppressive agents in the ICU patients. Subgroup 
analysis of this was not possible in my ICU cohort due to the small sample sizes. Low 
reads meant that there were only a small number of results for the fungal gene 
sequencing. This may represent lack of fungal organisms, however low reads are also 
found in processing issues, and this difference is indistinguishable.  
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3.5 Conclusions 
Long-term intubation has long been suggested as an independent causative agent in 
VAP development, providing a conduit for aspiration into the lower airway of virulent 
microorganisms (1, 14, 15). Subglottic mucus is gravitationally pooled above the cuff 
immediately above the lungs (1, 14, 15). The findings of this chapter identify a 
distinctly different microbiological environment in long-term intubated ICU patients 
compared to newly intubated controls. This is exemplified by the reduced diversity 
and increased proportion of pathogenic organisms in the ICU cohort, compared to 
controls (8, 9, 11). Subglottic suction drainage has repeatedly been demonstrated to 
effectively prevent VAP (27). I postulate that more effective, targeted subglottic 
drainage should remove this purulent material prior to aspiration and therefore prevent 
VAP. Chapter 4 of this thesis will investigate if there are host defence factors that 
may contribute to these microbiological differences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jason Powell  Chapter 3  
 
   87 
3.6 Future work 
Key considerations of the findings in this chapter are the cohorts used. I compared the 
organisms identified in two separate groups of patients. A longitudinal study in a 
group of newly intubated ICU patients (ideally followed up over several days), would 
demonstrate the changes in organisms identified. Furthermore it would more clearly 
be able to identify possible causes of microbiological changes, for example changes 
pre- and post-antibiotic therapy. These patients would however be difficult to identify 
and recruit for several logistical reasons, not least the consent process, which would 
need to include medical consent if next of kin cannot be identified acutely. However, 
based on these initial findings, this study would be a key next step.  
If a longitudinal study were not possible it would be necessary to validate these 
findings in a larger, adequately powered cohort of ICU and control patients. Due to 
the patient number in the current cohort it was impossible to perform any meaningful 
subgroup analysis of the ICU patients. Investigation of clinical variables, such as VAP 
development, antibiotic and proton pump inhibitor use, presence of a subglottic 
suction drain and survival, would be highly valuable (172). Another important 
correlation would be with the lower airway microbiological findings in those patients 
developing VAP. Furthermore correlation with other host defence factors (described 
in chapter 4 of this thesis) may give additional insights into the reason for 
microbiological differences between the two cohorts. Due to the potential for reflux to 
be an aetiological factor in VAP development it would also be useful to measure 
subglottic markers of reflux, such as bile acids, pepsin and pH changes, in correlation 
with microbiology and host factors (173-175). It would also be helpful to sample 
multiple aerodigestive sub-sites, such as the oral cavity, pharynx, stomach, trachea 
(below the cuff) and lung to compare microbiological differences.  
There are limitations in the ICU cohort that could be addressed in a future study. The 
main inclusion criterion was the presence of a tracheal tube for four or more days. 
This made for a highly heterogeneous ICU cohort, including patients intubated and 
ventilated for numerous reasons, from young patients with head injuries to elderly 
patients with hospital- or community-acquired pneumonia. Amongst the number of 
host differences that may contribute to the microbiological changes in this ICU 
cohort, it is likely that these patients would have different oropharyngeal 
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microbiology prior to intubation (176). This ICU cohort does however represent the 
heterogeneous nature of ICU patients (177). There are more homogeneous ICU 
cohorts, such as post-cardiac surgery patients, which could be utilised, however these 
findings would be less translatable to the wider ICU community at risk of VAP 
development (178, 179).  
There are also limitations in the control group used. They had only just been intubated 
(<30 minutes), and the nature of their planned procedure allowed access to their upper 
airway for sampling, with only limited additional procedures. This cohort are, 
however, having an upper airway examination for ‘persistent throat problems’, and 
while the upper airway examination demonstrated a structurally normal airway, it is 
possible they may have chronic inflammatory conditions, such as laryngopharyngeal 
reflux, that may impact on their subglottic microbiology or chronic infections, such as 
chronic laryngitis (180, 181). Another consideration is that the introduction of an 
endotracheal tube is likely to be responsible for the oropharyngeal commensal 
organisms identified in the control cohort. An ideal control population would be 
awake non-intubated volunteers, but sampling from this region would be technically 
challenging. However, as an ICU patient at risk of VAP has an endotracheal tube 
introduced the present controls offer an acceptable comparator. 
Another area for future work would be the use of more extensive and fully 
quantitative microbiology cultures. However, this would require extensive resources, 
such as cultures performed in triplicate and a wide range of selective culture media. 
The gene profiling could also be performed in a more quantitative manor to allow for 
measurement of organism density which would be an important factor in determining 
the potential pathogenicity of the subglottic mucus.  
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Chapter 4: Characterisation of subglottic mucosal host defences 
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4.1 Introduction  
It has previously been demonstrated that even short-term tracheal intubation (i.e. for several 
hours) can cause significant mucosal inflammation around the tracheal cuff (49, 50). 
Furthermore, tracheal intubation can radically impede the function of the mucociliary 
escalator (45-48).  
The mucus layer covering epithelial cells has a crucial role in maintenance of mucosal 
immune homeostasis (182). Mucus forms a physical barrier to protect the epithelium, helps to 
clear pathogens via the mucociliary escalator, and also has important interactions with 
cellular host defences (182). Mucus consists primarily of water and mucin (large molecular 
weight biopolymers), but also includes immune cells, DNA and anti-microbial proteinases, 
such as neutrophil elastase (77, 81). The most predominant secreted (and gel-forming) 
mucins in airway mucus are MUC5B and MUC5AC (77, 83, 84). Changes in the fractions of 
mucus constituents can have significant effects on the rheological properties of mucus and 
subsequently its function (81). A large number of inflammatory/immune response mediators 
have been shown to induce secretion of mucins by epithelial cells (77). These include 
common airway cytokines that have been shown to be increased in short-term tracheal 
intubation, such as IL-8, IL-6 and IL-1β (49, 50, 183-186). 
Short-term intubation has also been shown to induce a rapid introduction to the local 
environment of immune cells, particularly granulocytes, such as neutrophils (49, 50, 187). 
This is likely due to the local pro-inflammatory response of the epithelium to tracheal 
intubation (49, 50). A number of these pro-inflammatory agents and chemotactic cytokines, 
such as IL-8, IL-6, IL-1β and C5a, can stimulate immune cell recruitment to the region (188). 
Neutrophils are predominantly pro-inflammatory cells and this recruitment is likely to have a 
further impact on local inflammation, through further immune cell recruitment, and release of 
pro-inflammatory cytokines and proteinases (58, 189, 190).  
I therefore aimed to investigate the subglottic mucosal host defences in a group of long-term 
intubated ICU patents, intubated and mechanically ventilated for four or more days, and a 
cohort of newly intubated (<30 minutes) control patients. 
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4.2 Chapter aims 
In this chapter I sought to answer the following questions: 
1. What are the composition and physical properties of mucus derived from the 
subglottis of long-term intubated ICU patients and newly intubated control patients? 
3. What are the immunological characteristics of mucus derived from the subglottis of 
long-term intubated ICU patients and newly intubated control patients? 
4. How functional are neutrophils extracted from the subglottic mucus and whole blood 
of long-term intubated ICU patients and newly intubated control patients? 
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4.3 Results 
4.3.1 Cohort demographic data 
The demographic details of the newly intubated theatre attenders (control) cohort, in 
comparison with the ICU cohort, are described in section 3.3.1. Both groups provided the 
mucus samples described in this chapter. The ICU cohort also provided whole blood samples. 
An additional cohort of 16 healthy volunteers were recruited to provide only blood samples, 
and their demographic and clinical data are shown in Table 4.1 (in which the demographic 
details for the ICU cohort are repeated for comparative purposes). There was no significant 
difference in the age or gender of the ICU patients compared with either of the two control 
cohorts (Tables 3.1 and 4.1). Full inclusion and exclusion criteria for all groups are detailed 
in Tables 2.2 and 2.3. 
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Table 4.1 - Demographic and clinical data for patient and control groups 
Definition of abbreviations: ICU = intensive care unit; IQR = interquartile range; * By Mann–
Whitney U test, † By Chi Squared test  
 
 
 
 
 
 
 
ICU patients 
(n=24) 
Healthy blood 
volunteer 
controls (n=16) 
P Value 
Median age, years (range) 66 (20 – 79) 67 (23 – 89) 0.54* 
Percentage of patients male 63 50 0.43† 
Median (IQR) mechanically ventilated 5 (4 – 6) 0  
Mortality, % 42 0  
Percentage receiving immunosuppressive 
drugs (including corticosteroids) 
21 0  
Percentage receiving antibiotics  83 0  
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4.3.2 Constituents of mucus derived from the subglottis 	
I designed experiments to determine the composition and properties of mucus derived from 
the subglottic region of long-term (four or more days) ventilated ICU patients and newly 
intubated control patients.  
I assessed several factors that might contribute to the properties of the mucus samples, 
including the proportions of water to solids as measured via the dry weight. This 
demonstrated a significantly higher proportion of solids in the ICU samples, compared to 
controls (Figure 4.1). Next I investigated the concentration of the two most common gel-
forming airway mucins MUC5B and MUC5AC in these mucus samples. This demonstrated 
significantly higher concentrations of MUC5B (median concentration ICU 21.7 mg/mL 
versus controls 3.5 mg/mL), but not MUC5AC (Figure 4.2). In addition, I demonstrated 
significantly higher levels of DNA in ICU patients’ mucus compared to controls (Figure 4.3). 
One would expect dehydrated mucus with a high proportion of mucins and DNA to be more 
viscous (191). I therefore measured viscosity in a number of mucus samples using a 
rheometer. This demonstrated a significantly more viscous mucus gel in the ICU cohort 
compared with newly intubated control samples (Figure 4.4). 
These results demonstrate a difference in the fraction of key mucus constituents and 
subsequent changes in the rheological properties of mucus from long-term intubated ICU 
patients compared with newly intubated control patients. 
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Figure 4.1 - Percentage dry weight of mucus samples. 
Mucus samples were weighed before and after dehydration overnight at 80°C. The 
percentage solid was then calculated. Horizontal bars depict median values.  Mann–Whitney 
U test, *p < 0.05, ICU n = 12, control n = 7. 
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Figure 4.2 - MUC5B and MUC5AC concentrations in mucus samples. 
Mucin MUC5B and MUC5AC concentrations were quantified in mucus samples by ELISA. 
Horizontal bars depict median values. Mann–Whitney U test. MUC5B ****p<0.0001, ICU n 
= 19, control n = 16. MUC5AC non-significant (ns), ICU = 21, control n = 15. 
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Figure 4.3 - Double stranded (ds)DNA content in mucus samples. 
Mucus dsDNA concentration was quantified by Quant-i assay kit. Horizontal bars depict 
median values. Mann–Whitney U test, **p<0.01, ICU n = 21, control n = 20. 
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Figure 4.4 - Mucus viscosity measurements.  
Mucus samples’ shear viscosity were rheologically analysed at 37°C. Horizontal bars depict 
median values in Pascal-seconds (Pa·s) at a shear rate of 1 s-1. Mann–Whitney U test, 
**p<0.01, ICU n = 6, control n = 5. 
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4.3.3 Immune profile of mucus derive from the subglottis  
I further investigated the immunological properties of mucus derived from the subglottis. 
Firstly I found a significantly higher number of neutrophils in mucus derived from the 
subglottic region of long-term ventilated ICU patients compared to newly intubated control 
patients (Figure 4.5). There was no significant difference in the number of macrophages 
however. The percentage proportion of each cell type was significantly different (chi squared 
test p<0.001) (Figure 4.5). Given the large number of neutrophils found in the subglottic 
mucus of the ICU cohort I further investigated the viability of these cells using a flow 
cytometry-based assay on cells extracted from the mucus. This demonstrated that the 
majority of cells in both the ICU and control cohorts were viable, and that there was no 
significant difference in the proportion of viable, early/late apoptotic cells or necrotic cells 
(Figure 4.6). Neutrophils release a number of proteases, which are important in pathogen 
killing and mucosal immune homeostasis. I measured one of these key proteases, human 
neutrophil elastase. This was found to be at significantly higher concentrations in the mucus 
of ICU patients compared with controls (Figure 4.7).  
To investigate the potential mechanisms behind the observed neutrophil recruitment, and 
other host defence changes, the levels of cytokines were examined in plasma and mucus 
samples. These were analysed using an MSD immunoassay, except anaphylatoxin C5a, 
which was examined using a Cytometric Bead Array (CBA) kit. Cytokines IL-8, IL-6, IL-1β 
and IL-10 were at significantly higher levels in the mucus samples (Figure 4.8), as well as the 
plasma samples (Figure 4.9) of ICU patients compared with controls. In both cohorts the 
relative concentration of each agent was higher in mucus samples compared to plasma 
(Figures 4.8 and 4.9). There was no correlation between mucus and plasma concentration in 
matched ICU mucus and plasma samples (data not shown). The concentration of C5a was 
significantly higher in the mucus samples of ICU patients compared to controls, but no 
difference was demonstrated between plasma samples (Figure 4.10). I also measured 
granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is an important 
immune modulator that has profound effects on the functional activities of various circulating 
leukocytes, including neutrophils (192). I found that concentrations were significantly higher 
in mucus samples of ICU patients compared to controls (Figure 4.11). Levels of GM-CSF 
were undetectable in plasma samples using this assay. 
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Figure 4.5 - Immune cell profile of subglottic mucus 
Cells were extracted from the mucus of ICU patients or newly intubated control patients after 
treatment with 0.08% dithiothreitol. Differential cell count was then perfumed using a 
haemocytometer and cytospin preparations. The number of neutrophils (A) and macrophages 
(B) per mL is depicted. Horizontal bars depict median values. Mann–Whitney U test, 
****p<0.0001. The percentage proportion of each cell type is also demonstrated (C), Chi 
squared test p<0.001. ICU n=18, control n=7.  
 
ICU Control
0
2
4
6
8
10
Mucus origin
N
eu
tro
ph
ils
 p
er
 m
L 
(x
10
6 )
****
ICU Control
0
100000
200000
300000
400000
Mucus origin
M
ac
ro
ph
ag
es
 p
er
 m
L
ns
A B 
ICU Control
0
50
100
Mucus origin
%
 c
el
l t
yp
e
Neutrophils
Macrophages
Lymphocyte
C 
Jason Powell  Chapter 4 
   101 
 
 
 
 
 
Figure 4.6 - Subglottic mucus-derived neutrophil viability.   
Cells were extracted from the mucus of ICU patients or newly intubated control patients via 
treatment with 0.08% dithiothreitol. Cells were incubated with Annexin V and propidium 
iodide. Viability, apoptosis and necrosis were determined by flow cytometry gating of 
neutrophils with expression of these two agents. Horizontal bars depict median values. 
Mann–Whitney U test. No significant difference between the two cohorts was demonstrated, 
ICU n = 18, control n = 8. 
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Figure 4.7 - Human neutrophil elastase content in subglottic mucus. 
Human neutrophil elastase concentration in mucus was measured using ELISA. Horizontal 
bars depict median values. Mann–Whitney U test, ****p<0.0001, ICU n = 17, control n = 14. 
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Figure 4.8 - Cytokine content in subglottic mucus. 
Cytokines were measured using MSD immunoassay. Horizontal bars depict median values. 
Mann–Whitney U test, **p<0.01, ****p<0.0001, IL-8 ICU n = 20, control n = 26, IL-6 ICU 
n = 21, control n = 21, IL-1β ICU n = 23, control n = 22, IL-10 ICU n = 20, control n = 16. 
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Figure 4.9 - Cytokine content in circulating plasma. 
Cytokines were measured using MSD immunoassay. Horizontal bars depict median values. 
Mann–Whitney U test, *p<0.05, ****p<0.0001, *p<0.05, IL-8/IL-6/IL-1β ICU n = 24, 
control n = 15, IL-10 ICU n = 23, control n = 14. 
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Figure 4.10 - C5a quantification in subglottic mucus and circulating plasma. 
Anaphylatoxin C5a was measured using a Cytometric Bead Array (CBA) kit. Horizontal bars 
depict median values. Mann–Whitney U test, ****p<0.0001, mucus ICU n = 22, control n = 
22, plasma ICU n = 24, control n = 16. 
 
 
 
 
 
 
 
 
 
ICU Control
0
100
200
300
400
500
Mucus
C
5a
 (n
g/
m
L)
****
ICU Control
0
20
40
60
80
Plasma
C
5a
 (n
g/
m
L)
ns
Jason Powell  Chapter 4 
   106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 - GM-CSF content in subglottic mucus. 
GM-CSF concentration in mucus was measured using MSD single-plex immunoassay. 
Horizontal bars depict median values. Mann–Whitney U test, *p<0.05, ICU n = 12, control n 
= 7. 
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4.3.4 Functional studies of neutrophils derived from subglottic mucus and whole blood  
In light of the increased number of viable neutrophils found in the subglottic mucus of long-
term-ventilated patients, I aimed to investigate the functional capacity of these cells. I also 
attempted to investigate the functional ability of neutrophils derived from the systemic 
circulation of the same ICU patients. The control group for the blood-derived neutrophils was 
a cohort of healthy volunteers (Table 4.1). The ability of neutrophils to phagocytose is a key 
function in the clearance of pathogens (52, 53). This was measured using serum-opsonised 
pHrodo® green S. aureus Bioparticles®. No overall difference was observed in the 
percentages of blood-derived neutrophils involved in phagocytosis from the ICU cohort, 
compared to the cohort of healthy volunteers (Figure 4.12). Equally, no significant difference 
was detected between the percentages of neutrophils involved in phagocytosis from the 
mucus-derived neutrophils of ICU patients compared to newly intubated control patients 
(Figure 4.12). The overall level of phagocytosis in the ICU mucus-derived neutrophils was 
however significantly lower than that in the ICU blood-derived neutrophils (Figure 4.12). 
There was however no correlation between mucus- and blood-derived neutrophil phagocytic 
function in paired ICU samples (data not shown). 
I went on to investigate the surface marker expression of blood- and mucus-derived 
neutrophils. There was no significant difference in the expression of activation markers 
CD62L (shed with activation) or CD11b (increased with activation) in either mucus- (Figure 
4.13) or blood-derived cells (Figure 4.14). I also investigated neutrophil expression of the 
C5a surface receptor CD88 (which is internalised in response to C5a binding (42)). There 
was a significantly higher surface expression of CD88 on ICU-mucus derived neutrophils, 
compared to controls (Figure 4.13). Despite my previous findings of higher levels of C5a in 
subglottic mucus derived from ICU patients compared to controls (Figure 4.10). Further to 
this, the blood-derived neutrophil expression of CD88 was significantly lower in ICU patients 
compared to controls (Figure 4.14). This is in contrast to my previous findings that 
demonstrated no significant difference in C5a levels in plasma derived from ICU patients or 
controls (Figure 4.10). There was no correlation between mucus- and blood-derived 
neutrophil phagocytic function and any surface marker expression (data not shown). 
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Figure 4.12 - Blood- and mucus-derived neutrophils’ phagocytic function.  
Cells were extracted from the whole blood of ICU patients or healthy volunteers using 
dextran sedimentation, or from the mucus of ICU patients or newly intubated control patients 
after treatment with 0.08% dithiothreitol. Cells were incubated at 37°C for 1.5 hours with 
serum-opsonised pHrodo® green S. aureus Bioparticles®. Phagocytosis was determined by 
flow cytometry gating of viable neutrophils with ingested particles, versus a control sample 
on ice. Horizontal bars depict median values. Kruskal-Wallis test and Dunn’s post hoc test 
were used, ****p<0.0001, blood ICU n = 20, control n = 16, mucus ICU = 11, control n = 9. 
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Figure 4.13 - Surface marker expression on subglottic mucus-derived neutrophils.  
Cells were extracted from the mucus of ICU patients or newly intubated control patients via 
treatment with 0.08% dithiothreitol. Viable neutrophils were stained with antibodies to the 
C5a receptor CD88, and activation markers CD11b (increased with activation) and CD62L 
(reduced with activation). Horizontal bars depict median values. Mann–Whitney U test, 
*p<0.05, CD88 ICU n = 19, control n = 15, CD11b ICU n = 21, control n = 15, CD62L ICU 
n = 15, control n = 12. MFI = median fluorescent intensity. 
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Figure 4.14 - Surface marker expression on blood-derived neutrophils.  
Mixed leukocytes were extracted from the whole blood of ICU patients or healthy volunteers 
via dextran sedimentation. Viable neutrophils were stained with antibodies to C5a receptor 
CD88, and activation markers CD11b (increased with activation) and CD62L (reduced with 
activation). Horizontal bars depict median values. Mann–Whitney U test, **p<0.001, ICU n 
= 18, control n = 16. MFI = median flourecent intensity. 
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4.4 Discussion 
In this chapter I sought to identify differences in subglottic host factors between long-term 
ventilated ICU patients and newly intubated control patients that may have contributed to the 
differences identified (in chapter 3 of this thesis) in the microbiology of the subglottic region 
in these two groups. I was able to demonstrate potentially important differences in the 
constituents and physical properties of the mucus derived from ICU patients compared to 
controls. Subglottic ICU mucus was shown to have a lower water content and higher 
concentration of MUC5B and DNA. These factors are likely to have contributed to the higher 
viscosity found with ICU subglottic mucus compared to control mucus samples. There was 
also evidence of local subglottic, as well as systemic, inflammation in the ICU cohort, 
compared to controls. There was also a significantly higher proportion, and concentration, of 
viable neutrophils in the subglottic mucus of ICU patients, compared to newly intubated 
controls. Finally there was no substantial difference in the phagocytic function of blood- or 
mucus-derived neutrophils, from ICU patients compared with controls. 
Changes in the proportion of mucus constituents can have significant effects on the physical 
properties of mucus, influencing its ability to function as a lubricant and selective barrier 
(81). I was able to demonstrate significantly more viscous mucus in the ICU subglottic 
samples than in controls. A number of factors that I investigated could have contributed to 
this, including the ratio of liquid to solids. The percentage of solids in mucus in health has 
been reported as anywhere between 2 – 10%, depending on the sub-site (193). Reference 
values are not available for the subglottic region. However in CF, characterised by 
dehydrated airways, levels are reported as commonly above 8% solids (194). The proportion 
of solids in sputum from asthmatic patients has been reported in the region of 7 - 8% (195). 
Levels in chronic bronchitis and bronchiectasis have been reported as approximately 6% 
solids (194, 196). The median percentage solid in the ICU cohort was only 3.6, compared to 
2.5 in newly intubated controls. While this does not approach the levels reported for these 
chronic diseases there was a broad distribution of values in the ICU cohort up to the levels 
found in CF. Even small differences in the concentrations of mucins may be sufficient to 
cause significant changes in the mucus viscosity (81, 197). I demonstrated a higher 
concentration of MUC5B in the subglottic mucus of long-term intubated ICU patients 
(median 21.7 mg/mL), compared to newly intubated controls (median 3.5 mg/mL). Reference 
values are not available for the subglottic region and reports from other respiratory sub-sites 
are variable and often based on older or non-quantifiable assays (81, 198, 199). Previous 
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comparable studies have suggested normal total mucin levels in a non-diseased airway of 
between 2 – 3 mg/mL (76, 96). An interesting study from Dennesen et al demonstrated total 
mucin levels in the lower airway of healthy controls as 1.9 mg/mL, ventilated patients 
without infection as 3.1 mg/mL and patient with VAP as 15.6 mg/mL (96). Mucus rheology 
is not simply determined by the concentration of mucins however. Mucin glycosylation and 
sulphation can affect viscosity also, which can change with multiple host and non-host 
factors, such as age or the presence of pathogens in the airway (77, 81). Furthermore the ratio 
of different mucins can affect viscosity. I have demonstrated that in the subglottic region 
MUC5B is the predominant mucin in both cohorts sampled. MUC5B and MUC5AC are by 
far the most predominant mucins in the airway, however their ratio can also vary depending 
on the airway sub-site (77, 83, 84). The importance of these mucin ratios are not understood, 
however changes in these ratios, due to mucin over or under production, has been 
demonstrated in many respiratory diseases, including pulmonary fibrosis, COPD and asthma 
(77, 200-202). DNA is another important factor in the viscosity of mucus, particularly in 
diseased airways (81). DNA can originate from epithelial shedding, but also neutrophil lysis, 
as is found in certain respiratory diseases like CF where DNase markedly reduces the 
viscosity of mucus (81). I was able to demonstrate significantly higher levels of DNA in the 
mucus of ICU patients, compared to controls.  
Increased mucus viscosity is thought to aid innate immune defence by trapping particles that 
can subsequently be cleared by the mucociliary escalator (77, 84). However it has been 
previously demonstrated that tracheal intubation can reduce the function of the mucociliary 
escalator (45-48). Failure of the mucociliary escalator combined with prolonged, extensive or 
inappropriate mucin hypersecretion has been implicated in airway obstruction and poor 
clearance of pathogens in many respiratory diseases, such as asthma, COPD and CF (77, 78, 
81, 88, 203).  
It has previously been demonstrated that even short-term tracheal intubation can result in 
significant mucosal inflammation in humans and animal models (49, 50). Even at a median 
time of 3 hours of intubation Puyo et al demonstrated a significant rise in cytokines IL-6 and 
IL-1β, an increasing trend of IL-8 concentration and a significant increase in C5a 
concentrations in a longitudinal theatre patient cohort (50). There was also a ten-fold increase 
in the number of polymorphonuclear cells over the same time (50). Puyo’s findings were 
however based on uncorrected lavage samples, which are known to be unreliable due to 
variable dilution factors (97). My results do however corroborate the findings of Puyo et al, 
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in that I was able to demonstrate significantly higher levels of IL-6 IL-1β, IL-8 and C5a in 
the mucus of long-term intubated ICU patients compared to controls. There are several 
methodological differences between the two studies, for example in the length of intubation, 
and also in the patient groups, theatre patients (in Puyo’s study) are less unwell than ICU 
patients (in my study) in most cases. Further to Puyo’s findings I was able to demonstrate 
significantly higher levels of GM-CSF and human neutrophil elastase in long-term intubated 
patients, when compared with controls.  
There are a number of reasons why the demonstrated levels of pro-inflammatory agents in the 
subglottic mucus of long-term-ventilated patients may be important. Firstly this may explain 
a mechanism behind the higher levels of MUC5B. A large number of inflammatory/immune 
response mediators have been shown to induce secretion of mucins by epithelial cells (77). 
Secretagogues associated with MUC5AC have been investigated far more extensively than 
MUC5B (77). However IL-8, IL-6 and IL-1β have all been implicated in increased secretion 
of MUC5B by airway cells (183-186). Secondly these agents may influence the recruitment 
of immune cells, particularly the large number of neutrophils demonstrated in my results. IL-
8 is a highly potent neutrophil chemokine, and IL-6, IL-1β, C5a and GM-CSF are all potent 
chemoattractants with roles in immune modulation (188, 204).  
Neutrophils are crucial to the clearance of bacterial pathogens and are one of the key first 
lines of defence in the innate immune response (52, 53). However prolonged, extensive or 
inappropriate neutrophil presence in the airway is associated with propagation of a number of 
diseases in the airway, including CF, asthma, COPD and bronchiectasis (63, 69-71). 
Neutrophils are predominantly pro-inflammatory cells, and their role is to acutely clear 
pathogens, and then rapidly leave the site or apoptose, thereby resolving the inflammation 
(52, 53, 63, 189). The presence of a large number of neutrophils in the subglottic mucus of 
long-term ventilated ICU patients is an important finding. Neutrophils release a multitude of 
pro-inflammatory cytokines, such as IL-8, IL-6 and IL-1β, which will further precipitate the 
local inflammation, neutrophil migration and MUC5B secretion (205). Neutrophils also 
release proteases either through degranulation, cell necrosis or NETosis (52, 53). An 
important protease in inflammation and disease is neutrophil elastase (63). Although its 
physiological role is to degrade phagocytosed proteins, it can also cause significant damage 
to the airway. Neutrophil elastase has been implicated in directly damaging the epithelial 
membrane by degrading structural proteins, propagating inflammation through the epithelial 
production of cytokines, such as IL-8 (64-66). Also prolongation of the inflammatory process 
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by degrading complement and releasing C5a, a potent chemoattractant for neutrophils (67). 
Neutrophil elastase has also been shown to reduce ciliary beat frequency of the respiratory 
epithelium (65). An important consideration however is the role of antiproteases, which are 
crucial to counteracting the effects of proteases (206). Measurement of these agents in 
subglottic mucus would be an important future area of investigation. The presence of large 
numbers of neutrophils are also likely to contribute to the accumulation of DNA through cell 
necrosis or NETosis, further contributing to increased mucus viscosity.  
An intriguing finding was the lack of increased neutrophil apoptosis in the ICU mucus-
derived neutrophil cohort, compared to controls. Neutrophil apoptosis is crucial to the 
resolution of inflammation (207-210). The presence of several times more neutrophils and no 
greater proportion of apoptotic cells in the ICU cohort would likely lead to a precipitation of 
inflammation (63, 189). Several pro-inflammatory cytokines, including GM-CSF, prolong 
neutrophil survival (211, 212). I was able to demonstrate significantly higher concentrations 
of GM-CSF in the ICU cohort than controls, which may in part explain these findings.  
I went on to investigate the functional abilities of neutrophils extracted from subglottic 
mucus. This involved extraction of cells from the mucus using DTT. DTT is a potent agent 
capable of splitting glycoprotein disulphide bonds, thus releasing cells from the mucin 
glycoprotein matrix. The literature is conflicting as to what degree DTT affects neutrophils 
function (213-216). DTT was used in both mucus-derived neutrophil cohorts, therefore 
reliable comparisons between neutrophil functional outcomes in these groups is possible. 
This demonstrated no difference in the percentage of cells involved in phagocytosis between 
ICU patients and newly intubated control patients. This therefore highlights that the large 
number of neutrophils in the subglottic mucus of ICU patients are as functionally capable as 
those from newly intubated controls. The neutrophils therefore appear to have intrinsic ability 
to phagocytose and clear pathogens. It should however be noted that by extraction from the 
mucus, the cells are removed from the environment in which they are expected to 
phagocytose, as described earlier in this chapter. The question therefore is: do these 
neutrophils still function as effectively if they were returned to the ICU or control mucus 
environment? This question is examined in chapter 5 of this thesis.  
The proportion of mucus-derived neutrophils involved in phagocytosis was significantly 
lower than that of blood-derived neutrophils. Direct comparison between these measurements 
has to be considered with caution due to the different methodologies used to extract these 
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cells (dextran sedimentation for blood and DTT treatment for mucus samples). This data may 
therefore represent an artefact of processing. I was unable to demonstrate any overall 
difference in phagocytosis between the ICU blood-derived neutrophils and neutrophils from a 
cohort of healthy volunteers. It should however be noted that the ICU cohort was an 
extremely heterogeneous group, including elderly septic patients and young post-head injury 
patients (see table 3.2). This may explain the large range of phagocytic capacity demonstrated 
in the ICU cohort. Previous studies have determined that blood-derived neutrophils from 
critically ill ICU patients have phagocytic dysfunction, which is thought to be mediated 
through over-exposure to C5a (41, 42). My current ICU cohort was however very different 
from these previous studies. The inclusion criteria were primarily around length of 
intubation, and not severity of illness. However, I did demonstrate significantly lower 
expression of CD88 (which is internalised on exposure to C5a) in the whole blood sample of 
the ICU cohort compared to healthy volunteer blood samples. This was in contrast to the 
absence of significantly higher plasma concentration of C5a overall. Furthermore I was 
unable to demonstrate any correlation between C5a and its marker CD88 and neutrophil 
phagocytosis. In fact the results from mucus-derived neutrophils demonstrated the contrary, 
in that CD88 was actually expressed at a higher level on neutrophils in the ICU cohort, than 
in controls. This was despite significantly higher levels of C5a detected in subglottic mucus 
of ICU patients compared to controls. This does however corroborate previous studies that 
showed airway lavage samples derived from critically ill patients were able to inhibit 
neutrophil phagocytic function, but in a mechanism independent of C5a (42).  
I did not observe any significant difference in neutrophil activation surface markers on ICU 
mucus- or blood-derived neutrophils, compared with control samples. It might be expected 
that with higher levels of neutrophil-relevant cytokines in the systemic circulation and 
locally, neutrophils would present a more activated phenotype (52, 53, 217). In the systemic 
circulation this could reflect the heterogeneous cohort of ICU patients, who in many cases did 
not have disseminated infection (72, 218). In the mucus samples this is less understandable 
and may be the result of DTT exposure, which has been suggested to affect expression of 
activation markers CD11b and CD62L (215, 216). 
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4.5 Conclusions  
Subglottic mucus from long-term intubated ICU patients demonstrated distinct physical and 
immunological differences from that of newly intubated control patients. This may have 
contributed to the microbiological differences found in chapter 3 of this thesis. The presence 
of a tracheal tube for an extended period of time in long-term ventilated patients is likely to 
have led to the increased pro-inflammatory cytokine levels found in the subglottic mucus. IL-
8, IL-6, IL-1β, C5a and GM-CSF are likely to have contributed to the recruitment, and 
persistence of, a vast numbers of viable neutrophils in the subglottic region of long-term 
intubated ICU patients. These neutrophils are likely to have had a further pro-inflammatory 
effect through release of cytokines and inflammatory proteases, such as neutrophil elastase. 
In parallel, non-resolving inflammation is liable to have contributed to the differences in the 
mucus constituents and physical properties of ICU-derived mucus, when compared to 
controls. In particular the effect of IL-8, IL-6 and IL-1β may have propagated the higher 
levels of MUC5B found in the subglottic mucus of ICU patients. Finally, when extracted 
from their mucus environment, the neutrophils found in the subglottic mucus of ICU patients 
had no defect of phagocytosis, compared to that of newly intubated controls. Chapter 5 of this 
thesis will investigate further if the mucus of ICU patients is capable of inhibiting neutrophil 
function.  
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4.6 Future work 
Key considerations in interpreting the findings in this chapter include the cohorts used; this is 
discussed in section 3.6.  
Specific issues relevant to this chapter include the lack of matched control blood and mucus 
samples. This was to prevent an additional procedures on this patient group. However, in the 
design of a new study, a control volunteer/patient cohort that would have comparable mucus 
and blood samples would be highly valuable. Another consideration is the anaesthesia 
applied to the theatre attender controls, which can have systemic inflammatory effects on the 
body (219, 220). An ideal control population would be awake non-intubated volunteers, 
however sampling from this region would be highly technically challenging. 
It would be beneficial to increase the number of biological repeats of several key 
experiments. I was severely limited by the volume of mucus recovered from the control 
patients in particular. This limited the number of certain experiments I could do, particularly 
experiments such as viscosity measurements and phagocytosis assays, which require over 1 
mL of mucus. 
Further examination of mucus-derived neutrophil functions related to pathogen clearance 
would be useful (221). These would include: (a) neutrophil killing of live bacteria; (b) 
measurement of neutrophil oxidative burst, a key element of the neutrophil’s killing 
machinery; and (c) investigation of actin polymerisation, crucial to neutrophil phagocytosis 
and chemotaxis, which may give valuable insights into neutrophils’ functional abilities 
beyond just phagocytosis (52, 53). 
A further consideration of the neutrophil phagocytosis experiments is that the bioparticles 
were incubated with a population of mixed leukocytes. There were differing ratios of 
leukocytes in the ICU and control samples and this may introduce some bias. It should be 
also noted that all results were based on flow cytometry-gated viable neutrophil populations 
only. However, ideally a population of pure neutrophils would be incubated with bioparticles 
in each experiment to prevent any bias from the presence of other immune cells. This was, 
however, representative of the population found in this sub-site. Furthermore, it was 
technically impossible to separate the neutrophils from other immune cells in the mucus 
samples, without inducing further activation or loss of viability from the extended processing. 
Neutrophils are inherently more phagocytic than macrophages (the second most common cell 
type), it is therefore unlikely that the presence of these cells will have confounded the readout 
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for neutrophil phagocytic function significantly (222). A further potential confounding factor 
was the timing of blood and mucus sampling. Samples were obtained when pragmatic, rather 
than at a fixed time of day. Several studies have suggested that neutrophils have a circadian 
rhythm with variable function throughout the day and night (223). It was logistically 
impossible to sample at a uniform time within or between any cohort groups. Sampling at a 
uniform time of day in future studies would reduce this potential bias. 
The mucin ELISA used to measure MUC5B and MUC5AC were in-house ELISA kits 
developed within our research group. Optimisation of these ELISA techniques was 
performed within the research group. There are several limitations to the use of these types of 
assays. One key consideration is the use of standards, specifically purified pig gastric and 
human salivary mucin. Ideally the results of these ELISA would be confirmed by other 
techniques to confirm the validity of these important findings. Unfortunately there are limited 
antibodies available for these mucins and many other techniques rely on the same primary 
antibodies for detection.  
There are a multitude of other factors that could be measured (by ELISA or other techniques) 
from the subglottic mucus samples, and may be relevant to local host defences. These include 
the level of other antimicrobial peptides, antiproteases and defensins and also constituents 
such as protein and lipids, which may have also impacted on viscosity. Finally, there may be 
future value in the assessment of glycosylation and sulphation of mucin molecules, which are 
important to mucin function and mucus viscosity, as previously discussed.  
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Chapter 5: The effect of mucin on neutrophil function and epithelial-pathogen 
interactions 
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5.1 Introduction  
Mucus covers the epithelial lining of the respiratory tract (77, 84). Its role is in clearance of 
pathogens, through the mucocillary escalator, and as a chemical barrier protecting the 
epithelium beneath (78, 79, 84, 86). Mucus consists primarily of water and mucin (77, 81). 
More than 20 mucins are described, however by far the most predominant secreted (and gel-
forming) mucins in the airway are MUC5B and MUC5AC (77, 83, 84). Changes in the 
proportion or properties of mucins can have significant effects on the rheological properties 
of mucus, influencing its ability to function as a lubricant and selective barrier (81). Acute 
mucin hypersecretion is thought to aid innate immune defence by trapping particles (77, 84). 
Nevertheless, prolonged, extensive or inappropriate mucin hypersecretion has been 
implicated in airway obstruction and poor clearance of pathogens in many respiratory 
diseases, such as asthma, COPD and CF (77, 78, 81, 88, 203). In chapter 4 of this thesis I 
demonstrated a higher concentration of mucin MUC5B in the subglottic mucus of long-term 
intubated ICU patients (median 21.7 mg/mL), compared to newly intubated controls (median 
3.5 mg/mL). I therefore decided to investigate the impact of these higher mucin 
concentrations on aspects of innate immune defence relevant to the subglottic airway and 
potential VAP development. 
The neutrophil is the key innate immune cell involved in the clearance of bacterial pathogens 
(52, 53). It has previously been suggested in one in vitro study that high mucin concentrations 
(31.2 mg/mL total mucin) may adversely affect neutrophils’ capacity for chemotaxis and 
bacterial killing (76). These findings have, however, not been corroborated, nor have the 
mucin concentrations found in the subglottis of long-term intubated ICU patients been 
investigated. Mucins have also been implicated in promoting bacterial growth (89, 93). VAP-
causing bacteria, such as P. aeruginosa, have previously demonstrated the capacity to digest 
the highly glycosylated portions of mucins, using them as a nutrient source (89, 93).  
I therefore aimed to investigate the impact of relevant subglottic mucin concentrations on 
healthy volunteers’ neutrophil function, and secondly the impact on bacterial growth.  
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5.2 Chapter aims 
In this chapter I wished to answer the following questions: 
1. What effect does mucin concentration have on neutrophil function? 
2. What effect does mucin concentration have on bacterial-epithelial interactions? 
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5.3 Results 
5.3.1 The impact of mucin concentration on neutrophil phagocytic function 
I designed experiments to determine if mucin, purified from the mucus of long-term 
ventilated ICU patients, impacted on the function of neutrophils. The experiments described 
used healthy volunteer whole blood-derived neutrophils, and concentrations of mucin that 
were found in the subglottic region of; a) long-term ventilated ICU patients, and b) newly 
intubated control patients (demonstrated in chapter 4 of this thesis). 
Firstly neutrophil viability was assessed at various concentrations of mucin. This 
demonstrated no significant reduction in viability of neutrophils incubated in any of the 
mucin concentrations tested, compared to a no mucin control sample (Figure 6.1). A key role 
of neutrophils is their ability to kill bacteria. This was assessed though co-culture of 
neutrophils with P. aeruginosa lab strain PA01. This demonstrated significant reduction in 
killing at 20 mg/mL mucin (Figure 6.2). I went on to investigate possible reasons for this 
dysfunction. Using a chemotaxis assay to measure the ability of neutrophils to migrate 
towards an attractant, a significant reduction in chemotaxis at 20 mg/mL mucin was observed 
(Figure 6.3). 
In chapter 4 (Figure 4.12) of this thesis I demonstrated no significant difference in phagocytic 
function between neutrophils extracted from the subglottic mucus of long-term ventilated 
ICU patients (with high mucin levels) and newly intubated control patients (with lower mucin 
levels). I therefore investigated if mucin might induce a transient reduction in neutrophil 
function, impairing neutrophil function while in that high mucin environment, but reversible 
upon removal from it. Consequently I assessed the ability of neutrophils to phagocytose 
opsonised bacterial bioparticles while incubated in mucin, and after subsequent removal from 
the mucin, using a relevant mucolytic compound DTT (used to extract neutrophils derived 
from subglottic mucus samples). This assay demonstrated a significant phagocytic 
dysfunction in neutrophils cultured in 20mg/mL mucin, corroborating the bacterial killing 
results, but also demonstrated a significant restoration of this function after application of the 
mucolytic compound (Figure 6.4).  
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Figure 5.1 - Neutrophil viability in mucin.  
Blood-derived neutrophils from healthy volunteers (n = 5) were incubated at 37°C in purified 
mucin (in HBSS with Ca2+ and Mg2+) for 1 hour prior to flow cytometric analysis of viability, 
using Annexin V and propidium iodide. Data are expressed as median and 95% CI. Kruskal-
Wallis test and Dunn’s post hoc test were used to compare the differences against the control 
without mucin. No significant difference was found at any concentration. 
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Figure 5.2 - Neutrophil killing of live bacteria in mucin.  
Blood-derived neutrophils from healthy volunteers (n = 6) were incubated at 37°C in purified 
mucin (in HBSS with Ca2+ and Mg2+) for 30 minutes with autologous serum-opsonised P. 
aeruginosa PA01. Bacterial killing was determined by serial dilution on LB agar plates, and 
colonies counted at 24 hours to give a percentage reduction in colony forming units (CFU), 
compared to a sample without neutrophils. Data are expressed as median and 95% CI. 
Kruskal-Wallis test and Dunn’s post hoc test were used to compare the differences against 
the control without mucin, *p<0.05. 
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Figure 5.3 - Neutrophil chemotaxis in mucin. 
Blood-derived neutrophils from healthy volunteers (n = 5) were fluorescently labelled with 
CFSE and incubated at 37°C in purified mucin (in HBSS with Ca2+ and Mg2+) within a 
transwell insert (3.0 µm pore size). The number of neutrophils that migrated from the apical 
compartment to the lower compartment (containing 10,000 pg/mL IL-8) at 3 hours were 
counted using a confocal microscope and automated software. Data are expressed as median 
and 95% CI. Kruskal-Wallis test and Dunn’s post hoc test were used to compare the 
differences against the control without mucin, *p<0.05. 
 
 
Control 5 10 20
0
1000
2000
3000
Mucin concentration (mg/mL)
N
um
be
r o
f n
eu
tro
ph
ils
 m
ig
ra
te
d 
to
 th
e 
lo
w
er
 w
el
l 
*
Jason Powell  Chapter 5 
   126 
 
Figure 5.4 - Neutrophil phagocytic function in mucin and after extraction from mucin. 
Untreated - Blood-derived neutrophils from healthy volunteers (n = 6) were incubated at 
37°C in purified mucin (in HBSS with Ca2+ and Mg2+) for 1 hour with autologous serum-
opsonised pHrodo® green S. aureus Bioparticles®.  
Mucolytic-treated - Blood-derived neutrophils from healthy volunteers (n = 6) were 
incubated at 37°C in purified mucin (in HBSS with Ca2+ and Mg2+) for 30 minutes prior to 
treatment with 0.08% dithiothreitol for 5 minutes, centrifuged and re-suspended (in HBSS 
with Ca2+ and Mg2+), containing no mucin. Neutrophils were then incubated at 37°C for 1 
hour with autologous serum-opsonised pHrodo® green S. aureus Bioparticles®.  
Phagocytosis was determined by flow cytometric gating of viable neutrophils with ingested 
particles versus a control sample on ice. Data are expressed as median and 95% CI. Kruskal-
Wallis test and Dunn’s post hoc test were used to compare the differences against the control 
without mucin. Mann–Whitney U tests were used to compare individual concentrations with 
and without mucolytic treatment, *p<0.05. 
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5.3.2 The impact of mucin concentration on bacterial-subglottic epithelial interactions.  
I further sought to investigate the impact of mucin concentration on epithelial-bacterial 
interactions. Using P. aeruginosa lab strain PA01 and tissue relevant samples I performed 
bacterial-epithelial co-culture experiments. The development and characterisation of the 
differentiated subglottic epithelial cell cultures used are described in chapter 6 of this thesis. 
Bacterial-epithelial co-culture demonstrated that increased bacteria were present in the mucin 
layer and epithelial homogenate of cell cultures with an apical mucus layer of 20 mg/mL 
mucin (the highest tested concentration), compared with a no mucin control (Figure 6.5). 
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Figure 5.5 - Bacterial-mucin-epithelial interactions.  
The mucus layer of primary subglottic epithelial cells (PSEC), cultured at ALI (n = 4), was 
removed and replaced with 50 µL of purified mucin (in HBSS with Ca2+ and Mg2+), and 
incubated for 1 hour (37°C 5% CO2). P. aeruginosa [5 µl (2x107 CFU/mL), PA01] was then 
applied apically and incubated for 7 hours. Bacterial growth in the mucin layer and epithelial 
homogenate was determined by serial dilution on LB agar plates, counted at 24 hours. Data 
are expressed as median and 95% CI. Kruskal-Wallis test and Dunn’s post hoc test were used 
to compare the differences against the control without mucin, *p<0.05. 
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5.4 Discussion 
In this chapter I sought to investigate the impact of mucin on both neutrophil function and 
bacterial-epithelial interactions, using concentrations of mucin found in the subglottis of both 
long-term intubated ICU patients and newly intubated controls (as described in chapter 4 of 
this thesis). Using purified mucin extracted from the subglottic region of long-term intubated 
ICU patients and neutrophils extracted from the whole blood of healthy volunteers I 
demonstrated that 20 mg/mL mucin (representative of long-term intubated ICU patients), but 
not lower concentrations (representing newly intubated control patients), had a significant 
negative impact on phagocytosis, bacterial killing and chemotaxis. However no condition 
tested had a significant impact on neutrophil viability. Furthermore I demonstrated in 
bacterial-epithelial co-culture experiments that mucin concentrations found in long-term 
intubated ICU patients were associated with increased bacterial growth in vitro.  
This is the first time neutrophil function has been assessed in mucin concentrations found in 
the subglottis of long-term intubated ICU patients. Matsui et al (76), in the only other study 
investigating the impact of mucin on neutrophil phagocytic function, demonstrated reduced 
chemotaxis and bacterial killing at 31.2 mg/mL mucin, which they used as a model of CF. I 
was able to demonstrate similar dysfunction at 20 mg/mL, which is more relevant to the 
mucin concentration in the subglottis of long-term intubated ICU patients (median MUC5B 
concentration in long-term intubated ICU patients was 21.7 mg/mL, as described in chapter 4 
of this thesis). Matsui et al (76) also used purified mucin derived from in vitro air-liquid 
interface cultures of primary CF and non-CF lower airway cells. There is evidence suggesting 
that in vitro cultures have variable mucin ratios and differing properties, compared with in 
vivo mucins (77, 79). It has also been demonstrated that mucin proportions and properties are 
variable depending on the location within the airway (77). I therefore used mucin derived 
from direct sampling of mucus from the subglottic region of long-term intubated ICU 
patients, providing location- and disease-relevant mucin for experimentation. I was also able 
to extend the findings of Matsui et al (76), by changing the concentration of mucin, and by 
further investigating dysfunction using a variety of neutrophil functional assays. Further to 
this I was able to provide the first demonstration of the reversibility of this neutrophil 
dysfunction with a mucolytic agent DTT, suggesting a potential translational opportunity for 
these findings. 
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I was also able to demonstrate reduced bacterial killing and ingestion of opsonised bacterial 
bioparticles at mucin concentrations found in the subglottis of long-term intubated ICU 
patients. In contrast no reduction in these functions were observed at lower concentrations 
representative of those found in mucus from the subglottis of newly intubated controls. The 
ability of neutrophils to ingest and kill pathogens, which these assays test, are key to 
neutrophil function (52, 53). Failure to perform these functions are likely to result in an 
inability to clear pathogenic organisms. Furthermore, neutrophil presence in the airway 
mucosa has been implicated in the generation of inflammation, through degranulation and 
other mechanisms (63, 224-226). Therefore the presence of dysfunctional neutrophils within 
the subglottis of long-term intubated patients may actually have detrimental effects in driving 
harmful inflammation and further mucin secretion.  
An important finding was the impairment of neutrophil chemotaxis at high concentrations of 
mucin, further supporting the findings of Matsui et al (76). The ability of neutrophils to 
migrate towards an attractant is crucial to clearance of pathogens (52, 53). It has been 
extensively demonstrated that mucin has an impact on the rheological properties of mucus in 
the airway and that hypersecretion increases viscosity (79). It would therefore follow that 
high viscosity mucin may inhibit the migration of cells. However, I was unable to 
demonstrate that this was a purely rheological dysfunction in chemotaxis. I attempted to 
utilise a non-mucin agent, with similar rheological properties, to investigate this, however all 
agents tested were toxic to the neutrophils. The reversibility of the neutrophil dysfunction 
with DTT further supports the hypothesis that this is a rheological effect however. The 
finding that neutrophil chemotaxis increased at 5 mg/mL compared to the control (no mucin) 
concentration is intriguing and requires further investigation. I would hypothesise that this 
mucin concentration recapitulates a normal physiological concentrations of mucus (and 
viscosity), unlike the 0 mg/mL control, therefore is a preferential environment for neutrophil 
chemotaxis. 
The preservation of neutrophil viability after incubation with higher concentrations of mucins 
is an intriguing finding. This indicates that the loss of neutrophil function is due to a 
functional deficiency and not loss of viability. The assay used was also able to detect even 
early signs of death, such as apoptotic cells. There was however a slight, non-significant 
increases in the proportion of late apoptotic and necrotic cells at the highest mucin 
concentrations. A further vitality marker was included in experiments such as the pHrodo® 
Bioparticles® phagocytosis experiments to negate this potential bias. Necrosis is a form of 
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non-programmed cell death that allows for the release of inflammatory agents, previously 
contained within the cell, into the surrounding environment (227). It is often associated with 
precipitating airway inflammation in respiratory conditions, such as asthma, CF and COPD, 
unlike apoptosis which is considered non-inflammatory (227). Neutrophils are however 
predominantly pro-inflammatory cells when viable too (52, 53, 63, 189). Neutrophils release 
a multitude of pro-inflammatory cytokines and proteases through degranulation and in the 
formation of neutrophil extracellular traps (NET) (52, 53). NETs are produced by neutrophils 
as an additional method of pathogen killing, where intracellular contents, such as human 
neutrophil elastase and histones, are released into the extracellular environment (228, 229). It 
could be hypothesised that in response to impaired chemotaxis or phagocytosis in the high 
mucin environment, neutrophils may be stimulated into “netosis”. Production of NETs has 
been implicated in many respiratory and autoimmune diseases as precipitating inflammation 
(228, 229). I attempted to perform assessment of NET formation in vitro with mucin, 
however NETs are extremely fragile and the assay was impractical with viscous mucin.  
Bacterial-epithelial co-culture experiments demonstrated that high mucin concentrations, 
found in the subglottic mucus of long-term intubated ICU patients, induce increased bacterial 
growth, compared to lower mucin concentration (Figure 6.5). The mucus layer is intended to 
act as a chemical barrier and to clear pathogens via the mucociliary escalator (78, 79, 84, 86). 
Therefore mucin may be acting as a deterrent, protecting the epithelial membrane by 
providing an alternative location for bacterial growth (230). However the finding that there is 
also increased bacterial growth in the epithelial homogenate suggests a seriously detrimental 
effect of higher mucin levels. Once bacteria are able to adhere to the epithelial membrane 
they are more likely to invade, increasing their growth and potentially resulting in 
disseminated infection (231, 232). Furthermore in long-term intubation it is thought that 
aspiration of infected mucus from around the cuff that is responsible for VAP development; 
hence increase growth in the mucus layer may be more harmful (14, 233). Further to this, the 
protective effects of bacteria accumulating in the mucus layer (as apposed to in the 
epithelium) relies on the airways ability to clear these pathogens through cough or the 
mucociliary escalator (84). There is evidence that long-term intubation, through cuff pressure 
and inflammation, prevents cough and induces ciliary dysfunction, preventing clearance of 
infected mucus from the airway (1, 14). 
A key consideration when interpreting the findings in this chapter is the use of purified 
mucin. I used well-established methods to purify mucin from the patient mucus samples 
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(136-139), however it is possible that these methods may have altered the properties of the 
mucin molecules through the extensive processing (136-139). Steps were undertaken to 
ensure purity of the sample, including assessment of protein and DNA content (136-139). 
Furthermore it was not possible to purify all the samples of mucin together or individually, 
therefore I pooled batches of mucin into three purification runs, and this does introduce the 
potential for batch effects between these samples. Nevertheless non-purified mucin contains a 
multitude of substances, such as proteins, DNA and bacteria (81, 84), which would affect the 
assays described and not allow for reproducible in vitro investigation. 
The findings in this chapter will of course need further validation. However they do suggest 
potentially interesting translational aspects to be investigated. The reversibility of the mucin-
induced neutrophil dysfunction with a mucolytic agent would suggest the potential to trial 
mucolytic agents in the subglottis of long-term intubated ICU patients, as a method of 
potential VAP prevention. I utilised the mucolytic agent DTT in my experiments as it is a 
well established laboratory agent for neutrophil extraction from mucus samples (216). DTT is 
however a toxic agent and not used in humans (234). Nevertheless various other mucolytic 
agents have been effectively used in patients with cystic fibrosis, where mucin concentration 
is also thought to be a factor in disease development (235) (236). These agents include simple 
substances with milder and relatively acceptable side effect profiles, such as hypertonic saline 
(used successfully in cystic fibrosis (36)), which could be topically applied to the subglottic 
region, given the available access to this area in long-term intubated ICU patients.  
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5.5 Conclusions 
Mucin at concentrations found in the subglottis of long-term intubated ICU patients, but not 
newly intubated control patients, had a significant impact on neutrophil function. The 
neutrophil functions measured included several crucial to pathogen clearance in the airway 
(52). Furthermore, in an in vitro subglottic epithelial model, mucin at concentrations found in 
the subglottis of long-term intubated ICU patients was associated with increased bacterial 
growth, in both the mucus layer and epithelial membrane.  
These findings demonstrate, for the first time, that concentrations of mucin found in the 
subglottis of long-term intubated ICU patients may prevent neutrophil clearance of 
pathogenic bacteria, as well as contribute to bacterial growth. Neutrophil function and 
bacterial growth was unaffected at the concentrations of mucin found in newly intubated 
control patients. This may explain the microbiological differences between these two cohorts, 
as demonstrated in chapter 3 of this thesis. The data also demonstrated that mucin-induced 
neutrophil dysfunction is reversible with the application of a mucolytic agent, suggesting 
potential therapeutic strategies to restore host defences in this region and possibly prevent 
VAP development.  
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5.6 Future work 
The work in this chapter was limited by the yield of purified mucin from mucus available 
from patients in the ICU. Further validation of these findings with larger numbers of repeats 
would be vital. Another important consideration would be time course analysis, with 
extension of the mucin incubation time used. Finally the addition of higher concentrations of 
mucin would give greater understanding of the impact of mucin on neutrophil function and 
bacterial growth. 
Further understanding of the mucin-induced neutrophil dysfunction could be ascertained 
from analysis of other key neutrophil functions related to pathogen clearance (221). These 
would include: (a) measurement of neutrophil oxidative burst, a key element of the 
neutrophil’s killing machinery; (b) investigation of actin polymerisation, crucial to neutrophil 
phagocytosis and chemotaxis; and (c) measurement of neutrophil degranulation, which may 
give valuable insights into neutrophils’ functional abilities in mucin beyond just phagocytosis 
(52, 53).  
The finding that neutrophils have reduced chemotaxis in higher concentrations of mucins 
raises the question of whether this is a physical, viscosity-related dysfunction or whether it is 
a reversible physiological effect of the mucins on neutrophils. The use of an agent with a 
similar viscosity to the mucin concentrations used would allow investigation of this. I 
attempted some preliminary investigation into this but found all compounds available to be 
toxic to the neutrophils. Furthermore it would be interesting to expand on the impact of 
mucin on neutrophil chemotaxis over serial time points (rather than just at one time point) to 
investigate neutrophil chemotaxis speeds. 
While the lab strain of P. aeruginosa, PA01, used in the experiments described is 
appropriate, it would be useful to investigate clinical strains of P. aeruginosa and other 
organisms, such as S. aureus (9). This would be especially relevant in the case of the 
bacterial-epithelial co-cultures, where different organisms may interact differently with 
mucins. The bacterial-epithelial co-cultures would also benefit from the addition of immune 
cells, particularly neutrophils, to increase comparability of the model to that of the in vivo 
environment (237).  
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Chapter 6: Development of subglottic epithelial cell cultures 
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6.1 Introduction  
The subglottis is an anatomical region of the upper airway that forms the inferior portion of 
the larynx and is continuous inferiorly with the trachea (238, 239). Its boundaries are defined 
superiorly by the inferior arcuate line of the vocal cord and inferiorly by the lower margin of 
the cricoid cartilage (238). In ventilated patients, after introduction of a tracheal tube 
(endotracheal or tracheostomy), the cuff of the tube is inflated in the trachea, directly below 
the subglottic region (14). This close association suggests that the subglottic region may have 
a particular importance in the pathogenesis of VAP (14, 15). This significance is 
demonstrated by the universal incorporation of subglottic drainage into international 
guidelines as an effective method for VAP prevention (12, 25, 27, 240, 241). Despite this, 
little is known about the subglottic environment in long-term ventilated patients at high risk 
of developing VAP (242, 243) 
It follows that valid experimental models are required to further elucidate the pathogenesis of 
subglottic disease in ventilated patients prior to VAP development and to evaluate novel, 
potentially therapeutic compounds. A number of animal models of tracheal tube placement, 
ventilation and VAP development have been described, including mice, pig, primate, dog and 
cat (98-101). These models, while useful, have several limitations, including inter-species 
differences in submucosal gland distribution, innate immunity, epithelial cell composition 
and ion channel expression (108-111).  
Human primary cell cultures and cell lines have previously been established from other 
respiratory epithelial sub-sites, including the trachea and small airways of the lung (118-120). 
These are, however, unlikely to reflect the subglottic region. The subglottis is an 
anatomically distinct region of the airway, differentiated from the trachea due to its 
circumferential binding to the cricoid cartilage, giving it unique physical properties (26, 238). 
These unique properties include a large number of seromucous glands present in the 
submucosa of the subglottis (238). In addition, subglottic blood vessels include a dense sub-
epithelial capillary plexus with numerous anastomoses. This hypothetically results in stronger 
functional blood flow with resultant warming of air (238). During inflammation this is likely 
to lead to rapid widening of vessels with subsequent oedema and recruitment of defence cells 
into the region (238). Therefore in vitro culture of primary subglottic epithelial cells (PSECs) 
from newly intubated theatre attenders is likely to produce a superior cellular model to those 
produced by primary or immortalised cell lines from other respiratory sub-sites, with 
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characteristics that replicate more accurately those found in vivo. Furthermore, well 
differentiated PSEC cultures maintained at air-liquid interface (ALI) may therefore be a 
useful model of airway epithelial function and have the potential to allow for developments 
in our current knowledge of the pathophysiology of VAP and subglottic disease (121, 244, 
245).  
To the best of my knowledge, prior to the commencement of this work, PSECs had not been 
cultured. PSECs therefore represent a novel and potentially highly valuable resource for 
upper airway and VAP research. 
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6.2 Chapter aims 
In this chapter I wished to answer the following questions: 
1. Is it possible to collect and culture epithelial cells from the subglottic region? 
2. Can these cells be cultured at an air-liquid interface? 
3. What are the characteristics of subglottic epithelial cells subjected to in vitro culture 
and do they approximate to the in vivo environment? 
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6.3 Results 
6.3.1 Development of a method to culture primary subglottic epithelial cells (PSECs) 
The detailed methods that were used to collect and culture subglottic epithelial cells are 
described in the methods section (chapter 2). The culture techniques published by Forrest et 
al (118) and Fulcher et al (121) were used as an initial template, and were subsequently 
optimised through experience and supervisor input. 
The process of obtaining subglottic samples for culture from patients attending for a 
laryngeal examination under general anaesthesia required not only technical skills of 
sampling and culture, but also excellent working relationships between a multidisciplinary 
team within the otolaryngology unit. The most successful recruitment method was through 
the theatre waiting list team identifying suitable patients for recruitment. Clinic letters were 
then reviewed and potential study participants sent information packs. Furthermore the 
helpful co-operation of the operating surgeon, theatre scrub team and other team members 
was also vital to successful recruitment.  
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6.3.2 Outcomes of primary subglottic epithelial cell culture	
Subglottic brushings were collected between August 2014 and May 2016. In total, 33 patients 
were screened for recruitment, of these 26 had subglottic brushings taken. Reasons for not 
sampling were mainly related to theatre scheduling issues, such as patients not attending or 
being cancelled. There were 4 refusals to participate in the study. Feedback, at one-week post 
procedure, was received from 6 of the initial study participants. Patients reported some initial 
throat discomfort after the procedure as would be expected with intubation and laryngeal 
examination. There were no reported adverse events or complaints about the study process or 
sampling. 
The yield of ciliated respiratory epithelial cells was ascertained from the subglottic mucosal 
brushings by differential cell count on a haemocytometer. The median number of ciliated 
epithelial cells per brush was 940,000, of which 15% (median 145,000 cells) were alive and 
84% (median 790,000 cells) were dead (Figure 6.1). A number of other cells were visible on 
the haemocytometer and cytospin preparations. These included neutrophils, macrophages and 
squamous cells, which were not included in cell counts (Figure 6.2). 
Submerged culture was successful in 17/26 (65%) patients from whom samples were taken 
(Figure 6.3). When unsuccessful this was initially due to failed growth as the sampling and 
culture techniques were optimised. There was a steep learning curve for the optimal brushing 
technique, which is key to obtaining the appropriate number of cells for successful culture. 
Later failure was mainly due to fungal infection in the first three days of culture. Overall 6 
(23%) of all the samples taken had microbiologically proven Candida albicans infection 
despite the potent anti-fungal agent Amphotericin B being included in all the medium used 
for culture. 
In those samples passaged to ALI culture 13/17 (77%) were successfully cultured to full 
differentiation (presence of cilia and mucus production apically on visual inspection with a 
light microscope). Of those that were unsuccessful the failure was usually within the first 2 
weeks after the apical medium was removed. The cells became fibroblastic and lost epithelial 
resistance. Overall half of the total samples taken made it to full differentiation without 
incident.  
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Figure 6.1 - Ciliated epithelial cells extracted from subglottic mucosal brushings. 
Subglottic mucosal brushing samples (n = 6) were processed to extract cells, which were 
stained with Trypan Blue. Ciliated respiratory epithelial cells were counted under a light 
microscope using four quadrants on a haemocytometer. Live cells were identified through 
exclusion of Trypan Blue. Box and whisker plots are depicted which display median, 
quartiles and range.  
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Figure 6.2 - Cytospin image of a Giemsa stained subglottic brushing sample. 
Cytospins were prepared of the subglottic mucosal brushings to validate the morphology and 
appearance of the cell subsets identified by cell count. These demonstrated the presence of 
multiple cell types, including ciliated epithelial cells (arrows), red blood cells and immune 
cells. Cytospins were stained with Giemsa to visualise the cell nucleus.  
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Figure 6.3 - Phase-contrast micrograph of primary subglottic epithelial cells cultured 
under submerged conditions. 
Submerged cultures demonstrate typical ‘cobblestone’ appearance, typical of epithelial cells. 
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6.3.3 Characterisation of subglottic epithelial cells at air-liquid interface culture  
The median time at which samples were passaged onto transwells from submerged culture 
was 10 (range 6 - 16) days. After removal of apical medium motile cilia were first visible at 
light microscopy at a median of 20 (range 16 - 34) days. In ALI culture phase-contrast 
microscopy demonstrated, on repeated occasions, characteristic epithelial morphology and 
growth, including tight epithelial junctions, cilia coverage and beating and mucus production.  
I characterised these cultures using a variety of techniques. Firstly, subglottic epithelial cells 
grown on collagen-coated transwell membranes, and differentiated at ALI, were stained with 
an epithelial marker recognising pan-cytokeratin. The subglottic epithelial cells stained 
positively for cytokeratin (Figure 6.4) in a similar pattern to other respiratory epithelial sub-
site brushings (excluding fibroblast or other cell contamination) (118). Scanning electron 
microscopy (SEM) was used to confirm cilia coverage apically (Figure 6.5). The 
transmission electron microscopy (TEM) further demonstrated the structural appearance of 
an epithelial membrane (Figure 6.6).  
Paraffin-embedded sections of cultured cells were prepared. Haematoxylin and eosin (H and 
E) staining was used to highlight epithelial architecture within these sections. This allowed 
examination of the histological appearance of the in vitro epithelial culture and demonstrated 
a pseudostratified (rather than monolayer) epithelial culture, consistent with cellular 
differentiation (121) (Figure 6.7). Diastase resistant periodic acid-Schiff (DPAS) staining was 
used for recognition of mucin glycoproteins in paraffin-embedded epithelial sections. This 
demonstrated relevant glycoprotein coverage through purple staining on the apical surface. 
This is a classical marker for epithelial in vitro differentiation as it demonstrates mucus 
production  (Figure 6.8) (121). DPAS is a standard marker of cell differentiation but is non-
specific, as it stains for all glycoproteins. Therefore antibodies against MUC5B and 
MUC5AC were used to test for the individual mucins within paraffin-embedded sections of 
epithelial membranes. This suggested a predominance of MUC5B within the epithelium over 
MUC5AC (Figure 6.9). 
A characteristic of normal airway epithelial cells is the ability to form a tight epithelial 
junction and specific ion channel activity across the apical membrane (246). In order to 
investigate whether the differentiated subglottic epithelial cells retained electrophysiological 
phenotypes found in other respiratory epithelial sub-sites, Ussing chamber 
electrophysiological studies were performed on differentiated subglottic epithelial cells 
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grown on Snapwells at ALI over a period of days of exposure to air apically (247). At just 8 
days a high level of epithelial resistance was measured (>1000 Ω.cm2) (Figure 6.10). This 
continued to increase when measured at day 15. There was still an epithelial resistance of 
over 400 Ω.cm2 up to 79 days. The cells also retained the characteristic electrophysiological 
channel profile expected of a normal airway, such as apical epithelial sodium channel 
(ENaC) and cystic fibrosis transmembrane conductance regulator (CFTR) expression (Figure 
6.10). Tight epithelial junctions (>800 Ω.cm2) were further confirmed in the transwell culture 
systems at day 20 – 30 of apical air exposure using chopstick electrodes to measure trans-
epithelial electrical resistance (TEER) (Figure 6.11).  
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Figure 6.4 - Pan-cytokeratin staining of primary subglottic epithelial cells.  
Fully differentiated epithelial cells, fixed and permeabilised, were stained with anti-
cytokeratin (pan reactive) antibody, conjugated with Alexa Fluor® 647. The cells were then 
mounted in medium containing DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride). A 
confocal fluorescent camera (Zeiss Axio Imager II, Germany) was used to image the cells. (a) 
DAPI nuclear stain (blue), (b) anti-cytokeratin (pan reactive) antibody, conjugated with 
Alexa Fluor® 647 (red), (c) combined image of DAPI and cytokeratin, (d) unstained control 
to which the other images were referenced (no isotype control used).  
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Figure 6.5 - Scanning electron microscopy of a differentiated epithelial culture. 
Images taken by scanning electron microscopy (SEM) of the apical aspect of the epithelial 
cells cultured in air-liquid interface conditions. 
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Figure 6.6 - Transmission electron microscopy of a differentiated epithelial culture. 
Images taken by transmission electron microscopy (TEM) of the epithelial cells cultured at 
air-liquid interface conditions. 
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Figure 6.7 - Haematoxylin and eosin staining of a paraffin-embedded section of the 
differentiated epithelial culture. 
Fixed cells were sectioned to 5 µm thickness and stained with Haematoxylin (nuclear/blue) 
and Eosin Y (cytosolic/red). 
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Figure 6.8 - Diastase resistant periodic acid-Schiff staining of a paraffin-embedded 
section of a differentiated epithelial culture. 
DPAS was used as a stain for mucin glycoproteins (dark purple) and counter-stained with 
Haematoxylin (nuclear/blue) and Eosin Y (cytosolic/red). 
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Figure 6.9 - Immunohistological staining for MUC5AC and MUC5B  
Sections were incubated with primary antibodies to either MUC5B (Tepa II) or MUC5AC 
(45M1) and secondary horseradish peroxidase-conjugated antibody. The sections were 
counter-stained with haematoxylin. An isotype control (IgG) was also tested in place of the 
primary antibody in each experiment. Human tonsil tissue was used as a negative tissue 
control for the antibodies. MUC5AC and MUC5B (brown stain), counter stained with 
Haematoxylin (blue) - 1a and 2a respectively. 1b and 2b are isotype controls for MUC5AC 
and MUC5B antibodies respectively. 1c and 2c are tissue (tonsil) controls for MUC5AC and 
MUC5B antibodies respectively. 
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Figure 6.10 - Ussing chamber electrophysiological studies of the differentiated subglottic 
epithelial cell membranes over time.  
Ussing chamber electrophysiological studies were performed on differentiated subglottic 
epithelial cells grown on Snapwells at air liquid interface over a period of exposure to air 
apically. Short-circuit current (Isc) values reflect anion (Cl-) secretion and/or cation 
absorption (Na+). Exposure of the epithelium to 10µM Amiloride (AMIL) blocked the apical 
epithelial sodium channels (ENaC) in the polarised epithelial cells. 10µM forskolin (FSK) 
was then added to activate cAMP cascades and caused a significant elevation in whole 
epithelial current. 20µM inh172, a specific CFTR inhibitor, reversed this elevated Isc current, 
which demonstrated that the vast proportion of the Forskolin response was accountable by 
CFTR. Resistance was monitored by applying 5mV voltage pulses at 30 second intervals and 
monitoring the change in Isc (not shown). This was multiplied by the surface area of the 
transwell to give an electrical resistance value in Ω.cm2.  
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Figure 6.11 - Trans-epithelial electrical resistance measurements from differentiated 
epithelial membranes 
Trans-epithelial electrical resistance (TEER) measurements were taken using chopstick 
electrode probes across differentiated epithelial cells in a transwell culture system (day 20 – 
30 apical air exposure). Horizontal line represents median value, n = 9. 
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6.3.4 Characterisation of the mucus layer covering subglottic epithelial cells cultured at 
air-liquid interface  
Differentiated PSECs at ALI culture produced an apical mucus layer. This in vitro mucus 
layer was sampled and quantification of gel forming mucins and cytokines was performed. 
The in vitro mucus layer contained the two main gel-forming mucins MUC5AC and MUC5B 
expected in vivo (Figure 6.12). The mucus layer also contained important cytokines relevant 
the in vivo airway (Figure 6.13). The concentrations of these agents were variable, as one 
would expect with the heterogeneity of the patients they were derived from. 
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Figure 6.12 - Mucins MUC5B and MUC5AC concentration in mucus samples from in 
vitro air-liquid interface (ALI) subglottic epithelial cell cultures. 
Mucin MUC5B and MUC5AC concentrations were quantified from aspirates of the apical 
mucus layer of in vitro PSEC cultures at ALI and measured via ELISA. Horizontal bars 
depict median values, n = 11 MUC5B, n = 9 MUC5AC 
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Figure 6.13 - Cytokine content in in mucus samples from in vitro air-liquid interface 
(ALI) subglottic epithelial cell cultures. 
Cytokines were measured using MSD mutli-plex immunoassay. Horizontal bars depict 
median values, n = 8. 
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6.4 Discussion 
Despite the challenges of new sampling methodologies and the presence of resistant 
microorganisms I have been successful in establishing a programme to culture PSECs from 
newly intubated theatre attenders. The PSECs were characterised in terms of their 
morphology (light microscopy, electron microscopy and haematoxylin and eosin staining) 
and immunohistochemistry (cytokeratin staining). In addition, it was possible to perform 
electrophysiological experiments to demonstrate epithelial tight junctions and appropriate ion 
channel expression (143). Under unstimulated ALI conditions the PSECs produced a mucus 
layer with relevant expression of mucins MUC5B and MUC5AC, in addition to a number of 
cytokines that would be expected in vivo (182). 
A key consideration when using primary tissue in research is that the clinical care of patients 
is not compromised. The method described in this chapter allows PSECs to be collected from 
newly intubated theatre attenders without biopsy or significant airway trauma. This is 
important because the subglottic region is prone to stenosis after irritation or trauma, such as 
post-intubation (248).  
The subglottis is an anatomically discrete region of the airway, distinct from the trachea due 
to the circumferential binding to the cricoid cartilage, giving it unique physical properties 
(26, 238). Furthermore there is increasing understanding of the importance of the laryngeal 
airway in immune signalling (249, 250). Therefore use of appropriate sub-site sampling is 
important to ensure that the in vitro model system accurately recapitulates the situation in 
vivo.  
The culture of PSECs is demanding, both in terms of effort and expense, and is limited by 
their finite lifespan. However, immortalised cell lines have inevitably undergone significant 
mutations, thus limiting their applicability to the in vivo environment (26, 238, 251). 
Furthermore, well differentiated PSEC cultures maintained at ALI are an excellent model of 
airway epithelial function and have the potential to allow for developments in our current 
knowledge of the pathophysiology of VAP and upper airway disease (121). 
While my aim was to develop a model of the subglottic region, it is clear from in vivo work 
(described in chapter 4 of this thesis) that the subglottic environment varies between 
individuals. The PSECs generally seem to reflect this inherent biological heterogeneity in 
terms of their function. The expression of mucins closely approximated the in vivo 
environment of newly intubated theatre attenders (from which population they are derived). 
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This recapitulation of the in vivo mucin environment is absent in many other epithelial 
models, which demonstrate significant up or down regulation of specific mucins in vitro (77, 
252, 253). Interestingly the cytokine expression varied among common airway cytokines, 
some being up-regulated and some down-regulated. This is likely related to culture 
techniques and the lack of immune cells or other external stimuli in the in vitro culture (251).  
It is often difficult to get large airway-derived primary airway samples from volunteers 
without respiratory co-morbidities (because there is no clinical indication for bronchoscopy). 
Therefore these cells, taken from theatre attenders without significant respiratory co-
morbidities or acute disease may represent a useful ‘control’ tissue for respiratory 
researchers. Furthermore there are a number of subglottic diseases, including subglottic 
stenosis and malignancy that this model could be used to investigate (254-256). 
While these theatre attenders were attending Ear, Nose and Throat (ENT) theatres for a 
laryngeal examination, and did not have significant respiratory co-morbidities or airway 
malignancy, these patients often had laryngeal symptoms. The origin of these symptoms was 
often not found but there may have been a multitude of undetected influences including 
laryngopharyngeal reflux (257). One must therefore be cautious in calling the participants 
‘healthy volunteers’. However given the difficulty of sampling this region via other methods, 
such as awake bronchoscopy (due to the close association with the vocal cords), this cohort 
represent an important resource. 
Ideally I would have liked to develop a similar model taken from long-term ventilated 
patients on the intensive care unit (ICU). This was attempted in a small cohort of patients, 
however I found that it was not possible, due firstly to low yield of viable cells and secondly 
to fungal or bacterial infections, despite various antibiotic regimens trialled.  
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6.5 Conclusions 
To my knowledge this is the first primary human epithelial model of the subglottic region to 
be described. I have characterised this model via a number of methodologies and have 
confirmed it to be highly representative of the subglottic environment of newly intubated 
theatre attenders. This unique model provides the potential to study subglottic diseases and 
potentially test therapeutic agents with a sub-site-specific in vitro model. 
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6.6 Future work 
PSECs have been established in a number of newly intubated theatre attenders. Further 
sampling and establishment of cultures would of course be beneficial. An area for future 
work would be the development of PSECs from long-term intubated ICU patients. This 
would give a more relevant model of long-term ventilation from the specific patients who are 
most susceptible to VAP. However, it is not entirely clear whether these cells would retain 
their in vivo characteristics, such as mucin hypersecretion, when cultured in vitro (121). A 
further area for investigation would be the response of these cells at ALI culture to 
stimulations (such as LPS or cytokines) to investigate if the mucin and cytokine profile of 
ICU patients could be better recapitulated. There are a number of potential ways to improve 
the in vitro model through various advanced culture techniques. Firstly the co-culture of these 
epithelial cells with human immune cells, particularly neutrophils, as found in the airway 
(258, 259). Additionally, the use of a feeder lay (such as fibroblasts). These layers supply 
metabolites to their supporting epithelial cells and can better recapitulate inflammatory 
responses to challenges (260). These feeder layers can also be used in the context of three-
dimensional culture systems (using supports such as collagen) which more recapitulate the in 
vivo environment (261). Another potential area for exploration is the development of 
immortal clones of these subglottic epithelial cells using commercially available kits (262). 
Viral agents can be introduced (by other viral transfection vectors), to provoke mutations in 
epithelial cells. These mutations can prevent or slow cellular senescence with division (262). 
Immortal subglottic cells would have the benefits of allowing rapid expansion of cell 
numbers and would be subsite specific. However these mutants would have the limitations of 
other cell lines, as discussed in section 6.4.   
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7.1 General discussion 
7.1.1 Overview 
VAP is associated with significant morbidity, mortality and costs (5, 263). Furthermore the 
excessive use of antimicrobial agents in VAP treatment and prevention is contributing to 
antibiotic resistance (150). The subglottic region appears key to VAP pathogenesis, however 
lack of understanding of the pathophysiology of VAP is limiting the development of further 
prevention strategies (1, 15, 24). I therefore chose to investigate the subglottic region in long-
term intubated ICU patients, with a particular focus on mucins. I used a variety of techniques 
to address these questions and the four main strands of interest to emerge from this work are 
discussed below. 
 
7.1.2 The microbiology of mucus derived from the subglottis 
It is hypothesised that infected mucus pooled in the subglottis, immediately above the 
tracheal tube cuff, is aspirated into the lung and results in VAP. I therefore aimed to 
characterise the microbiology of subglottic mucus from patients on the ICU who were 
intubated for four or more days and compared these findings to newly intubated control 
patients’ mucus. Utilising semi-quantitative microbiology cultures as well as bacterial/fungal 
gene sequencing I was able to demonstrate significant differences in the microbiology of the 
mucus from the two groups. Importantly there was significantly less diversity of organisms in 
the ICU mucus, compared to controls. Reduced microbial diversity has been associated with 
progression of several inflammatory respiratory conditions, particularly in CF (154-157, 
264). However the importance of this change is debated in the literature, with some studies 
finding the converse (264). An important consideration is why the microbial diversity was 
lower in the ICU cohort compared to newly intubated controls. An obvious consideration 
would be the effect of antibiotics and immunosuppressive agents, received by 83% and 21% 
of the ICU cohort respectively. These rates were well within those expected from previously 
published studies (149, 150). It has however been suggested that lung microbiome changes 
during intubation and ventilation, are independent of antibiotic administration (151). Another 
consideration is whether my control population of newly intubated patients may have had 
increased microbial diversity due to the placement of the endotracheal tube, contaminating 
the subglottis with oropharyngeal commensal organisms (158, 159). Assessment of the 
microbiology of the subglottis in non-intubated patients would be needed to fully examine the 
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‘normal’ subglottic microbiome. However, all the ICU patients had also undergone 
endotracheal intubation (not tracheostomy), it could therefore be contended that the newly 
intubated group represented an appropriate control group. It has been extensively 
documented that oral health deteriorates with hospital admission, even without intubation, 
and this leads to subsequent microbiological changes (176, 265). Not all ICU patients were 
intubated at the time of hospital admission and this may be a confounding variable. If the oral 
microbiology had already changed with hospital admission or illness, and the patient was 
subsequently intubated, this could have potentially introduced different organisms into the 
subglottis, compared to a well patient, admitted for theatre (as in the control cohort). 
Subgroup analysis would be needed in a larger cohort to further investigate this.  
I was also able to demonstrate different organisms in the two cohorts. Broadly the organisms 
identified in the ICU cohort were more pathogenic, in that they are more often associated 
with respiratory disease and antimicrobial resistance (genera such as Pseudomonas, 
Escherichia and Klebsiella) (266-270). However many organisms have the ability to be 
pathogenic, given the right circumstances. Furthermore, the microbiology of VAP is highly 
variable, depending on several factors, including the geographical location and patient group 
(8, 9, 11, 271). A large proportion of VAP cases, particularly early VAP (usually classified as 
up to day 3 after intubation) are associated with airway commensal organisms, including 
Streptococcus and Actinomyces, both found more frequently in the control cohort (8, 9, 11, 
271). All ICU patients were intubated and mechanically ventilated for four or more days. 
Therefore based on previous VAP studies I would have expected the non-commensal type of 
organisms identified (8, 9, 11). The greater proportion of samples with fungal organisms in 
the ICU cohort, compared with controls, was an intriguing finding. The rates of fungus in 
VAP lavage samples are relatively low (8, 9, 11, 271). Further investigation of the potential 
synergistic relationship between fungal and bacterial organisms, in the upper airway, would 
be of interest. 
When considering these results it is important to note that I sampled patients at four or more 
days after intubation. This was in order to understand the effect of prolonged intubation on 
the subglottic microbiology and host defences. One critique could be that most ICU patients 
are not in fact intubated for so long (median length of ICU stay is 1.4 days), and a shorter 
period would be more relevant (272). Further longitudinal sampling over the period of 
intubation would be beneficial. Another consideration is that these findings are not as 
translatable to the proportion of ICU patients who are tracheotomised. There is increasing 
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emphasis on early tracheostomies to improve lung mechanics, decrease the need for 
sedatives, enhance communication and prevent long-term complications, such as subglottic 
stenosis (273, 274). A tracheostomy provides a conduit between the skin and the trachea and 
it is likely that these patients would have different airway microbiology from the patients 
with endotracheal tubes (9).  
Antimicrobial resistance is increasing and ICU patients are large contributors to antibiotic use 
and the propagation of resistance (275-277). It is obvious that prevention of VAP is 
preferable to treatment of the condition, in terms of reduced mortality and antibiotic usage 
(278). The subglottis is crucial to VAP development, therefore greater understanding of the 
reasons for these subglottic microbiological differences may lead to greater understanding of 
the pathophysiology of VAP, and inform novel, non-antimicrobial, preventive strategies (27). 
I therefore went on to investigate if the microbiological differences described could be 
associated with changes in local host defences.  
 
7.1.3 Characterisation of subglottic mucosal host defences 
Critical illness and subsequent intubation and mechanical ventilation are usually associated 
with an acute illness, possibly on the background of chronic disease (32). The most engaged 
host defences will therefore most likely be primarily from the innate immune system (30). 
This consists of structural defences, such as epithelial mucosal membranes, antimicrobial 
molecules, the complement system, as well as immune cells, such as neutrophils and 
macrophages (31). I utilised a number of techniques to quantify various aspects of host 
defences in the subglottic mucus and in the systemic circulation. Comparing long-term 
intubated ICU patients and newly intubated controls I was able to demonstrate a number of 
physical/constituent and immunological differences between the mucus samples (Figure 7.1).  
Broadly the differences demonstrated were, within the ICU cohort, greater concentrations of 
MUC5B (but not MUC5AC), greater DNA content and lower water content, compared to 
controls. As would be expected the ICU mucus also exhibited increased viscosity. It is 
reasonable to hypothesise that this is related, in part at least, to the differences in the 
individual mucus components I demonstrated (81). Other mucus constituents, such as protein 
and lipids, can also contribute to viscosity, but to a lesser degree than elements such as 
mucins. In this sub-site MUC5B was found to be at far higher concentrations than MUC5AC. 
To my knowledge this has not been described previously, although the ratio of MUC5B and 
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MUC5AC (the two main secreted airway mucins) can vary according to the airway sub-site 
(77, 83, 84). Changes in the mucus constituents and viscosity can have significant impact on 
the function of mucin as a lubricant and selective barrier (81). Increased mucus viscosity is 
characteristic of several acute and chronic respiratory diseases, but is best characterised in 
CF, where this is thought to be crucial to disease pathogenesis and deterioration of respiratory 
health (77, 78, 81, 88, 203). 
The immunological differences were broadly demonstrative of an inflamed airway in the ICU 
cohort, compared to controls (279, 280), with significantly greater concentrations of pro-
inflammatory cytokines, higher neutrophil counts, and greater concentrations of neutrophil 
elastase and C5a. There was no significant difference in macrophage counts.  
I went on to investigate the phagocytic function and activation markers expressed on 
neutrophils extracted from the mucus. No difference was observed in phagocytic function 
between neutrophils extracted from long-term intubated ICU patients and newly intubated 
controls. There was also no significant difference in activation markers CD62L or CD11b. I 
therefore proceeded to investigate these differences in ICU blood-derived neutrophils, and in 
blood-derived neutrophils from a cohort of healthy volunteers. Once again no differences 
were demonstrated. Neutrophils from critically ill patients have previously been shown to 
have an activated phenotype and significant phagocytic dysfunction (42, 72, 73). There are a 
number of potential explanations for these findings in both blood and mucus. A noteworthy 
consideration must be the ICU cohort I recruited. This was a heterogeneous cohort, not 
unified by any one severe illness, such as sepsis, as in other studies (42). Furthermore 
neutrophil dysfunction is typically only found in significant disease states, and even then only 
in a limited proportion of patients (42). The spread of results for phagocytic function was far 
greater in the ICU blood and mucus samples, compared to the corresponding controls. With 
the mucus samples in particular there is also the confounding variable of DTT used to extract 
neutrophils from mucus. This has been demonstrated to affect surface marker expression and 
possibly the functional ability of neutrophils (213-216). There is however another 
consideration; that the mucus-derived neutrophils are removed from the in vivo mucus 
environment, which they would normally function within. 
Previous studies have demonstrated that even short-term (median time 3 hours) tracheal 
intubation can result in significant tracheal mucosal inflammation in humans, with a 
significant migration of neutrophils, rise in cytokines IL-6 and IL-1β, and a significant 
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increase in C5a concentrations in a longitudinal theatre patient cohort (50). My cohort of ICU 
patients had a median intubation time of 5 days, therefore it can be postulated that placement 
of the tracheal tube results in early inflammation and the increased neutrophil counts that 
persist. Neutrophils are predominantly pro-inflammatory cells (52, 53, 63, 189). Therefore 
are likely to be an important driver of further inflammation, in addition to the recruitment and 
retention of neutrophils through agents such as IL-8 IL-6, IL-1β, C5a and GM-CSF (188, 
204). It has been previously established that tracheal intubation can reduce the function of the 
mucociliary escalator (45-48). This would likely lead to mucus stasis and accumulation of 
mucus constituents, such as DNA and MUC5B. Furthermore, IL-8, IL-6 and IL-1β have all 
been implicated in increased secretion of MUC5B by airway cells (183-186). A key 
consideration is why this inflammatory process is not attenuated by corresponded anti-
inflammatory mechanisms. One possibility is because of the continued presence of the 
inflammatory stimulus (i.e. the tracheal tube) this is not possible. However another possibility 
is related to the microbiology differences I revealed between the two cohorts. The presence of 
bacterial agents would likely modulate local immune responses, through tissue damage and 
the presence of bacterial agents, such as LPS, leading to further inflammation (157). 
Nevertheless, given the larger number of neutrophils in the subglottic mucus of long-term 
ventilated ICU patients, it should be expected that pathogenic bacteria would be cleared by 
these highly phagocytic cells (52, 53). I therefore went on to investigate if the high 
concentration of mucin may have an effect on neutrophil function and bacterial growth. 
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Figure 7.1 - Summary of findings related to the subglottic mucus constituents of long-
term intubated ICU patients, compared with newly intubated controls. 
 
 
7.1.4 The effect of mucin on neutrophil function and epithelial-pathogen interactions 
VAP is typically a bacterial infection, and the neutrophil is the key innate immune cell 
involved in the clearance of bacterial pathogens (8, 9, 11, 52, 53, 271). I therefore 
investigated the relationship between purified mucin, extracted from the subglottic region of 
long-term intubated ICU patients, and neutrophils extracted from the whole blood of healthy 
volunteers. I established that 20 mg/mL mucin (representative of long-term intubated ICU 
patients), but not lower concentrations (representing newly intubated control patients), had a 
significant negative impact on neutrophil phagocytosis, bacterial killing and chemotaxis. The 
data also revealed that mucin-induced phagocytic dysfunction was reversible with the 
application of a mucolytic agent. It has previously been suggested in one in vitro CF model 
that high mucin concentrations (31.2 mg/mL total mucin) may adversely affect neutrophils’ 
capacity for chemotaxis and bacterial killing (76). I extended these findings by using further 
assays and a lower concentration of mucin more representative of most of the ICU subglottic 
mucus. 
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In an in vitro subglottic epithelial model, I was also able to demonstrate that mucin 
concentrations found in long-term intubated ICU patients were associated with increased 
bacterial growth, in both the mucus layer and epithelial membrane, compared with 
concentrations found in control patients. The relationship between mucin and bacteria is 
contentious and poorly understood, particularly in the airway (77, 87). Mucins have no 
recorded anti-bacterial activity (281). However, they are able to offer binding sites similar to 
those of epithelial cells, preventing pathogen adhesion to the underlying epithelial cells, and 
clear pathogens via the mucociliary escalator (78, 79, 84, 86). This process is however 
subverted by pathogens in cases where the mucociliary escalator is dysfunctional, such as 
when there is particularly viscous mucus, or importantly during intubation (1, 14, 77). In 
these conditions mucins have been implicated in aiding bacterial propagation and biofilm 
formation, through acting as binding sites for pathogens (90-92). Another consideration is 
whether mucins may also act as a nutrient source for pathogens. This has been described 
mainly in the gastrointestinal tract, where a multitude of bacteria have been shown to be able 
to digest mucins and use them as an energy source (281-285). Increasingly there is evidence 
that similar processes may exist between airway pathogens and airway mucins (89, 93, 94, 
286, 287). These studies are however limited by the nature of the mucus membrane. Mucus 
layers contain a multitude of constituents and understanding the relationship between any two 
components is challenging. For example, several other small molecules in the mucus layer 
could support the growth of pathogens, including sugars, fatty acids, phospholipids, and 
amino acids (84, 146).  
I have summarised my hypothesised mechanism for the role of the subglottic region in VAP 
development in Figure 7.2. There are a multitude of potential interventions that could target 
various stages of the proposed pathogenic environment in the intubated subglottis, principally 
to restore the hypothesised neutrophil dysfunction and prevent bacterial proliferation. These 
could include agents to reduce inflammation, such as steroids or non-steroidal anti-
inflammatory drugs (NSAIDs). However, many patients are already on systemic anti-
inflammatory agents (149). Studies investigating the effect of these agents on infection are 
inconclusive (149, 288, 289). There would also be concerns about the impact of anti-
inflammatory agents reducing the immune response too greatly, and precipitating bacterial 
growth (149). A far more targeted approach would be to change the mucus constituents, and 
in particular the concentration of mucin directly. This could be achieved through a variety of 
simple methods. Many of these interventions are already safely used in respiratory 
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conditions, for example nebulised saline, which increases mucus water content, thereby 
diluting mucins and other viscous agents (36). A host of other mucus-altering therapies are 
also in use, including anticholinergics, β2‐adrenoceptor agonists, mucolytics and macrolide 
antibiotics (290). There are also some interesting recent advances in targeted therapeutic 
agents, specifically focusing on mucin granule release. These include the myristoylated 
alanine-rich C-kinase substrate (MARCKS) protein (291). Several studies have demonstrated 
that diminished MARCKS expression reduces the mucin secretory response to stimulation 
(291-294). Conversely mucins cover all mucosal membranes and serve a multitude of 
purposes within the body (295). Their importance was elegantly exhibited in a murine 
knockout model of MUC5B, which revealed (amongst other harms) increased respiratory 
infection and earlier death compared to controls (86). The ease of access to the subglottis 
would however allow for the potential use of local, topical agents, reducing the likelihood of 
systemic complications. 
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Figure 7.2 - Summary schematic regarding the proposed pathogenesis of a subglottic 
environment favouring development of ventilator-associated pneumonia (VAP). 
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7.1.5 Development of subglottic epithelial cell cultures 
The development of human in vitro models is an important step in understanding disease 
pathophysiology and in allowing the testing of potential therapeutic agents. It is likely that 
preventive strategies for VAP are hampered by lack of good human cellular models of 
disease (100, 112). I therefore describe the establishment of human ALI primary subglottic 
epithelial cell (PSECs) cultures. A number of animal models of tracheal tube placement, 
ventilation and VAP development have been described (98-101). These models, while useful, 
have several limitations (108, 296). Firstly there are a large number of inter-species 
differences; particularly relevant to this work are differences in innate immunity and 
epithelial cell composition (108-111). There are also ethical considerations around the use of 
animals in laboratory research. The UK NC3Rs (National Centre for the Replacement, 
Refinement and Reduction of Animals in Research) have encouraged the development of 
advanced, human-derived, in vitro models (296). It is likely that animal testing would be 
needed at some stage in the future, particularly in the development of therapeutics, prior to 
human trials. However, the in vitro model allows for the reduction of animal use and may 
give superior early objective outcomes (108, 296). There are a number of in vitro models of 
respiratory epithelial sub-sites described, such as the small airways and trachea (118-120). 
However the subglottis is an anatomically discrete region, giving it unique physical 
properties (26, 238). Therefore a sub-site-specific model is likely to recapitulate the in vivo 
environment more faithfully. PSEC cultures at ALI were extensively characterised in terms 
of morphology, cytokeratin immunohistochemistry, electrophysiology and mucus 
constituents. Cultures demonstrated features typical of what would be expected of the in vivo 
subglottic region. A limitation of this model is that the samples originated from the control 
cohort of theatre attenders, not critically unwell ICU patients. The development of a model of 
the subglottic airway from ICU patients remains a future aim. This was not possible in the 
current work due to infections in the cultures, despite the use of appropriate antimicrobial 
agents. Greater understanding of the subglottic microbiology of ICU patients, as described in 
chapter 3 of this thesis, will hopefully allow more targeted antimicrobial use in the culture 
medium, and prevention of infections in these cultures. 
I have therefore described, to my knowledge, the first primary human epithelial model of the 
subglottic region. This unique model will hopefully provide the potential to study subglottic 
diseases and test therapeutic agents.  
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7.2 Strengths and weaknesses 
Strengths and weaknesses related to specific scientific approaches are summarised in Table 
7.1. A global consideration is that this work comes under the umbrella term of translational 
research. This aims to define human disease and unmet clinical need through the 
characterisation of patients and disease mechanisms, thereby defining potential therapeutic 
targets, such as mucin (297). A limitation of early translational research is that it often uses in 
vitro methodology or small numbers of human samples. ICU patients are a heterogeneous 
group of patients and the sub-group who develop VAP are equally heterogeneous (148-150, 
298-302). These patients are of varying ages, co-morbidities, and have differing reasons for 
attendance to the ICU, all of which may impact on their immune function and risk of VAP 
development (303, 304) (305). Furthermore there are a plethora of other potential genetic and 
environmental factors that may impact on these risk factors (306, 307). This variability is 
challenging and requires sufficiently sized cohorts to discover and validate observations. 
Another consideration is that even when associations are identified they cannot robustly link 
cause and effect. The work described in this thesis broadly fits into the remit of a proof of 
concept study (147). Many of the techniques describe here were novel and even aspects such 
as the acceptability of sampling in the ICU and control populations constitute methodological 
advances. Further work is needed to validate observations made here in larger cohorts. It is 
also likely that in vivo models would need to be utilised in order to study potential disease 
mechanisms or therapeutic targets. These models have intrinsic limitations when compared 
with human tissue, but also advantages, such as the whole body model of disease (98-101, 
108-111). Ultimately human experimentation will be required to provide the most relevant 
insights into human disease. 
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Table 7.1 - Outline of specific strengths and weaknesses of the experimental design.  
 
 
 
 
 
 
Strengths Weaknesses 
• Long-term intubated ICU cohort 
• Newly intubated control cohort 
• Subglottic mucus examined from 
long-term intubated patients - unique 
• Matched ICU blood and mucus 
samples 
• Matched neutrophil functional assays 
from mucus and blood  
• Bacterial and fungal gene sequencing 
allowing microbiome assessment 
• Unique subglottic epithelial sampling 
and culture 
• Novel air-liquid interface cultures 
• No longitudinal cohort data 
• Only one mucus sub-site sampled 
• No ‘healthy’ mucus controls 
• Unable to perform all assays in all 
subjects due to limited mucus yields  
• No matched blood and mucus samples 
from controls 
• Heterogeneous ICU cohort 
• No fully quantitative microbiology data 
• No subgroup analysis of clinical 
outcomes, such as VAP development 
• Inadequate volumes of purified mucin 
limited in vitro experimentation 
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7.3 Future work 
The findings discussed here are intriguing and suggest multiple avenues for further 
investigation. The first direction would be to increase the participant numbers and 
experimental repetitions in key experiments. This would help to validate the current findings 
described in this thesis. I would attempt to do this in two parallel strands. Firstly I would 
recruit an appropriately sized longitudinal cohort of ICU patients, performing microbiological 
and host defence measures, as describe in this thesis. This would allow for assessment of 
clinical outcomes and subgroup analyses of potentially important clinical factors or outcome 
measures. This may also lead to the identification of important biomarkers and further 
elucidate the pathogenesis of VAP. Secondly, I would perform further in vitro 
experimentation, investigating the interaction between ICU-derived mucin, neutrophils and 
bacterial organisms. There are several areas for further exploration, all of which could 
promote additional understanding of the mechanistic effect of mucins. These experiments 
would include use of agents other than purified mucin to investigate if it is specifically 
mucin, or the viscosity of the mucus, that inhibits neutrophil function. This would be a key 
consideration when contemplating potential therapeutic targets. Another key area for further 
research is further improvement of the subglottic epithelial model and utilising this to 
investigate the complex interaction between the epithelium, ICU-derived mucins, and 
bacterial species. These in vitro findings would be of interest to VAP and upper airway 
researchers, but also researchers in other fields where mucins are thought important, such as 
in CF, asthma, COPD, bronchiectasis and otitis media (202, 308-311).  
Ultimately this research will hopefully lead to; a) a greater understanding of VAP 
pathogenesis, b) identification of potential biological markers for VAP risk, which are 
urgently needed, and c) trials of novel therapeutic/preventive targets (312, 313). There are a 
number of relatively low risk interventions available to target subglottic mucus, which have 
previously been used safely in other conditions, and could be trialled in VAP prevention 
studies. These include agents such as nebulised saline, which could be applied directly into 
the subglottic airway (235).  
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7.4 Final conclusions 
In conclusion, the microbiology of subglottic mucus from long-term intubated ICU patients is 
distinctly different from newly intubated controls. I propose that these differences are due to 
changes in the composition and constituents of the subglottic mucus, particularly the greater 
concentration of the mucin MUC5B. These changes are likely caused by the inflammatory 
nature of long-term intubation, as illustrated by larger neutrophil counts in ICU subglottic 
mucus, as well as increased concentrations of inflammatory cytokines, proteases and other 
agents. I further propose that the high mucin concentrations, found in long-term intubation, 
prevent neutrophils from clearing pathogens from the subglottic mucus, and may further 
directly promote bacterial growth. I was unable to demonstrate any significant difference in 
the ability of subglottic mucus-derived neutrophils to perform phagocytosis, once removed 
from the mucus layer. However, blood-derived neutrophils from healthy volunteers became 
functionally deficient in representative ICU-derived mucin concentrations in vitro, and 
regained their function upon treatment with a mucolytic agent. I also describe a novel air-
liquid interface culture of subglottic epithelial cells, which could be utilised for future 
translational research studies of disease mechanisms and testing of potential therapeutics. 
Given the morbidity, mortality and costs associated with VAP development, early prevention 
strategies are crucial. I suggest that reducing mucin concentrations in the subglottic region 
could reduce the infective burden of subglottic mucus prior to aspiration into the lungs, 
therefore potentially preventing VAP.  
Overall I offer an intriguing preliminary insight into the microbiology and host defences of 
the subglottic region in long-term intubated ICU patients. These findings have implications 
for VAP disease pathogenesis, disease markers, as well as the generation of novel 
therapeutics. I believe that further research will allow optimisation of new VAP prevention 
strategies, such as the administration of mucolytic agents to the subglottic region in ICU 
patients. 
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Full results of semi-quantitative microbiology cultures 
 
Control mucus  
(n = 25) 
ICU mucus  
(n = 23) 
Fisher's 
exact test 
No of samples % No of samples % P 
Streptococcus 23 92 9 39 0.0001 
Streptococcus salivarius 17 68 0 0 <0.0001 
Streptococcus vestibularis 2 8 0 0 0.4902 
Streptococcus mitis 1 4 0 0 >0.9999 
Staphylococcus epidermidis 0 0 1 4 0.4792 
Streptococcus anginosus 0 0 2 9 0.2243 
Other alpha haemolytic 
streptococci 
22 88 7 30 <0.0001 
Rothia 14 56 0 0 <0.0001 
Rothia mucilaginosa 12 48 0 0 <0.0001 
Rothia dentocariosa 1 4 0 0 >0.9999 
Other rothia species 2 8 0 0 0.4902 
Actinomyces 10 40 0 0 0.0007 
Actinomyces odontolyticus 4 16 0 0 0.1105 
Acinetomyces oris 2 8 0 0 0.4902 
Actnomyces odontolyticus 1 4 0 0 >0.9999 
Actinomyces graevenitzii 1 4 0 0 >0.9999 
Other actinomyces species 1 4 0 0 >0.9999 
Neisseria 7 28 2 9 0.1402 
Neisseria flavescens 5 20 0 0 0.0507 
Neisseria mucosa 1 4 1 4 >0.9999 
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Other Neisseria species 1 4 1 4 >0.9999 
Haemophilus 6 24 2 9 0.2487 
Haemophilus influenzae 3 12 1 4 0.6099 
Haemphilus parainfluenzae 1 4 1 4 >0.9999 
Haemophilus 
parahaemolyticus 
2 8 0 0 0.4902 
Haemophilus haemolyticus 0 0 1 4 0.4792 
Staphylococcus 4 16 3 13 >0.9999 
Staphylococcus aureus 2 8 1 4 >0.9999 
Staphylococcus capitis 0 0 0 0 >0.9999 
Staphylococcus epidermidis 2 8 1 4 >0.9999 
Staphylococcus pasteuri 0 0 1 4 0.4792 
Gemella 3 12 0 0 0.2354 
Gemella haemolysans 3 12 0 0 0.2354 
Veillonella 3 12 0 0 0.2354 
Veillonella atypica 2 8 0 0 0.4902 
Veilonella dispar 1 4 0 0 >0.9999 
Candida 2 8 9 39 0.0157 
Candida glabrata 1 4 2 9 0.6011 
Candida tropicalis 0 0 1 4 0.4792 
Other candida species 1 4 0 0 >0.9999 
Candida guilliermondii 0 0 1 4 0.4792 
Candida nivariensis 0 0 1 4 0.4792 
Candida albicans 0 0 4 17 0.0455 
Candida lusitaniae 0 0 1 4 0.4792 
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Candida parapsilosis 0 0 1 4 0.4792 
Moraxella 1 4 0 0 >0.9999 
Moraxella catarrhalis 1 4 0 0 >0.9999 
Capnocytophaga 1 4 0 0 >0.9999 
Capnocytophaga gingivalis 1 4 0 0 >0.9999 
Lactobacillus 1 4 2 9 0.6011 
Lactobacillus fermentum 1 4 0 0 >0.9999 
Lactobacillus rhamnosus 0 0 1 4 0.4792 
Lactobacillus gasseri 0 0 1 4 0.4792 
Pseudomona 0 0 2 9 0.2243 
Pseudomonas aeruginosa 0 0 2 9 0.2243 
Enterococcus 0 0 4 17 0.0455 
Enterococcus faecalis 0 0 4 17 0.0455 
Achromobacter 1 4 2 9 0.6011 
Achromobacter xylosoxidans 1 4 2 9 0.6011 
Bifidobacterium 0 0 3 13 0.1024 
Bifidobacterium breve 0 0 2 9 0.2243 
Bifidobacterium dentium 0 0 1 4 0.4792 
Atopobium vaginae 0 0 2 9 0.2243 
Alloscardovia 0 0 2 9 0.2243 
Alloscardovia omnicolens 0 0 2 9 0.2243 
Enterobacteriaceae* 1 0 11 43 0.0185 
Escherichia* 1 4 1 4 0.9520 
Escherichia coli 1 4 1 4 0.9520 
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Raoultella* 0 0 1 4 0.4792 
Raoultella ornithinolytica 0 0 1 4 0.4792 
Prevotella* 0 0 1 4 0.4792 
Prevotella melaninogenica 0 0 1 4 0.4792 
Morganella* 0 0 1 4 0.4792 
Morganella morganii 0 0 1 4 0.4792 
Hafnia* 0 0 1 4 0.4792 
Hafnia alvei 0 0 1 4 0.4792 
Providencia* 0 0 1 9 0.2243 
Providencia stuartii 0 0 1 4 0.4792 
Enterobacter* 0 0 2 9 0.2243 
Enterobacter cloacae 0 0 2 9 0.2243 
Klebsiella* 0 0 1 4 0.4792 
Klebsiella oxytoca 0 0 0 0 >0.9999 
Klebsiella variicola 0 0 1 4 0.4792 
Serratia* 0 0 2 9 0.2243 
Serratia marcescens 0 0 2 9 0.2243 
 
*Enterobacteriaceae family
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West Midlands - Edgbaston Research Ethics Committee 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
Telephone: 0115 8839695 
23 September 2015 
 
Professor Janet Wilson 
Prof of Otolaryngolgoy Head and Neck Surgery; Hon Consultant Otolaryngologist 
Newcastle University 
Department of Otolaryngolgoy Head and Neck Surgery  
Freeman Hospital 
Newcastle upon Tyne 
NE7 7DN 
 
 
Dear Professor Wilson 
 
Study title: Modulation of the upper airway host defences to prevent 
pneumonia in ventilated patients - ENT volunteers 
REC reference: 15/WM/0349 
 
Thank you for your letter of 22 September 2015.  I can confirm the REC has received the 
documents listed below and that these comply with the approval conditions detailed in our letter 
dated 18 September 2015 
 
Documents received 
 
The documents received were as follows: 
 
Document   Version   Date   
Participant information sheet (PIS)  2  22 September 2015  
Response to Request for Further Information [Covering Letter]    22 September 2015  
 
Approved documents 
 
The final list of approved documentation for the study is therefore as follows: 
 
Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Zurich Municipal insurance certificate]  
  30 July 2015  
GP/consultant information sheets or letters [GP letter]  1  08 July 2015  
IRAS Checklist XML [Checklist_07092015]    07 September 2015  
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A Research Ethics Committee established by the Health Research Authority 
 
 
North East - Newcastle & North Tyneside 2 Research Ethics Committee 
Room 001 
Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
NE32 3DT 
 
Telephone: 0191 4283563 
  
17 November 2015 
 
 
Dr Stephen Wright 
Consultant in Anaesthesia and Intensive Care 
The Newcastle upon Tyne Hospitals NHS Foundation Trust 
Perioperative and Critical Care 
Freeman Hospital 
Newcastle upon Tyne 
NE7 7DN 
 
 
Dear Dr Wright 
 
Study title: Modulation of the upper airway host defences to prevent 
pneumonia in ventilated patients - ICU attenders 
REC reference: 15/NE/0323 
IRAS project ID: 186924 
 
Thank you for your letter of 9 November 2015, responding to the Committee’s request for further 
information on the above research [and submitting revised documentation]. 
 
The further information has been considered on behalf of the Committee by myself as Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require 
further information, or wish to make a request to postpone publication, please contact the 
REC Manager, Mrs Helen Wilson, 
nrescommittee.northeast-newcastleandnorthtyneside2@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation [as revised], subject to the conditions specified below. 
 
Mental Capacity Act 2005 
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PerLR Consent form – Subglottic study - ICU   Version 4: 08/11/2015 
 
 
 
 
 
CONSULTEE CONSENT FORM 
 
 
 
Title of Project: Subglottic study - ICU       
         
                
Principal investigator: Dr Stephen Wright 
   
Please initial  
 
1. I (_______________) have been consulted about (_________________)’s participation 
 in this research project. I confirm that I have read and understand the information  
 sheet dated 8th November 2015 (Version 4) for the above study. I have had the  
 opportunity to consider the information, ask questions and have had these questions  [           ] 
 answered satisfactorily .   
  
2.  In my opinion he/she would have no objection to taking part in the above study. [           ] 
 
3.  I understand that I can request he/she is withdrawn from the study at any time,  [          ] 
 without giving any reason and without his/her care or legal rights being affected. 
 
4. i) I understand that relevant sections of his/her medical notes and data collected during the 
     study may be looked at by individuals from: the study team; the Sponsor (Newcastle 
     upon Tyne Hospitals NHS Foundation Trust) or their representatives; and from                   [          ] 
     regulatory authorities, where it is relevant to my taking part in this research.  
 
5. I agree to their GP or other care professional being informed of their participation in the  [          ] 
     study.  
 
 
 
 
________________________ ________________ ____________________ 
Name of consultee  Date Signature 
 
 
________________________ 
Relationship to patient 
 
 
________________________ ________________ ____________________ 
Researcher   Date  Signature 
 
 
1 copy for consultee; 1 for research site file; 1 for case notes 
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Participant Consent form – Subglottic study – ICU  Version 4:  08/11/2015 
 
 
 
 
 
PARTICIPANT CONSENT FORM 
 
 
Title of Project: Subglottic study - ICU       
                        
Principal investigator: Dr Stephen Wright 
Please initial  
1. I confirm that I have read and understand the information sheet dated 8th November 2015  
 (Version 4) for the above study I have had the opportunity to consider the information,   [           ] 
 ask questions and have had these questions answered satisfactorily .   
         
2.  I understand that my participation is voluntary and that I am free to withdraw at any  
 time, without giving any reason, and without my medical care or legal rights                       [           ] 
      being affected.     
 
3. i)I understand that relevant sections of my medical notes and data collected during the 
      study may be looked at by individuals from: the study team; the Sponsor (Newcastle 
      upon Tyne Hospitals NHS Foundation Trust) or their representatives; and from                   [          ] 
      regulatory authorities, where it is relevant to my taking part in this research. 
 
    ii) I give permission for these individuals to have access to my records, even if I withdraw 
      from the study, and  I understand that my records will only be reviewed for information  
      related to my participation in the study.                                                                                   [         ]                                                                                                  
 
4.  I agree that the research team may record information from my 
     case records solely for the purpose of this study.                                                                  [          ]                                       
 
5.  I agree that my throat samples may be used for this study.                             [          ] 
 
6.   I agree that my throat samples can be used in future studies  
                                  
7.  I agree that my blood samples may be used for this study.                              [          ] 
 
8.   I agree that my blood samples can be used in future studies  [          ]                                                                                           
 
9.   I consent to my GP being informed of my participation in this study.                                     [          ] 
 
10. I wish to receive a research summary after completion of the study.  [          ] 
 
 
 
________________________ ________________ ____________________ 
Name of Patient  Date Signature 
 
 
 
________________________ ________________ ____________________ 
Researcher   Date  Signature 
 
 
1 copy for patient; 1 for research site file; 1 for case notes 
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Version	4				Patient	information	sheet	(prospective)		
	
	
INFORMATION	SHEET	FOR	PATIENT	(Personal	consultee)	
	
Subglottic	study	–	ICU	
	
Introduction	
	
We	feel	your	relative/friend	is	unable	to	decide	for	himself/herself	whether	to	participate	in	
this	research	study.	
To	help	decide	if	he/she	should	join	the	study,	we’d	like	to	ask	your	opinion	whether	or	not	
they	would	want	to	be	 involved.	We’d	ask	you	to	consider	what	you	know	of	their	wishes	
and	 feelings,	 and	 to	 consider	 their	 interests.	 Please	 let	us	 know	of	 any	advance	decisions	
they	may	have	made	about	participating	in	research.	These	should	take	precedence.	
If	you	decide	your	relative/friend	would	have	no	objection	to	taking	part	we	will	ask	you	to	
read	and	 sign	 the	 consultee	declaration	on	 the	 last	page	of	 this	 information	 leaflet.	We’ll	
then	give	you	a	copy	to	keep.		We	will	keep	you	fully	informed	during	the	study	so	you	can	
let	us	know	if	you	have	any	concerns	or	you	think	your	relative/friend	should	be	withdrawn.	
If	 you	 decide	 that	 your	 friend/relative	 would	 not	 wish	 to	 take	 part	 it	 will	 not	 affect	 the	
standard	of	care	they	receive	in	any	way.	
If	you	are	unsure	about	taking	the	role	of	consultee	you	may	seek	independent	advice.		
We	will	understand	if	you	do	not	want	to	take	on	this	responsibility.	
	
The	 following	 information	 is	 the	 same	 as	 would	 have	 been	 provided	 to	 your	
relative/friend:	
You	 are	 being	 consulted	 about	 your	 opinion	 to	 take	 part	 in	 a	 research	 study.	 Before	 you	
decide	whether	or	not	to	take	part	it	is	important	for	you	to	understand	why	the	research	is	
being	 done	 and	 what	 it	 will	 involve.	 Please	 take	 time	 to	 read	 the	 following	 information	
carefully	and	discuss	it	with	others	if	you	wish.	
• Part	1	 tells	 you	 the	purpose	of	 the	 study	and	what	will	 happen	 to	 you	 if	 you	 take	
part.	
• Part	2	gives	you	more	detailed	information	about	the	conduct	of	the	study.	
	
Please	ask	if	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.		
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PART	1	
	
What	is	the	purpose	of	the	study?	
	
Patients	in	intensive	care	units	(ICUs)	often	require	help	with	their	breathing.	This	involves	
placing	 a	 plastic	 tube	 between	 the	 vocal	 cords	 of	 the	 unconscious	 patient,	 and	 into	 the	
windpipe,	after	which	the	tube	is	attached	to	a	ventilator	machine.	The	tube	is	kept	in	place	
by	 inflating	 a	 balloon	 (or	 "cuff")	 at	 the	 end	 of	 the	 tube,	 to	 hold	 the	 tube	 against	 the	
windpipe,	just	below	the	vocal	cords.	In	health,	the	vocal	cords	and	a	normal	cough	prevent	
germs	 entering	 the	 lung.	 Unfortunately,	 the	 combination	 of	 illness,	 reduced	 cough,	 and	
having	 a	 tube	 "bypassing"	 the	 vocal	 cords,	 leaves	 these	 patients	 extremely	 vulnerable	 to	
lung	infection.	This	infection	termed	"ventilator-acquired	pneumonia",	causes	more	deaths	
than	any	other	hospital-acquired	infection.	New	ways	to	prevent	it,	preferably	without	using	
antibiotics,	are	urgently	required.		
A	key	starting	point	would	be	identifying	how	germs	begin	their	journey	into	the	lung.	We	
know	germs	grow	rapidly	just	above	the	cuff	of	the	tube	in	the	voice	box	(an	area	known	as	
the	"subglottis"),	before	passing	into	the	lung.	To	understanding	how	this	happens	we	need	
samples	 from	people	 in	 ICU	 to	use	 in	 the	 laboratory	 for	 experiments	 and	 to	 identify	new	
treatments.		
What	will	happen	to	you	if	you	agree	to	take	part	in	the	study?	
	
In	addition	to	your	normal	care	you	will	receive	the	following	procedures–	
1)	An	extra	blood	test.	
2)	Samples	of	mucus	will	be	taken	from	your	throat	using	a	suction	tube.	
3)	A	sampled	of	 the	 lining	of	your	voice	box	will	be	taken	using	a	small	brush	passed	 into	
your	throat	via	a	small	telescope.	
	 	
Rather	than	throw	away	any	excess	blood	or	throat	samples	that	are	not	needed,	with	your	
permission,	we	will	keep	some	of	the	samples	to	be	used	in	any	future	research	by	our	
research	group	where	ethical	approval	has	been	granted.	
	
Why	have	you	been	chosen?	
	
The	research	is	specifically	looking	at	the	factors	in	the	throat	and	blood	that	put	patients	in	
the	intensive	care	unit	(ICU)	at	risk	of	serious	chest	infection.	The	fact	that	you	are	on	the	
ICU	for	several	days	means	that	you	are	eligible	for	entry	into	the	study.	
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Do	you	have	to	allow	your	information	and	samples	to	be	used	for	the	study?	
	
No,	it	is	up	to	you	to	decide	whether	to	take	part	in	the	research.	If	you	decide	to	take	part	
you	will	 be	 free	 to	 change	 your	mind	 at	 any	 time	 and	without	 giving	 a	 reason.	 It	 is	 very	
important	to	understand	that	if	you	do	not	wish	for	your	samples	/	clinical	information	to	be	
used	for	the	research	then	we	shall	fully	understand	and	this	will	not	in	any	way	alter	your	
care	now	or	at	any	stage	in	the	future.	
	
If	you	decide	you	would	rather	not	have	taken	part,	the	consent	form	that	comes	along	with	
this	document	will	give	you	2	options.	These	are	either	to	say		
1. That	you	do	not	wish	us	to	collect	any	further	information	about	you	for	the	study,	
but	we	may	keep	any	information/samples	collected	up	to	now.		
2. That	 you	wish	us	 to	destroy	all	 samples	and	 information	 relating	 to	 you	 that	have	
been	collected	as	part	of	the	study.	
	
What	are	the	possible	disadvantages	and	risks	of	taking	part	in	the	study?	
	
You	 should	 not	 experience	 any	 side	 effects	 from	 the	 drawing	 of	 blood.	 You	 should	 not	
experience	any	side	effects	from	the	sampling	from	your	throat.	
	
What	are	the	potential	benefits	of	you	taking	part	in	the	study?	
	
There	are	no	benefits	to	you	personally	in	taking	part	in	the	study.	Our	research	in	the	lab,	
however,	 is	 aimed	 at	 helping	 prevent	 people,	 such	 as	 you,	 from	 getting	 serious	 infection	
while	on	the	intensive	care	unit	in	the	future.	
	
Is	there	any	reimbursement	for	taking	part?	
	
No	
	
What	if	there	is	a	problem?	
	
Any	complaint	about	the	way	you	have	been	dealt	with	during	the	study	will	be	addressed.	
The	detailed	information	on	this	is	found	in	Part	2.	
	
Is	the	study	confidential?	
	
Yes.	We	will	follow	ethical	and	legal	practice	and	all	information	about	you	will	be	handled	
in	confidence.	The	details	are	included	in	Part	2.	
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If	 the	 information	 in	 Part	 1	 has	 interested	 you	 and	 you	 are	 considering	 participation,	
please	read	the	additional	information	in	Part	2	before	making	a	decision.	
	
PART	2	
	
What	happens	if	you	change	your	mind?	
	
You	can	change	your	mind	at	any	point.	If	you	subsequently	decide	that	you	do	not	want	to	
take	part	in	the	study	you	can	insist	that	all	research	data	and	samples	be	destroyed.	
	
What	if	there	is	a	problem?	
	
If	 you	 wish	 to	 complain,	 or	 have	 any	 concerns	 about	 the	 way	 in	 which	 you	 have	 been	
approached	 or	 treated	 during	 the	 course	 of	 this	 study	 you	 should	 ask	 to	 speak	 to	 the	
researchers	who	will	 do	 their	best	 to	answer	your	questions.	 If	 you	 remain	unhappy,	 and	
with	to	complain	formally,	you	can	do	so	via	the	normal	NHS	complaints	procedure.	
	
What	if	something	goes	wrong?	
	
In	the	event	that	something	goes	wrong,	and	you	are	harmed	during	the	research,	and	this	
is	 due	 to	 someone’s	 negligence,	 then	 you	 may	 have	 grounds	 for	 legal	 action	 for	
compensation	against	Newcastle	Upon	Tyne	Hospitals	Foundation	Trust,	but	you	may	have	
to	pay	your	legal	costs.	The	normal	NHS	complaints	service	will	still	be	available	to	you.	
	
Will	your	taking	part	be	kept	confidential?	
	
Yes,	 personal	 data	will	 be	 regarded	as	 strictly	 confidential.	 Any	 samples	or	 data	 collected	
about	 you	 (such	as	 your	 age	and	medical	 conditions)	will	 be	marked	with	 a	unique	 study	
number	only,	preventing	you	being	recognised	by	anyone	outside	the	study	team.	This	study	
number	 will	 allow	 only	 an	 authorized	 member	 of	 the	 research	 team	 to	 identify	 you	 if	
absolutely	necessary.	Data	will	be	stored	in	a	secure	location	within	your	hospital	and	at	the	
central	 study	 location	 at	 Newcastle	 University.	 Data	 will	 be	 retained	 at	 these	 sites	 for	 5	
years,	following	this	time	it	will	be	disposed	of	as	confidential	waste.	
Can	you	access	the	results	of	the	research?	
	
Yes.	 We	 aim	 to	 send	 all	 participant	 a	 summary	 of	 the	 study	 finding	 after	 the	 study	 is	
completed	and	analysis	performed.	This	may	take	several	years.	Should	you	wish	to	know	
details	 before	 then	 please	 contact	 Dr	 Wright	 at	 the	 address	 shown	 at	 the	 end	 of	 this	
document.		
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Involvement	of	the	GP	
	
With	permission	we	will	inform	your	GP,	by	letter,	that	you	have	taken	part	in	our	study.		
	
Will	anyone	else	know	I	am	involved	in	the	study?	
	
Only	key	member	of	the	research	team,	your	clinical	team,	and	your	GP,	will	know	you	are	in	
the	study.		
	
Authorised	people	from	the	research	team	will	look	at	anonymised	data	collected	from	the	
study	whilst	conducting	the	analysis.	Auditors	representing	Newcastle	Upon	Tyne	Hospitals	
Foundation	 Trust	 may	 have	 access	 to	 personalised	 data	 like	 consent	 forms	 as	 they	 are	
responsible	for	the	research.		
	
What	will	happen	to	the	samples	we	obtained?	
	
The	 samples	 will	 be	 stored	 in	 our	 laboratory	 and	 used	 in	 a	 series	 of	 experiments	 to	
investigate	 the	 interactions	 between	 airway	 cells,	mucus,	 blood	 cells	 and	 germs.	 Samples	
may	be	retained	for	5	years	before	being	destroyed.	They	will	be	used	by	members	of	the	
study	team	and	by	our	scientific	collaborators.	
	
Will	any	genetic	tests	be	done?	
	
No	genetic	tests	will	be	performed	as	part	of	this	study.	
	
What	will	happen	to	the	results	of	the	research	study?	
	
We	aim	to	publish	 the	study	results	 in	high	quality	scientific/medical	 journals	and	present	
them	at	medical	and	scientific	meetings.	You	will	not	be	identified	in	any	report/publication.	
We	 also	 propose	 to	make	 results	 of	 the	 study	 available	 to	 patient	 groups	 (eg	 CritPal	 and	
ICUSteps	–	support	groups	for	patients	who	have	been	on	ITU	and	their	relatives).		
	
Who	is	funding	this	study?	
	
The	study	is	funded	by	the	Wellcome	Trust.	
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Who	has	reviewed	the	study?	
	
All	research	in	the	NHS	is	 looked	at	by	an	independent	group	of	people,	called	a	Research	
Ethics	Committee,	to	protect	the	safety,	rights,	wellbeing	and	dignity	of	patients.	This	study	
has	been	reviewed	and	given	a	 favourable	opinion	by	such	a	Research	Ethics	Committee	-
Newcastle	 &	 North	 Tyneside	 2	 Research	 Ethics	 Committee.	 The	 scientific	 rigour	 and	
importance	of	the	study	was	reviewed	by	several	independent	specialists	and	by	a	scientific	
panel	chaired	by	the	Wellcome	Trust.	
	
Contact	for	further	information	
	
If	 you	 would	 like	 further	 information	 now	 or	 at	 any	 stage	 in	 the	 future,	 please	 do	 not	
hesitate	to	contact		
	
Dr	Stephen	Wright	
Intensive	Care	Unit	
Freeman	Hospital	
Freeman	Road	
Newcastle	upon	Tyne	
NE7	7DN		
0191	223	1059		
Stephen.Wright@nuth.nhs.uk	
	
If	 you	 would	 like	 to	 talk	 to	 an	 expert	 who	 is	 not	 involved	 in	 the	 project,	 we	 have	 an	
independent	 advisor	 for	 this	 specific	 purpose.	 This	 person	 is	 a	 fully	 qualified	 medical	
practitioner	 who	 is	 there	 to	 answer	 any	 questions	 or	 concerns	 you	may	 have	 about	 the	
study.	He	is	not	in	any	way	involved	in	the	study,	but	understands	all	of	the	medical	aspects	
of	this	particular	project.	The	contact	details	are	
	
Dr	Bryan	Yates	
Consultant	Intensive	Care	and	Respiratory	Medicine	
North	Tyneside	General	Hospital	
Rake	Lane	
North	Shields	
Tyne	and	Wear	
NE29	8NH	
0191	2932582	
	
You	will	be	given	a	copy	of	this	Information	Sheet	and	a	signed	consent	form	to	keep.	
Thank	you	for	taking	time	to	read	this	sheet	and	for	considering	taking	part.	
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INFORMATION	SHEET	FOR	PATIENT	(Participant)	
	
Subglottic	study	-	ICU	
	
PART	1	
	
You	are	being	invited	to	take	part	in	a	research	study.	Before	you	decide	whether	or	not	to	
take	part	it	is	important	for	you	to	understand	why	the	research	is	being	done	and	what	it	
will	involve.	Please	take	time	to	read	the	following	information	carefully	and	discuss	it	with	
others	if	you	wish.	
• Part	1	 tells	 you	 the	purpose	of	 the	 study	and	what	will	 happen	 to	 you	 if	 you	 take	
part.	
• Part	2	gives	you	more	detailed	information	about	the	conduct	of	the	study.	
	
Please	ask	if	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.		
Thank	you	for	reading	this.	
	
	
What	is	the	purpose	of	the	study?	
	
Patients	in	intensive	care	units	(ICUs)	often	require	help	with	their	breathing.	This	involves	
placing	 a	 plastic	 tube	 between	 the	 vocal	 cords	 of	 the	 unconscious	 patient,	 and	 into	 the	
windpipe,	after	which	the	tube	is	attached	to	a	ventilator	machine.	The	tube	is	kept	in	place	
by	 inflating	 a	 balloon	 (or	 "cuff")	 at	 the	 end	 of	 the	 tube,	 to	 hold	 the	 tube	 against	 the	
windpipe,	just	below	the	vocal	cords.	In	health,	the	vocal	cords	and	a	normal	cough	prevent	
germs	 entering	 the	 lung.	 Unfortunately,	 the	 combination	 of	 illness,	 reduced	 cough,	 and	
having	 a	 tube	 "bypassing"	 the	 vocal	 cords,	 leaves	 these	 patients	 extremely	 vulnerable	 to	
lung	infection.	This	infection	termed	"ventilator-acquired	pneumonia",	causes	more	deaths	
than	any	other	hospital-acquired	infection.	New	ways	to	prevent	it,	preferably	without	using	
antibiotics,	are	urgently	required.		
A	key	starting	point	would	be	identifying	how	germs	begin	their	journey	into	the	lung.	We	
know	germs	grow	rapidly	just	above	the	cuff	of	the	tube	in	the	voice	box	(an	area	known	as	
the	"subglottis"),	before	passing	into	the	lung.	To	understanding	how	this	happens	we	need	
samples	 from	people	 in	 ICU	 to	use	 in	 the	 laboratory	 for	 experiments	 and	 to	 identify	new	
treatments.		
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What	happened	to	you	during	the	study?	
	
You	were	unaware	of	our	study	at	the	time	it	was	performed.	This	is	because	you	were	not	
well	enough	for	the	details	of	the	study	to	be	discussed	with	you.		
	
We	 received	 permission	 (consent)	 from	 your	 relative/friend/carer	 (_________________),	
who	was	not	aware	of	you	having	any	objection	to	helping	with	medical	research.		
	
In	addition	to	your	normal	care	you	received	the	following	procedures–	
1)	An	extra	blood	test	was	performed.	
2)	We	took	samples	of	mucus	from	your	throat.	
3)	We	sampled	some	of	the	lining	of	your	throat	using	a	small	brush	passed	into	your	throat	
via	a	small	scope.	
	 	
We	also	kept	some	of	the	samples	we	collected,	this	includes	the	liquid	part	of	your	blood	
(called	plasma	or	 serum)	and	some	glass	 slides	with	 some	white	blood	cells	on	 them.	We	
also	kept	some	of	the	samples	from	your	throat.	We	now	need	to	check	with	you	whether	
you	give	us	permission	for	these	samples	to	be	used	in	any	future	research	by	our	research	
group,	where	ethical	approval	has	been	granted.	We	should	emphasise	that	all	samples	and	
information	collected	up	to	now	are	marked	with	a	unique	study	number	only,	preventing	
you	being	recognised	by	anyone	outside	the	study	team.	
	
Why	have	you	been	chosen?	
	
The	research	is	specifically	looking	at	the	factors	in	the	throat	and	blood	that	put	patients	in	
the	intensive	care	unit	at	risk	of	serious	chest	infection.	The	fact	that	you	are	on	the	ICU	for	
several	days	means	that	you	are	eligible	for	entry	into	the	study.	
	
Do	you	have	to	allow	your	information	and	samples	to	be	used	for	the	study?	
	
No,	it	is	up	to	you	to	decide	whether	to	take	part	in	the	research.	If	you	decide	to	take	part	
you	will	 be	 free	 to	 change	 your	mind	 at	 any	 time	 and	without	 giving	 a	 reason.	 It	 is	 very	
important	to	understand	that	if	you	do	not	wish	for	your	samples	/	clinical	information	to	be	
used	for	the	research	then	we	shall	fully	understand	and	this	will	not	in	any	way	alter	your	
care	now	or	at	any	stage	in	the	future.	
	
If	you	decide	you	would	rather	not	have	taken	part,	the	consent	form	that	comes	along	with	
this	document	will	give	you	2	options.	These	are	either	to	say		
1. That	you	do	not	wish	us	to	collect	any	further	information	about	you	for	the	study,	
but	we	may	keep	any	information/samples	collected	up	to	now.		
2. That	 you	wish	us	 to	destroy	all	 samples	and	 information	 relating	 to	 you	 that	have	
been	collected	as	part	of	the	study.	
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What	are	the	possible	disadvantages	and	risks	of	taking	part	in	the	study?	
	
You	should	not	experience	/	have	experienced	any	side	effects	from	the	drawing	of	blood.	
You	should	not	experience	/	have	experienced	any	side	effects	from	the	sampling	from	your	
throat.	
	
	
What	are	the	potential	benefits	of	you	taking	part	in	the	study?	
	
There	are	no	benefits	to	you	personally	in	taking	part	in	the	study.	Our	research	in	the	lab,	
however,	 is	 aimed	 at	 helping	 prevent	 people,	 such	 as	 you,	 from	 getting	 serious	 infection	
while	on	the	intensive	care	unit	in	the	future.	
	
	
Is	there	any	reimbursement	for	taking	part?	
	
No	
	
	
What	if	there	is	a	problem?	
	
Any	complaint	about	the	way	you	have	been	dealt	with	during	the	study	will	be	addressed.	
The	detailed	information	on	this	is	found	in	Part	2.	
	
	
Is	the	study	confidential?	
	
Yes.	We	will	follow	ethical	and	legal	practice	and	all	information	about	you	will	be	handled	
in	confidence.	The	details	are	included	in	Part	2.	
	
	
	
	
If	 the	 information	 in	 Part	 1	 has	 interested	 you	 and	 you	 are	 considering	 participation,	
please	read	the	additional	information	in	Part	2	before	making	a	decision.	
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PART	2	
	
	
What	happens	if	you	change	your	mind?	
	
You	can	change	your	mind	at	any	point.	If	you	subsequently	decide	that	you	do	not	want	to	
take	part	in	the	study	you	can	insist	that	all	research	data	and	samples	be	destroyed.	
	
	
What	if	there	is	a	problem?	
	
If	 you	 wish	 to	 complain,	 or	 have	 any	 concerns	 about	 the	 way	 in	 which	 you	 have	 been	
approached	 or	 treated	 during	 the	 course	 of	 this	 study	 you	 should	 ask	 to	 speak	 to	 the	
researchers	who	will	 do	 their	best	 to	answer	your	questions.	 If	 you	 remain	unhappy,	 and	
wish	to	complain	formally,	you	can	do	so	via	the	normal	NHS	complaints	procedure.	
	
	
What	if	something	goes	wrong?	
	
In	the	event	that	something	goes	wrong,	and	you	are	harmed	during	the	research,	and	this	
is	 due	 to	 someone’s	 negligence,	 then	 you	 may	 have	 grounds	 for	 legal	 action	 for	
compensation	against	Newcastle	Upon	Tyne	Hospitals	Foundation	Trust,	but	you	may	have	
to	pay	your	legal	costs.	The	normal	NHS	complaints	service	will	still	be	available	to	you.	
	
	
Will	your	taking	part	be	kept	confidential?	
	
Yes,	 personal	 data	will	 be	 regarded	as	 strictly	 confidential.	 Any	 samples	or	 data	 collected	
about	 you	 (such	as	 your	 age	and	medical	 conditions)	will	 be	marked	with	 a	unique	 study	
number	only,	preventing	you	being	recognised	by	anyone	outside	the	study	team.	This	study	
number	 will	 allow	 only	 an	 authorized	 member	 of	 the	 research	 team	 to	 identify	 you	 if	
absolutely	necessary.	Data	will	be	stored	in	a	secure	location	within	your	hospital	and	at	the	
central	 study	 location	 at	 Newcastle	 University.	 Data	 will	 be	 retained	 at	 these	 sites	 for	 5	
years,	following	this	time	it	will	be	disposed	of	as	confidential	waste.	
Can	you	access	the	results	of	the	research?	
	
Yes.	 We	 aim	 to	 send	 all	 participant	 a	 summary	 of	 the	 study	 finding	 after	 the	 study	 is	
completed	and	analysis	performed.	This	may	take	several	years.	Should	you	wish	to	know	
details	 before	 then	 please	 contact	 Dr	 Wright	 at	 the	 address	 shown	 at	 the	 end	 of	 this	
document.		
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Involvement	of	the	GP	
	
We	also	asked	your	 relative/friend/carer	 for	permission	 to	 inform	your	GP,	by	 letter,	 that	
you	have	taken	part	in	our	study.		
	
	
Will	anyone	else	know	I	am	involved	in	the	study?	
	
Only	key	member	of	the	research	team,	your	clinical	team,	and	your	GP,	will	know	you	are	in	
the	study.		
	
Authorised	people	from	the	research	team	will	look	at	anonymised	data	collected	from	the	
study	whilst	conducting	the	analysis.	Auditors	representing	Newcastle	Upon	Tyne	Hospitals	
Foundation	 Trust	 may	 have	 access	 to	 personalised	 data	 like	 consent	 forms	 as	 they	 are	
responsible	for	the	research.		
	
	
What	will	happen	to	the	samples	we	obtained?	
	
The	 samples	 will	 be	 stored	 in	 our	 laboratory	 and	 used	 in	 a	 series	 of	 experiments	 to	
investigate	 the	 interactions	 between	 airway	 cells,	mucus,	 blood	 cells	 and	 germs.	 Samples	
may	be	retained	for	5	years	before	being	destroyed.	They	will	be	used	by	members	of	the	
study	team	and	by	our	scientific	collaborators		
	
	
Will	any	genetic	tests	be	done?	
	
No	genetic	tests	will	be	performed	as	part	of	this	study.	
	
	
What	will	happen	to	the	results	of	the	research	study?	
	
We	aim	to	publish	 the	study	results	 in	high	quality	scientific/medical	 journals	and	present	
them	at	medical	and	scientific	meetings.	You	will	not	be	identified	in	any	report/publication.	
We	 also	 propose	 to	make	 results	 of	 the	 study	 available	 to	 patient	 groups	 (eg	 CritPal	 and	
ICUSteps	–	support	groups	for	patients	who	have	been	on	ITU	and	their	relatives).		
	
	
Who	is	funding	this	study?	
	
The	study	is	funded	by	the	Wellcome	Trust.	
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Who	has	reviewed	the	study?	
	
All	research	in	the	NHS	is	 looked	at	by	an	independent	group	of	people,	called	a	Research	
Ethics	Committee,	to	protect	the	safety,	rights,	wellbeing	and	dignity	of	patients.	This	study	
has	been	reviewed	and	given	a	 favourable	opinion	by	such	a	Research	Ethics	Committee	-	
Newcastle	 &	 North	 Tyneside	 2	 Research	 Ethics	 Committee.	 The	 scientific	 rigour	 and	
importance	of	the	study	was	reviewed	by	several	independent	specialists	and	by	a	scientific	
panel	chaired	by	the	Wellcome	Trust.	
Contact	for	further	information	
	
If	 you	 would	 like	 further	 information	 now	 or	 at	 any	 stage	 in	 the	 future,	 please	 do	 not	
hesitate	to	contact		
	
Dr	Stephen	Wright	
Critical	Care	Unit	(Ward	37)	
Freeman	Hospital	
Freeman	Road	
Newcastle	upon	Tyne	
NE7	7DN		
0191	223	1059		
Stephen.Wright@nuth.nhs.uk	
	
If	 you	 would	 like	 to	 talk	 to	 an	 expert	 who	 is	 not	 involved	 in	 the	 project,	 we	 have	 an	
independent	 advisor	 for	 this	 specific	 purpose.	 This	 person	 is	 a	 fully	 qualified	 medical	
practitioner	 who	 is	 there	 to	 answer	 any	 questions	 or	 concerns	 you	may	 have	 about	 the	
study.	He	is	not	in	any	way	involved	in	the	study,	but	understands	all	of	the	medical	aspects	
of	this	particular	project.	The	contact	details	are	
	
Dr	Bryan	Yates	
Consultant	Intensive	Care	and	Respiratory	Medicine	
North	Tyneside	General	Hospital	
Rake	Lane	
North	Shields	
Tyne	and	Wear	
NE29	8NH	
0191	2932582	
	
You	will	be	given	a	copy	of	this	Information	Sheet	and	a	signed	consent	form	to	keep.	
Thank	you	for	taking	time	to	read	this	sheet	and	for	considering	taking	part.	
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Patient Consent form – Upper airway host defences – theatre attenders Version 1: 08/07/2015 
 
 
 
 
 
CONSENT FORM 
 
      
 
Title of Project: Modulation of the upper airway host defences to prevent pneumonia in 
ventilated patients – theatre attenders   
                        
Chief investigator: Prof Janet Wilson 
Principal investigator at site: Mr Jason Powell 
Please initial  
1. I confirm that I have read and understand the information sheet dated 22nd September  
 2015 (Version 2) for the above study I have had the opportunity to consider the   [           ] 
 information, ask questions and have had these questions answered satisfactorily. 
          
 2.  I understand that my participation is voluntary and that I am free to withdraw at any  
 time, without giving any reason, and without my medical care or legal rights                       [           ] 
      being affected.     
 
3. i)I understand that relevant sections of my medical notes and data collected during the          [         ]                                                                                                  
      study may be looked at by individuals from: the study team or the Sponsor (Newcastle 
upon Tyne Hospitals NHS Foundation Trust), where it is relevant to my taking part in this   
research. 
 
    ii) I give permission for these individuals to have access to my records, even if I withdraw 
      from the study, and  I understand that my records will only be reviewed for information  [         ]                                                                                                  
      related to my participation in the study.                                                                                    
 
4.  I agree that the research team may record information from my 
     case records solely for the purpose of this study.                                                                   [          ]                                       
 
5.  I agree that my throat samples may be used for this study.                             [          ] 
 
6.   I agree that my throat samples can be used in future studies on     [          ] 
      condition that my identity cannot be determined from the sample.      
 
7.   I consent to my GP being informed of my participation in this study.                                     [          ] 
 
 
 
________________________ ________________ ____________________ 
Name of Patient  Date Signature 
 
 
________________________ ________________ ____________________ 
Researcher   Date  Signature 
 
 
1 copy for patient; 1 for researcher; 1 for case notes 
 
 
 
  
 
 
  
 
 
Attach patient  
label here 
Subject Number: 
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Patient Information Sheet 
 
 
Modulation of the upper airway host defences to prevent pneumonia in 
ventilated patients – ENT volunteers 
 
Invitation 
You are being invited to take part in a research study. Before you decide whether or 
not to take part it is important for you to understand why the research is being done 
and what it will involve. Please take time to read the following information carefully 
and discuss it with relatives, friends and your GP if you wish. Please ask us if there is 
anything that is not clear or if you would like more information. 
 
What is the purpose of the study? 
Critically ill patients in intensive care units (ICUs) are more prone to infections than 
other people. These patients are particularly vulnerable to a lung infection termed 
"ventilator-acquired pneumonia" (VAP). This infection causes more deaths than any 
other hospital-acquired infection. New ways to prevent it, preferably without using 
antibiotics, are urgently required. A key starting point would be identifying how 
germs begin their journey into the lung from the upper airway or throat. In order to 
understand why this happens we need samples of the throat from both patients on the 
ICU, and people who are not on ICU, to look at the differences, and to use these 
samples to devise new treatments. 
 
Why have I been chosen? 
You have been chosen because you are going to have an examination of the throat 
under a general anaesthetic - ‘asleep’. This is something your doctor has planned but 
during this procedure is a good time to take these samples from your throat while you 
are asleep and don’t feel anything. 
 
Do I have to take part? 
No, you do not have to take part in this study. If you do not agree, your care will not 
be affected in any way. You may also change you mind later and ask to be withdrawn 
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from the study. No reason need be given. If you do withdraw, your samples will be 
destroyed and your data will be removed from the study entirely, provided that the 
results of the study have not already been published in a scientific journal.  
 
Will taking part affect my treatment? 
Donating your tissue samples will not affect your treatment. We would like to 
perform brushings and collect mucus from your voice box. This would be done in 
agreement with your hospital doctor and it would not affect your treatment and should 
not cause you any further discomfort. 
 
What will happen to me if I take part? 
In theatre when your throat is being examined we will, with your hospital doctor’s 
consent, take brushings, swabs and a sample of mucus from your voice box. You will 
be asleep during this and will not be aware of it. The samples taken by us will not be 
used for diagnostic purposes. The samples may be stored in our laboratory for future 
research studies. The samples will not be used for research that involves reproductive 
cloning, or be tested for inherited diseases. During the procedure, we may find we are 
unable to take the study samples for some reason. If this happens, we will discuss this 
with you afterwards. The findings of experiments using your tissue will only be 
presented as group results. No individual information about you will be shown or 
published. Only research staff will have access to your information and tissue 
samples.  
 
What do I have to do? 
You do not have to do anything right now. On the day of your procedure a member of 
the research team will contact you again and ask if you are happy to take part in the 
study. You will not have to come to the hospital again other than on the date planned 
by your doctor. After we take the samples during your procedure we will only contact 
you once more, by post, to let you know about the pooled results of the research 
study, if you wish us to. We will not contact you again at any other time. If you 
decide not to be involved with the study simply inform the researcher and we will not 
contact you further. If you have any further questions or are not sure, then please 
discuss your concerns with a member of the research team. 
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What are the possible risks and disadvantages of taking part? 
You will be asleep while all these events happen and unaware so should not feel any 
discomfort at the time of sampling. We will be stroking the voice box with a 
miniature brush that is less than a centimetre wide, this takes a very small sample of 
superficial cells of the voice box lining. These cells will quickly grow back and be 
replaced. This will not affect your speaking voice. In order to sample your throat 
mucus we will suction this out with a small tube through your mouth. This should not 
cause any ill effect and your body will naturally replace this. Finally we will take a 
swab of the voice box to see what bacteria/fungus/viruses we might find. These 
procedures should not add on more than 5-10 minutes to the length of your procedure 
and time asleep under anaesthetic. This should not make the procedure or anaesthetic 
any more risky for you. 
 
What are the possible benefits of taking part? 
The results will not be of direct benefit to you, but will help towards better treatments 
for seriously unwell patients in hospital. If we find any unexpected incidental findings 
that relate to your sample we will contact your GP who will contact you to discuss 
this. This is highly unlikely. After the study has finished we will let you know about 
the findings of the research study in writing, for your interest. This will be related to 
general pooled findings, not personal results. 
 
What if something goes wrong? 
We do not envisage any complications but we really would like to hear about any 
possible side effects of taking part, please contact Prof Janet Wilson, Hon Consultant, 
ENT Department, Freeman Hospital, NE7 7DN, Tel: 01912231086, if you experience 
anything negative that you fell may be related to the study, however minor. 
If you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the study, you can speak directly in 
confidence to any member of research team. The National Health Service complaints 
procedure is also available to you. Details can be found on our hospital web site 
www.newcastle-hospitals.org.uk or by contacting the Patient Relations Department on 
0191 223 1382 
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Will my taking part in this study be kept confidential? 
Yes. All patient data is treated as confidential and will be anonymised before any 
analysis. Only group data, not individual data, will be produced in this study. With 
your permission we will let your General Practitioner (GP) know that you have been 
in the study. 
 
What happens when the research stops? 
The pooled results of this project may be presented at scientific meeting or in 
scientific journals. 
 
Who is organising and funding the research? 
This study is being funded by the Wellcome Trust. None of the research team will 
receive payment for this study. 
 
Who has reviewed the study? 
The study has been reviewed by the West Midlands - Edgbaston Research Ethics 
Committee, and the Research and Development Department within the Newcastle 
upon Tyne Hospitals NHS Trust. 
 
What happens if I change my mind? 
You have the right to change your mind at any time before the procedure. If you 
change your mind after the samples have been taken we will withdraw your samples 
from the study as long as they have not been analysed. If you choose to do so, please 
contact the research team:  
Contact Person- Prof Janet Wilson  
Postal address- ENT Department, Freeman Hospital, Freeman Road, High Heaton, 
Newcastle upon Tyne, NE7 7DN 
Telephone number: 01912231086 
 
Who can I contact for further information? 
For further information about the study: 
Prof Janet Wilson, Hon Consultant, ENT Department, Freeman Hospital, NE7 7DN, 
Tel: 01912231086 
Or for confidential advice about taking part: The Patient Advice and Liaison 
Service: 08000 320202, northoftynepals@nhct.nhs.uk 
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Presentations 
• Powell J, Garnett J, Verdon B, Wilson J, Pearson J, Ward C. A human in vitro 
model of the subglottic airway. (Oral presentation) 
29th September 2015, American Academy of Otolaryngology - Head and Neck Surgery 
(AAO-HNS) Annual Meeting, Dallas, USA.  
• Powell J, Garnett J, Verdon B, Wilson J, Pearson J, Ward C. A primary in vitro 
model of the Subglottic Airway. (Oral presentation) 
9th October 2015, ORS Autumn Meeting, Liverpool.  
• Powell J, Garnett J, Verdon B, Wilson J, Pearson J, Ward C. A human in vitro 
model of the subglottic airway. (Poster presentation) 
5th November 2015, British Laryngological Association Annual Conference, 
London  
• Powell J, Garnett J, Verdon B, Wilson J, Pearson J, Ward C. A human in vitro 
model of the subglottic airway. (Oral presentation) 
9th November 2015, Faculty Development Day - Otolaryngology, Newcastle upon Tyne.   
 
Prizes 
• David Howard Prize, British Laryngological Association annual meeting, poster 
presentation prize, November 2015. 
• Munro Black Prize, Northern Deanery Otolaryngology oral presentation prize, 
November 2015. 
 
Publications 
• Powell J, Garnett J, Verdon B, Wilson J, Pearson J, Ward C. A human in vitro 
model of the subglottic airway. Otolaryngol Head Neck Surg. 2015; 153(1s):83 
	
	
	
	
